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ABSTRACT
The alarming rise in HIV-1 associated neurocognitive disorder (HAND) is, at least in
part, associated with HIV-1 viral proteins shed from infected macrophages, including
transactivator of transcription (Tat) despite the success of anti-retroviral therapies. The
dopamine (DA) system is greatly involved in the progression of HAND and is influenced by
psychostimulants like cocaine. The DA transporter (DAT), a key regulator of neurocognitive
functions, is a major molecular target for both Tat and cocaine. Our lab previously reported
that exposure to Tat decreases DA uptake through allosteric regulation and alters cocaine
binding sites in DAT.
In this research project the hypothesis ‘HIV-1 Tat protein via allosteric modulation of
DAT induces inhibition of DA transport, leading to dysfunction of the DA system’ was
tested. Initially, it was shown that Tat protein directly interacts with DAT to impair DA
translocation. Based on the predictions of computational modeling and simulations, Y470,
Y88 and K92 residues of the human DAT (hDAT) are essential to stabilize the compact
structure of DAT and potentially recognize Tat. Mutating these residues in hDAT – Y470H,
Y88F, and K92M attenuated Tat-induced inhibition of DA uptake. Additional substitutions
Y470A and Y470F at 470 displayed attenuated or no effect on Tat-induced inhibition of DA
uptake respectively, indicating the significant role of aromatic ring of Y470 in DAT and Tat
interaction. Pharmacological characterization showed that compared to wild type hDAT,
Y470H and K92M but not Y88F reduce Vmax with no change in the Km values for DA
uptake. Moreover, Y470H, K92M, and Y88F mutants exhibited no alterations in IC50 values
v

of DA to inhibit [3H]DA uptake but increased [3H]DA uptake potency or [3H]WIN35,428
binding potency for cocaine and GBR12909, suggesting that these three Tat-recognition
residues do not overlap with substrate DA binding but influence binding of small molecule
inhibitors. Besides, all five mutants reversed zinc-induced increase of [3H]WIN35,428
binding and differentially altered basal DA efflux properties of the DAT, indicating that Tat
protein through interaction at these recognition residues disrupts intermolecular interactions
that are critical for maintenance of the outward-facing conformation of DAT.
Another study was conducted to determine the effects of Tat on DAT
phosphorylation, trafficking and its influence on sequestration of [3H]DA by vesicular
monoamine transporter 2 (VMAT2). We found that protein kinase C (PKC) inhibitor,
bisindolylmaleimide-I eliminates Tat effects on DA uptake and Tat increases intracellular
DAT immunoreactivity. Moreover, Tat also produced inhibitory effects on VMAT2
function. Collectively, these findings revealed that Tat inhibits DAT function through PKC
and trafficking- dependent mechanisms; besides, both DAT and VMAT2 proteins may
involve in Tat-induced dysregulation of the DA system.
In conclusion, Tat inhibits DA translocation process principally by altering the
conformational states of the DAT through interaction at specific recognition residues.
Furthermore, regulatory pathways that control the functional attributes of DAT may play a
vital role in Tat-mediated impairment of the DA system. Future studies will be necessary to
identify and characterize other recognition residues for Tat binding and these molecular
insights will be helpful to develop adjunctive therapies to restore the impaired DA system in
HIV-1 positive individuals.

vi

TABLE OF CONTENTS
DEDICATION ....................................................................................................................... iii
ACKNOWLEDGEMENTS........................................................................................................ iv
ABSTRACT ............................................................................................................................v
LIST OF TABLES .................................................................................................................. ix
LIST OF FIGURES ...................................................................................................................x
LIST OF ABBREVIATIONS.................................................................................................... xii
CHAPTER 1: INTRODUCTION ..................................................................................................1
1.1 HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND)....................................1
1.2 DOPAMINE TRANSPORTER (DAT) .......................................................................11
1.3 OBJECTIVE OF THE RESEARCH ............................................................................17
1.4 SPECIFIC AIMS .....................................................................................................17
CHAPTER 2: MUTATION OF TYROSINE 470 OF HUMAN DOPAMINE TRANSPORTER IS CRITICAL
FOR HIV-1 TAT-INDUCED INHIBITION OF DOPAMINE TRANSPORT AND TRANSPORTER
CONFORMATIONAL TRANSITIONS ........................................................................................23
2.1 INTRODUCTION ...................................................................................................24
2.2 MATERIALS AND METHODS ................................................................................26
2.3 RESULTS .............................................................................................................34
2.4 DISCUSSION ........................................................................................................41
CHAPTER 3: POINT MUTATIONS AT TYR 88, LYS 92 AND TYR 470 OF HUMAN DOPAMINE
TRANSPORTER ATTENUATE TAT-INDUCED INHIBITION OF DOPAMINE TRANSPORTER
FUNCTION............................................................................................................................59
3.1 INTRODUCTION ...................................................................................................60

vii

3.2 MATERIALS AND METHODS ................................................................................63
3.3 RESULTS .............................................................................................................70
3.4 DISCUSSION ........................................................................................................78
CHAPTER 4: HIV-1 TAT PROTEIN DECREASES DOPAMINE TRANSPORTER CELL SURFACE
EXPRESSION AND VESICULAR MONOAMINE TRANSPORTER-2 FUNCTION IN RAT STRIATAL
SYNAPTOSOMES ..................................................................................................................98
4.1 INTRODUCTION ...................................................................................................99
4.2 MATERIALS AND METHODS ..............................................................................101
4.3 RESULTS ...........................................................................................................108
4.4 DISCUSSION ......................................................................................................110
CHAPTER 5: GENETICALLY EXPRESSED HIV-1 VIRAL PROTEINS ATTENUATE NICOTINEINDUCED BEHAVIORAL SENSITIZATION AND ALTER MESOCORTICOLIMBIC ERK AND CREB
SIGNALING IN RATS ...........................................................................................................124
5.1 INTRODUCTION .................................................................................................125
5.2 MATERIALS AND METHODS ..............................................................................129
5.3 RESULTS ...........................................................................................................134
5.4 DISCUSSION ......................................................................................................140
CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS .....................................................160
6.1 SUMMARY AND CONCLUSIONS .........................................................................160
6.2 FUTURE DIRECTIONS .........................................................................................173
REFERENCES .....................................................................................................................177
APPENDIX A: GENERAL STATISTICAL ANALYSES CONSIDERATIONS ...............................208

viii

LIST OF TABLES
Table 2.1 Summary of inhibitory activities in [3H]DA uptake in WT
and mutated hDAT in the presence of DA, cocaine or GBR12909 ...................48
Table 3.1 Summary of kinetic properties and inhibitory activities in
[3H]DA uptake in CHO cells expressing WT and mutated hDATs...................84
Table 3.2 Summary of kinetic properties and inhibitory activities in [3H]WIN35,428
binding in PC12 cells expressing WT and mutated hDATs ............................85

ix

LIST OF FIGURES
Figure 1.1 Overview of HIV-1 Tat and cocaine synergistic or additive effects on
dopamine neurotransmission in HIV-1 infected individuals ............................19
Figure 1.2 DAT is localized to the presynaptic terminal of the dopaminergic neurons ....20
Figure 1.3 Illustration of potential regulatory pathways that control the function and
availability of the DAT .....................................................................................21
Figure 1.4 Model of substrate translocation cycle for DAT ..............................................22
Figure 2.1 A direct interaction between Tat and DAT and the energy-minimized
hDAT(DA) binding complex following the MD simulation ............................49
Figure 2.2 Inhibition of DA uptake by released Tat from
Tat-expressing cells ..........................................................................................51
Figure 2.3 [3H]DA uptake and DAT surface expression in WT
hDAT and mutant ............................................................................................53
Figure 2.4 Effects of Tat on kinetic analysis of [3H]DA uptake in WT
hDAT and mutant..............................................................................................55
Figure 2.5 Mutation of Tyr470 alters transporter conformational transitions ...................56
Figure 3.1 MD simulated structure of outward-open DAT (A and B) and
structure of inward-open DAT (C and D) .........................................................86
Figure 3.2 MD simulated structure of HIV-1 Tat-DAT binding complex .......................88
Figure 3.3 Interaction between Tat-M1 and DAT-Y470 mutations ..................................90
Figure 3.4 [3H]DA uptake and DAT surface expression in WT
hDAT and mutants ............................................................................................91
Figure 3.5 Effects of Tat or Tat Cys22 on [3H]DA uptake in WT
hDAT and mutants ............................................................................................93
Figure 3.6 Effects of Y470F, Y470A and Y470H mutants on
transporter conformational transitions .............................................................94
x

Figure 3.7 Effects of Y88F and K92M mutants on
transporter conformational transitions ...........................................................96
Figure 4.1 PKC inhibition attenuated Tat- and d-amphetamine (AMPH)induced reduction of [3H]DA uptake in rat striatal synaptosomes .................118
Figure 4.2 Tat protein decreased DAT cell surface expression .......................................119
Figure 4.3 Tat protein decreased the specific [3H]WIN35,428 binding
in plasma membrane enriched fraction ...........................................................120
Figure 4.4 Inhibitory effects of Tat on synaptosomal [3H]DA uptake
and vesicular [3H]DA uptake in rat striatum...................................................121
Figure 4.5 Pharmacological profiles of vesicular [3H]DA uptake in
rat striatum in the presence of Tat1-86, Tat Cys22, or tetrabenazine ..............122
Figure 5.1 Body weights of HIV-1 Tg and F344 rats during the nicotine
or saline treatment period...............................................................................149
Figure 5.2 The time-course data during the habituation
and the saline baseline sessions .....................................................................150
Figure 5.3 The time-course data during the behavioral sensitization phase ....................151
Figure 5.4 The time-course data for total horizontal activity during
day 1 and day 19 of the behavioral sensitization phase .................................152
Figure 5.5 Levels of ERK, CREB and TH proteins in the PFC
in HIV-1 Tg and F344 rats ...........................................................................153
Figure 5.6 Levels of ERK, CREB and TH proteins in the NAc
in HIV-1 Tg and F344 rats ............................................................................155
Figure 5.7 Levels of ERK, CREB and TH proteins in the VTA
in HIV-1 Tg and F344 rats ............................................................................157
Figure 6.1 Structure of DAT-Tat-Dopamine-Cocaine complex ......................................175
Figure 6.2 Proposed model of HIV-1 Tat protein effects
on DAT and VMAT2 proteins .......................................................................176

xi

LIST OF ABBREVIATIONS
3D............................................................................................................. Three dimensional
AMPH ..........................................................................................................d-Amphetamine
ANOVA ............................................................................................... Analysis of Variance
ART....................................................................................................Anti retroviral therapy
BD ......................................................................................................... Brownian dynamics
BIM-1.............................................................................................. Bisindolyl maleimide -1
Bmax ............................................................................................................ Binding capacity
CNS .................................................................................................. Central nervous system
Co-IP .............................................................................................. Co-Immunoprecipitation
CREB .......................................................... Cyclic AMP response element binding protein
CSF .........................................................................................................Cerebrospinal fluid
DA ......................................................................................................................... Dopamine
DAT ....................................................................................................Dopamine transporter
Dox.................................................................................................................... Doxycycline
ERK........................................................................................ Extracellular regulated kinase
FBS ......................................................................................................... Fetal bovine serum
Flot-1 ......................................................................................................... Flotillin/Reggie-1
Gag .................................................................................................... Group specific antigen
GBR12909 ..........1-[2-(bis[4-fluorophenyl]methoxy)ethyl]-4-[3-phenylpropyl] piperazine
GFAP ...................................................................................... Glial fibrillary acidic protien
GFP ............................................................................................... Green fluorescent protein
xii

GST ............................................................................................... Glutathione S-transferase
HAND .................................................................HIV-1 associated neurocognitive disorder
hDAT ...................................................................................... Human dopamine transporter
HIV-1 ............................................................................ Human Immunodeficiency Virus-1
HIV-1 Tg .................................................................................................... HIV-1 transgenic
HVA ......................................................................................................... Homovanillic acid
IB..................................................................................................................Immunoblotting
IC50 .....................................................................The half maximal inhibitory concentration
IP ......................................................................................................... Immunoprecipitation
IPTG................................................................... Isopropyl beta-D-1-thiogalactopyranoside
Kd ........................................................................................................ Dissociation constant
Km............................................................................................... Michaelis-Menten constant
KRH ................................................................................................... Krebs-Ringer-HEPES
LTR ...................................................................................................... Long terminal repeat
MAPK ............................................................................... Mitogen-activated protein kinase
MD ........................................................................................................ Molecular dynamics
MPP........................................................................................ 1-methyl-4-phenylpyridinium
NAc ........................................................................................................ Nucleus accumbens
NIH ............................................................................................ National Institute of Health
NMR ........................................................................................ Nuclear magnetic resonance
PAGE ............................................................................ Polyacrylamide gel electrophoresis
PFC .............................................................................................................Prefrontal cortex
PKC ........................................................................................................... Protein kinase - C
RRE .................................................................................................... Rev response element
RTI-55 .............................. 3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester
xiii

SDS .................................................................................................. Sodium dodecyl sulfate
SEM ..................................................................................................Standard error of mean
SLCA3 .............................................................................................. Solute carrier 6 family
SoRI-20040 ........................................ N-(2,2-diphenyl ethyl)-2-phenyl-4-quinazolinamine
SoRI-20041 ....................................... N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine
SoRI-9804 .............................................. N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine
SPR ............................................................................................ Surface plasmon resonance
TAR.................................................................................. Transactivation response element
Tat ........................................................................................Trans-activator of transcription
TBZ ................................................................................................................. Tetrabenazine
TH ....................................................................................................... Tyrosine hydroxylase
VMAT2 ....................................................................... Vesicular monoamine transporter - 2
Vmax ........................................................................................................... Maximal velocity
VTA .................................................................................................. Ventral tegmental area
WIN 35,428........................................ 2beta-carbomethoxy-3beta-(4-fluorophenyl) tropane
WT ......................................................................................................................... Wild type

xiv

CHAPTER 1
INTRODUCTION
1.1 HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND)
The devastating effects of Human Immunodeficiency Virus-1 (HIV-1) infection were
substantially reduced in HIV-infected individuals with the introduction of antiretroviral
therapies (ARTs) in 1996 (Carpenter et al., 1996; Deeks et al., 2013). This resulted in
reclassification of HIV-1 from life threatening disease to a manageable chronic illness
(Clifford and Ances, 2013). However, HIV-1 has the propensity to have broad effects on
central nervous system (CNS) and impairs CNS functions which results in serious
consequences that lead to HIV-associated neurocognitive disorder (HAND). Approximately
70% of HIV-1 positive adults and children exhibit a neurological disease at one point during
the course of their infection (Grovit-Ferbas and Harris-White, 2010; Simioni et al., 2010;
Bilgrami and O'Keefe, 2014). The spectrum of neurological complications in HAND ranges
from asymptomatic neurocognitive impairment, to mild neurocognitive disorder, to the more
severe form HIV-associated dementia (Antinori et al., 2007). The clinical impairments in
HAND include attention, memory, learning, motor functioning and behavioral changes.
ARTs improve the survival rate of infected people but cannot eliminate the virus from their
brain (Antiretroviral Therapy Cohort, 2008; Heaton et al., 2010) meaning that these therapies
do not offer complete cure. In addition, the incidences and progression of HAND are further
compounded by the consumption of recreational drugs like cocaine and methamphetamine
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(Buch et al., 2011; Nair and Samikkannu, 2012). If HAND can be prevented at early
infection stage, quality of patient’s life will be improved and economic burden will be
lessened on the health care system.
During the course of HAND, HIV-1 infected monocytes infiltrates the brain by
crossing the blood-brain barrier at the early infection stage approximately 2-3 weeks after
primary infection (Davis et al., 1992; Nath and Clements, 2011; Williams et al., 2013).
Subsequently, virus spreads to perivascular macrophages and microglia and establishes a
reservoir within the brain. These infected cells release large number of viral particles daily
which ultimately increase the viral load in the CNS. Moreover, these cells secrete neurotoxic
HIV-1 viral proteins that include structural protein gp120 and nonstructural protein Tat
(trans-activator of transcription) as well as proinflammatory cytokines and chemokines
(Mattson et al., 2005). Several studies observed that HIV-1 cannot directly infect
dopaminergic neurons but extracellularly discharged viral proteins through direct interaction
progressively destruct the neurons and cause subsequent neurodegeneration (Nath et al.,
2000b; Ferris et al., 2008). Among these proteins, Tat has been highly linked to progressive
neuronal dysegulation leading to the development of HAND. Lastly, dopamine (DA)
dysregulation has been associated with cognitive deficits in HIV-1 positive people (Purohit
et al., 2011; Jacobs et al., 2013). Long-term viral proteins exposure can accelerate the
damage in the DA system (Del Valle et al., 2000; Ferris et al., 2008; Hudson et al., 2010;
Nath, 2010). Considering the oxidative stress-induced damage to the dopaminergic neurons,
long lasting exposure to viral proteins and elevated DA eventually lead to DA deficits which
enhance the severity and acceleration of the HAND (Purohit et al., 2011). For the purpose of
this dissertation, the following literature review broadly discusses HIV-1 viral proteins, DA
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transporter (DAT) structure, function and regulation, and general effects of Tat protein on
dopaminergic neurons through impairment of DAT function.
1.1.1 HIV-1 VIRAL PROTEINS
The proviral DNA of HIV-1 is composed of at least nine genes flanked by a repeated
sequence called the long terminal repeats (LTRs). These genes encode proteins that can
principally be divided into three categories: (1) major structural proteins – Gag, Pol and Env,
(2) regulatory proteins – Tat and Rev, (3) accessory proteins – Vpu, Vpr, Vif and Nef (Gallo
et al., 1988). These proteins are required at various stages of virus life cycle.
Structural proteins
The Gag (group-specific antigen) codes for Gag precursor protein (p55) which is
associated with cell membrane after post-translational modifications. Viral protease
processes this p55 to generate the following proteins: matrix protein (p17) – facilitates
nuclear transport of viral genome, capsid (p24) protein – forms conical core of the viral
particle, nucleocapsid (p9) – recognizes packaging signal and helps in reverse transcription,
and p6 protein – aids in interaction of p55 and vpr, and release of viral particles from
infected cells (Göttlinger et al., 1989; King, 1994; Lee et al., 2012). The pol gene expresses
four essential enzymes that include, reverse transcriptase – transcribes DNA from RNA
template, RNase H – facilitates complementary DNA strand synthesis by cleaving original
RNA template, integrase – required for integration of proviral DNA into the host genome,
protease – necessary to p55 protein (Lee et al., 2012). Furthermore, Env (for ‘envelope’)
codes for gp160 protein and this protein is glycosylated in the endoplasmic reticulum before
being processed by a cellular protease to produce gp41 and gp120 proteins. While gp41 acts
as an anchor in the viral envelope, gp120 mediates HIV-1 infection by interacting with CD4
receptor that is present on the lymphocytes (King, 1994; Merk and Subramaniam, 2013).
3

Regulatory proteins
Tat, an RNA-binding protein is absolutely required for the HIV-1 replication. Tat acts
as the transcriptional activator by interacting with transactivation response element (TAR) at
the 5’ terminus of HIV-1 RNA template (Ruben et al., 1989; Feinberg et al., 1991). Rev
(regulator of expression of virion proteins) is an RNA-binding protein that binds at Rev
response element (RRE) within the second intron of the HIV-1 genome. Rev is essential to
activate late genes and thus for synthesis of viral proteins to produce virions (Zapp and
Green, 1989; Vercruysse and Daelemans, 2014).
Accessory proteins
The other four viral genes such as Nef, Vpu, Vif and Vpr encode accessory proteins.
These proteins perform multiple functions at different stages of viral infection (Trono, 1995;
Strebel, 2013). It appears that they mostly work toward evasion of innate and adaptive
immune systems. Specifically, Nef and Vpu proteins manipulate the localization and
functional aspects of host cell membrane proteins. These alterations greatly influence viral
replication and also help the virus to escape the immunity shield. Vif and Vpr proteins
protect the virus by inhibiting cytoplasmic host defense molecules and by modifying host
cell intracellular environment.
1.1.2 HIV-1 TAT PROTEIN
Tat is a key early regulatory protein for viral gene expression and replication. It is a
small polypeptide encoded from two separate exons, length varies from 86 to 101 amino
acids depending on the viral strain (Ratner et al., 1985; Jeang et al., 1999). Tat protein has
been divided into five different protein domains. The first exon encodes the first four well
conserved domains that include acidic domain (residues 1-21), cysteine rich domain
4

(residues 22-37), hydrophobic core (residues 38-48) and basic domain (residues 49-72),
whereas sixth domain (residues 73-101) is encoded by second exon (Li et al., 2012). Clinical
isolates from HIV-infected patients’ display the presence of Tat1-101 or its truncated form,
Tat1-86 in different target organs (Jeang et al., 1999; Barré-Sinoussi et al., 2004; Strazza et al.,
2011). Besides its canonical function as a transcriptional activator, Tat is actively secreted
from infected cells and can be detected in cell culture supernatants, in serum and in
cerebrospinal fluid of HIV-1 infected individuals (Ensoli et al., 1990; Westendorp et al.,
1995; New et al., 1997; Bachani et al., 2013; Midde et al., 2013). Westendorp et al. (1995)
reported ~1 to 3 ng/mL and ~16 ng/mL of Tat levels in the plasma and the cerebrospinal
fluid (CSF) of HIV-1 infected patients respectively. Furthermore, another study using 80
anonymous HIV-1 positive patients’ sera found that soluble Tat levels range from 2 ng/ml to
40 ng/ml (Xiao et al., 2000). However, authors argued that these estimations may be lower
than the actual concentration present in the system (Westendorp et al., 1995; Xiao et al.,
2000). Although the precise Tat concentration in the brain is not yet known, one could
expect that this level to be markedly elevated in CSF than plasma because of close proximity
of HIV-1-infected cells in the brain (Hayashi et al., 2006). This secreted Tat can act as
neurotoxin by effecting bystander cells including neurons (Del Valle et al., 2000) . The
precise mechanism by which Tat damages neurons is not clear. However, it has been
suggested that Tat can interact with specific cell surface proteins or can be taken up by
neurons to manipulate intracellular signaling and trafficking events (Ensoli et al., 1990; Nath
et al., 2000a; Chang et al., 2011).
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1.1.3 EFFECT OF HIV-1 TAT PROTEIN ON DOPAMINERGIC NEURONS
DA, a key catecholamine neurotransmitter is involved in a variety of functions
including cognition, locomotion, reward and neuroendocrine secretion (Lyon et al., 2011;
Money and Stanwood, 2013). A plethora of investigations suggest that HIV-1 infection
damages DA-rich regions in the brain that include substantia nigra, caudate nucleus, basal
ganglia and globus pallidus. Interestingly, studies using animal models and human subjects
revealed that HIV-mediated damage to the DA neurons occurs at the early infection stage of
the disease (Lopez et al., 1999; Koutsilieri et al., 2002). Moreover, in vitro studies showed
that increased levels of DA enhances the replication of the virus in the infected lymphocytes
and macrophages (Scheller et al., 2000; Gaskill et al., 2009) and promotes oxidative stress
which subsequently causes neuronal death. In this backdrop, DAT, a crucial player to
maintain DA homeostasis in the brain, is central focus for this dissertation for the following
reasons (1) DAT is the primary regulator for the termination of the DA neurotransmission at
the synapse; (2) it has been reported that DAT density is strikingly reduced in HIV-1
infected patients and Tat protein inhibits DAT function (Wang et al., 2004; Chang et al.,
2008; Ferris et al., 2009a; Zhu et al., 2009); and (3) DAT is a major target for highly
addictive psychostimulants like cocaine and methamphetamines. Studies demonstrated that
HIV-1 viral protiens in concert with these abused drugs have additive or synergistic effects
to elevate the extracellular synaptic DA levels. This escalation of DA concentration leads to
increased viral load and DA metabolism which ultimately cause neuronal death (Nath et al.,
2000b; Gaskill et al., 2009; Gannon et al., 2011). While some investigators worked broadly
on connections of HIV-1 infection, dysregulation of the DA system and drugs of abuse,
limited studies have focused on the influence of Tat protein on DAT. This project is focused
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to understand the effects of Tat protein on structure and functional regulation of DAT.
Neurotoxic effects of Tat protein were first described in a study using neurblastoma
cells (Sabatier et al., 1991). Although these cells are not dopaminergic, they provided basic
idea of Tat protein interaction with the neurons and associated neurotoxicity. Application of
synthetic Tat to the striatal regions of rat brain in vivo causes deleterious effects on the
neurons (Hayman et al., 1993). Studies using Tat exposed cultured human fetal neurons and
microinjection of Tat into striatal neurons showed that Tat protein promotes neurotoxicity by
triggering inflammatory cascades that eventually induce neuronal death by apoptosis (New et
al., 1997; Jones et al., 1998; Zauli et al., 2000; Aksenov et al., 2001), suggesting that the
dopaminergic neurons are predominantly susceptible to Tat protein. Moreover, Tat protein
direct interaction with dopaminergic neurons increases intracellular calcium levels which in
turn activate the caspases and generation of reactive oxygen species leading to neuronal
injury (Kruman et al., 1998; Bonavia et al., 2001; Haughey and Mattson, 2002; Mattson et
al., 2005). Elevated levels of Tat mRNA have been detected in the brain tissue extracts of
HIV-1 infected patients (Wiley et al., 1996; Hudson et al., 2000) and these brain derived Tat
sequences showed mutations at second exon region (Bratanich et al., 1998; Cowley et al.,
2011), indicating that the Tat protein exhibits significant molecular diversity and this
heterogeneity may render the neuronal cells vulnerable to this protein. Extracellular Tat uses
neuronal transport to reach different anatomical pathways that are distant from viral
replication site (Bruce-Keller et al., 2003) and its passage to the spinal cord through
cerebrospinal fluid (Pocernich et al., 2005) clearly implicate secreted Tat as a major
contributor to HIV-1 associated dementia. Along these lines, an in vivo microdialysis study
showed compromised DA levels in the striatum of the Tat-treated animals (Ferris et al.,
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2009b). Specifically, Tat protein contributed to the alterations in the dopaminergic markers
expression levels that include tyrosine hydroxylase and dopamine receptor like-1 (Zauli et
al., 2000; Silvers et al., 2006; Silvers et al., 2007). Thus, the above findings suggest that Tat
protein directly or indirectly causes injury to dopaminergic pathways which are highly
correlated with the dementia and motor deficits observed in HIV-1 positive individuals (Fig.
1.1).
1.1.4 ANIMAL MODELS OF HIV-INFECTED BRAINS
Animal models for HAND are critical to understand the disease onset and
progression, and to develop and test adjunctive therapies along with retroviral drugs. Nonhuman primates such as chimpanzees are logical models to mimic HIV-1 infection and
disease progression due to their genetic similarities to humans (van Maanen and Sutton,
2003). However, financial considerations, maintenance, difficulty to obtain sufficient
numbers to achieve statistically significant outcomes and public apprehensions limit their use
in HAND research. Rodent models in contrast are extensively used to study HIV-1 and
associated neurological dysfunctions despite the need of quite challenging efforts to generate
disease in rodents because of species-specific nature of HIV-1 infection. These models offer
several advantages that include low cost, easy maintenance during housing and subsequent
experimental stage and well characterized genome that can be exploited to alter a particular
cell or region of interest (Gorantla et al., 2012). These models may be created by employing
several approaches that include stereotactic injection of viral proteins directly into the brain,
expressing viral transgenes in animals, and transplantation of infected human cells into
immunodeficient rodents (Van Duyne et al., 2009; Barreto et al., 2014).

8

In vivo mouse model was initially developed by introducing human neurofilament
promoter controlled the whole HIV-1 proviral DNA into a mouse genetic background
(Thomas et al., 1994). The transgene was expressed in anterior thalamic and spinal motor
neurons, and animals exhibited neurological complications both in central and peripheral
nervous systems. Another proviral mouse model that expresses gap-pol deleted mutant of the
HIV-1 full length genome demonstrated that viral proteins and accessory genes may be
sufficient to produce neurotoxicity and motor abnormalities observed in HIV-1 positive
patients (Santoro et al., 1994). Further studies showed that individual viral components that
include gp120/gp160, gp140, Tat, Nef, Vpr and Rev are capable of eliciting neurotoxicity in
the brain (Nath, 2002; Li et al., 2005). Efforts were made to determine the role of Tat and
gp120 in producing neurotoxic effects by direct injection of these proteins into the rodent
brains (Jones et al., 1998; Bansal et al., 2000).
In advanced approaches, transgenic models were generated by inserting gp120 or Tat
coding genes into the animal genome. Transgenic expression of HIV-1 env gene that encodes
for gp120 revealed that extracellularly released gp120 is neurotoxic and produces alterations
in neuronal and glial cells. These modifications are similar to the changes in HIV-1 infected
human brains (Toggas et al., 1994). These transgenic animals also showed impairment in
open filed activity and spatial reference memory in an age-dependent manner suggesting the
role of gp120 in cognitive and motor decline observed in HIV-1 positive patients (D'Hooge
et al., 1999). Another study created a transgenic mouse model that expresses Tat protein
under the control of both GFAP promoter and doxycycline (Dox) inducible promoter (Kim et
al., 2003). Interestingly, findings from these studies suggest that presence of Tat expression
is adequate to attain neuronal damage in the brain and this neurotoxicity is severe than that
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observed in gp120 transgenic animals (Toggas et al., 1994; Kim et al., 2003). Thus, these
transgenic animal models are quite useful to study the HIV-associated neuropathogenesis.
However, there are certain limitations to fully utilize these models to understand the HIV-1
mediated neurocognitive dysfunctions. For example, these models can replicate certain
features of the disease but do not represent the whole spectrum of neuropathology associated
with HIV-1 (Nath, 2010; Jaeger and Nath, 2012).
For the purpose of our project-2, to study whether HIV-1 viral proteins and nicotine
together produce molecular changes in mesolimbic structures that mediate psychomotor
behavior, we used HIV-1 transgenic (HIV-1 Tg) rat as small animal model that was
developed by reid et al. (2001). HIV-1 Tg rats are derived from Fisher344/ BHsd strain
and carry proviral DNA that is devoid of Gag and Pol genes. Expressing only seven of
nine HIV- 1 genes makes this model as noninfectious, and displays immune, motor and
behavioral abnormalities (Reid et al., 2001). Deficits in learning and cognition that are
associated with asymptomatic HIV-1 infection have been reported in these animals
(Vigorito et al., 2007; Lashomb et al., 2009). Observed dopaminergic alteration,
neuroinflammation and deficits in several synaptic proteins (Persidsky and Fox, 2007;
Webb et al., 2010; Rao et al., 2011) make HIV-1 Tg rat as a suitable animal model to
study the effects of HIV-1 viral proteins on nicotine induced behavioral sensitization and
associated signaling protein changes. Furthermore, HIV-1 Tg rats have also been
successfully employed to study the concerted effects of HIV-1 viral proteins and drugs of
abuse (Liu et al., 2009; Kass et al., 2010; Moran et al., 2012).
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1.2 DOPAMINE TRANSPORTER (DAT)
1.2.1 STRUCTURE AND FUNCTION
The DAT, a member of the Solute Carrier 6 family (SLCA3), comprises of 620
amino acids with 12 putative transmembrane domains with both amino and carboxy termini
located in the cytoplasmic side of the cells (Kristensen et al., 2011). The DAT, clears
extracellular DA via rapid reuptake, is a primary determinant for the regulation of DA
neurotransmission and maintaining DA homeostasis in the brain (Fig. 1.2). In addition to DA
transport, DAT can move endogenous trace amines tyramine and β-phenethylamine;
neurotoxin 1-methyl-4-phenylpyridinium (MPP+) and amphetamines (Sulzer, 2011) into
presynaptic terminal. Great insights into structure and function relations of DAT come from
the mutagenesis analysis, engineering of zinc binding sites, substituted-cysteine accessibility
method and homology modeling to bacterial leucine transporter LeuT, a prokaryotic
homolog of DAT (Kitayama et al., 1992; Javitch, 1998; Chen and Reith, 2000; Loland et al.,
2003; Loland et al., 2004; Lin and Uhl, 2005; Yamashita et al., 2005). DAT uses Na+ and Cldependent process to translocate DA back into dopaminergic neurons against its
concentration gradient. Active substrate translocation by DAT follows the alternating access
model (Jardetzky, 1966; Yamashita et al., 2005). This model suggests that the transporter
cycles through at least three conformational states: outward, occluded and inward, in order to
re-accumulate DA into cell interiors. Correspondingly, recent studies suggest that substrate
translocation is a dynamic process and it requires multiple interaction sites within DAT
(Schmitt and Reith, 2011; Shan et al., 2011).
Different chemical classes of ligands induce specific conformations in DAT to
achieve a particular physiological or behavioral effect. For example, cocaine-like inhibitors
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have inclination to outward facing conformation (Beuming et al., 2008; Reith et al., 2012)
whereas benztropine and related analogs preferentially interact with inward facing
conformation of the transporter (Loland et al., 2008; Schmitt and Reith, 2011). It is worth
noting that benztropine was established as an anticholinergic agent in the management of
Parkinson’s disease (Katzenschlager et al., 2003) and, it may also be used to treat
extrapyramidal reactions caused by use of antipshycotics (Teoh et al., 2002; González-Lugo
et al., 2010). Consistent with these findings, a recently solved X-ray crystal structure of DAT
shows that tricyclic antidepressant nortriptyline occupies the substrate binding site and
stabilizes the Drosophila melanogaster transporter in outward conformation and thus
preventing substrate translocation (Penmatsa et al., 2013). Substrate efflux or reversal of
transport is mechanistically distinct from the translocation process. Recent studies implied
that synthetic compounds like N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI20041) and point mutations at specific residues in DAT cause subtle alterations in the
transporter conformation which in turn have differential effects on inward transport and
efflux properties (Guptaroy et al., 2009; Rothman et al., 2009; Guptaroy et al., 2011). Thus,
conformational transitions in the transporter protein and associated structural changes
provide a basic framework for ligand binding and have a great impact on transport kinetics
and functionality of the DAT.
1.2.2 REGULATION
DAT regulation is a complex and vital process for the spatial and temporal
management of DA concentration in the brain. DAT mediated behavioral and physiological
functions are dynamically controlled by multitude of exogenous factors, macromolecules and
signaling cascades. Many of these check points work interactively while exerting their
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actions. Although there is a lack of complete understanding of regulation of DAT, available
information suggest that the diverse set of DAT-affecting molecules achieve their function
through ligand-transporter interactions, trafficking, post-translational modifications and
protein-protein interactions (Fig. 1.3). In recent years, several reviews comprehensively
presented extensive details about DAT regulation (Chen et al., 2010; Eriksen et al., 2010;
Schmitt and Reith, 2011; Vaughan and Foster, 2013) and for the purpose of this dissertation,
I briefly discuss some of these DAT regulatory processes that are relevant to HIV-1 Tat
protein and DAT interaction.
1.2.2.1 ALLOSTERIC MECHANISM DEPENDENT REGULATION
Initial evidence for the existence of allosteric binding site for DA, a modulatory
binding site on the transporter that is topographically distinct from the primary binding site
comes from molecular dynamics and simulation studies (Shi et al., 2008; Shan et al., 2011).
These studies suggest that direct interaction of substrates and ions at allosteric sites elicit
progressive rearrangements in the transporter structure that help to shift the conformational
state in order to transport substrate DA (Fig. 1.4). Furthermore, different structural classes of
DAT ligands that include tricyclic antidepressants and selective reuptake inhibitors have
been shown to influence this allosteric binding site (Zhou et al., 2007; Zhou et al., 2009).
Likewise, investigations conducted by schmitt and reith (2010) further supported the
presence of allosteric binding by using bivalent phenethylamines (two substrate like
molecules connected with aliphatic spacer) that act as potent inhibitor rather than substrate
molecule. In addition to the secondary binding site for DA, the existence of allosteric binding
sites for synthetic DAT ligands were reported (Pariser et al., 2008). According to this study,
N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenyl ethyl)-213

phenyl-4-quinazolinamine (SoRI-20040), and SoRI-20041 compounds inhibit the binding of
[125I]3beta-(4'-iodophenyl) tropan-2beta-carboxylic acid methyl ester ([125I]RTI-55) by
following allosteric inhibitory patterns, meaning that these compounds do not follow
classical dose dependent competitive inhibition paradigm irrespective of the concentration of
[125I]RTI-55. These modulators also slowed down the dissociation rate of prebound
[125I]RTI-55 and presented a decrease in Bmax and increase in Kd values for [125I]RTI-55
binding, further confirming the allosteric binding of these 4-quinazolinamine derivatives
with the DAT. Taken together, these investigations strongly imply that various ligands
allosterically regulate local rearrangements in the structural elements of the DAT that finally
contribute to the formation of functionally unique conformation of the transporter to achieve
targeted function.
1.2.2.2 TRAFFICKING AND POST-TRANSLATIONAL DEPENDENT REGULATION
Post-translational modifications, in particular phosphorylation of the transporter or its
binding partners are the key strategy for controlling the function and distribution of the
transporter. Numerous studies have showed that DAT trafficking to and away from plasma
membrane is precisely regulated by various protein kinases that include protein kinase C
(PKC), Ca2+/calmodulin kinase, phosphoinositide 3-kinase, protein tyrosine kinase and
members of mitogen-activated protein kinase (MAPK) family (Foster et al., 2006;
Ramamoorthy et al., 2011). Of these, PKC-mediated processes are most well characterized.
Activation of PKC causes decrease in Vmax without effecting Km value by directing active
transporter population to intracellular regions (Melikian, 2004). This mode of internalization
controls short and long-term availability of the transporter on the surface. While acute
endocytic regulation targets DAT to early and recycling endosomes, long-term endocytosis
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triggers lysosomal degradation of the protein (Chen et al., 2010; Rao et al., 2011; Hong and
Amara, 2013; Sorkina et al., 2013). Interestingly, it has also been reported that PKCstimulated direct phosphorylation of DAT does not require for internalization (Granas et al.,
2003; Pramod et al., 2013) indicating the involvement of accessory proteins for the
regulation of DAT endocytosis. Correspondingly, protein-protein interactions have been
implicated as the crucial regulators that dictate DAT function (Eriksen et al., 2010; Sager and
Torres, 2011). For example membrane raft protein Flotillin-1/Reggie-1 (Flot-1) has been
shown to be required for the PKC-mediated internalization of DAT (Cremona et al., 2011).
Besides eliciting DAT endocytosis, PKC also induces DAT down regulation in the presence
of endocytotic blockers (Foster et al., 2008; Foster and Vaughan, 2011), indicating
phosphorylation led intrinsic kinetic alterations in the transporter. On the other hand, MAPK
family kinases enhance the functionality of the DAT by potentially phosphorylating serine
and threonine residues in the transporter (Schmitt and Reith, 2010; Vaughan and Foster,
2013). Overall, these studies reveal that a plethora of convergent and divergent pathways
regulate DAT activities: substrate translocation, substrate efflux and ion conductance
through alterations in conformational states and endocytosis of the transporter.
1.2.3 DAT AND HIV-1 TAT PROTEIN
The apparent indirect evidence for dysregulation of the DAT in HIV-1 positive
patients comes from reduced DA levels observed in infected brains. Decreased DA and its
major metabolite homovanillic acid (HVA) were observed in post mortem brain samples and
CSF (Larsson et al., 1991; Berger et al., 1994; Sardar et al., 1996; Kumar et al., 2009). These
DA deficits differ from region to region in the brain, however, greater neuronal loss is
associated with dopaminergic neurons especially at the subcortical area. These claims were
15

further substantiated by imaging studies and neuropsychological performance tests (Aylward
et al., 1993; Kieburtz et al., 1996; Kumar et al., 2011). Although the above studies do not
explain the underlying mechanism of HIV-infection and impairment of DA system, the
possible explanation would be dysregulation of DAT that results from HIV-1 viral proteins.
Because HIV-1 viral proteins load is usually peak in the dopaminergic rich areas, where the
highest density of DAT protein is situated, it is reasonable to hypothesize that Tat protein
impairs DAT function to promote neuronal injury. However, we cannot exclude the
possibility of involvement of other HIV-1 neurotoxic proteins like coat glyco protein gp120,
HIV-induced host chemokines and free radicals for the loss of dopaminergic neurons
(Purohit et al., 2011). Indeed, significantly reduced DAT levels were reported in HIV-1
associated dementia patients’ using positron emission tomography (Wang et al., 2004;
Sporer et al., 2005; Chang et al., 2008). In contrary to these imaging studies, a recent
biochemical characterization on human brain specimen collected from HIV-1 encephalitis
subjects demonstrated elevated levels of DAT protein (Gelman et al., 2006). Furthermore, a
single photon emission tomography imaging on treatment naïve HIV-1 patients showed
enhanced DA levels with no change in the DAT density (Scheller et al., 2010). These
contradictory outcomes for DAT levels suggest that the stage of the disease, treatment
condition of the patient and host as well as viral factors may play a defining role in
dopaminergic neuronal degeneration. Taken together, these findings indicate the altered
regulation of DAT function in HIV-1 infected individuals. Although these studies clearly
show the pivotal role of DAT in Tat-induced DA system impairment, mechanisms
underlying alterations in the DAT activity remain elusive.
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1.3 OBJECTIVES OF THE RESEARCH
The overall objective of this research is to understand how Tat protein interacts with
DAT at specific recognition sites and thereby modulating transporter structure-function
coordination in DA translocation process. This study provides valuable information of Tat
binding residues and mechanistic understanding of Tat action on DAT at the molecular level,
which is important to study Tat induced DA deficits in the animal models. This project seeks
to delineate structural and molecular basis of how Tat protein interacts with DAT through
conceptual and technical innovations. First, this work aims to address the novel concept of
allosteric influence of Tat on DAT via interaction at specific binding sites. Second, our study
is technically innovative because combining computational modeling and neuropharmacology represent a novel approach that allowed us to define potential Tat interacting
residues on DAT. While previous studies broadly established Tat mediated dysfunction of
the DAT, they have fallen short in precisely locating the molecular determinants of Tat
recognition sites on DAT. This is the first time that this state-of-art-technique, integrated
with conventional approaches was used to determine Tat and DAT protein interaction. We
also employed molecular biological and cell surface biotinylation techniques to answer the
fundamental question how Tat protein controls dynamic surface expression and trafficking of
the DAT. Findings of this work lay a platform to study the relationship between Tat
interaction and associated changes in DAT structure-function, and open the door to rational
drug development to treat cognitive and motor deficits associated with neuroAIDS.
1.4 SPECIFIC AIMS
Our lab previously reported that Tat inhibits DAT function and that inhibition is due
to a protein-protein interaction (Zhu et al., 2009). Recently, we have also demonstrated that
Tat protein allosterically inhibits DAT function and influences cocaine binding sites on DAT
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(Zhu et al., 2011). Moreover, our preliminary three dimensional computational modeling
predicts that amino acid Tyr470 of human DAT is an important residue for favorable
intermolecular interaction between DAT and HIV-1 Tat. Our initial pharmacological data for
Tyr470His (Y470H) mutant DAT revealed significant attenuation of Tat-induced effects on
DA uptake without changes in the binding affinity of DA to the DAT. This is consistent
with the observed attenuated effects of Cys22Gly mutant Tat on DA transport (Zhu et al.,
2009). Collectively, these observations ascertain the critical role of recognition sites for Tatmediated influence on DAT structure and function.
Therefore, we hypothesized that HIV-1 Tat protein via allosteric modulation of
DAT induces inhibition of DA transport, leading to dysfunction of the DA system. This
central hypothesis was tested with the specific aims outlined below.
Aim 1: To create and validate computational modeling predicted HIV-1 Tat recognition sites
(Y88, K92 and Y470) on human DAT. (Chapter 2 and 3)
Aim 2: To determine whether Tat has any influence on the trafficking and phosphorylation
dependent regulation of DAT. (Chapter 4)
In addition to the above stated aims, the findings from my second project, combined
effects of HIV-1 viral proteins and nicotine on nicotine-induced behavioral sensitization and
associated changes in the expression of intracellular signaling proteins were described in
Chapter 5. Finally, Chapter 6 provides overall summary and conclusions for the dissertation
followed by the future directions for this research.
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Figure 1.1 Overview of HIV-1 Tat and cocaine synergistic or additive effects on dopamine
neurotransmission in HIV-1 infected individuals. HIV-1 penetrates the brain at the early
infection stage and infects macrophages and microglial cells. These cells exude viral proteins
that including Tat and other neurotoxic factors. Cocaine, a major psycho stimulant blocks
DAT to inhibit DA translocation. Both Tat and cocaine elevate synaptic DA levels by
inhibiting DA reuptake into presynaptic terminal. This increased DA induces further
replication of virus in infected cells. Persistent exposure to the viral proteins, oxidative stress
induced by increased DA levels and other chemokines aggravate the severity of the
neurocognitive deficits in HIV-1 positive population.
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Figure 1.2 DAT is localized to the presynaptic terminal of the dopaminergic neurons. It
regulates the DA availability at the synapse by rapid reuptake into the terminal. In addition to
the DA, amphetamine and MPP+ (1-methyl-4-phenylpyridinium) act as substrates for DAT.
Selective pharmacological inhibitors for DAT such as cocaine, GBR12909, WIN 35,428 and
RTI-121 were also shown. The image was taken from Torres et al. (2003).
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Figure 1.3 Illustration of potential regulatory pathways that control the function and
availability of the DAT. (A) The surface localization of DAT is maintained by trafficking
and endocytosis to and from the surface of the membrane. (B and C) Direct interaction of
small molecules such as substrates and inhibitors may modulate the function of the DAT
through conformational alterations. (D) Phosphorylation of DAT or its accessory proteins
controls the catalytic activity of the transporter by influencing protein kinase signaling
cascades. (E) Activation of G-protien coupled receptors and (F) direct interaction with D2like autoreceptors modulate the DAT function. (G) Post-translational modification such as
ubiquitination of the DAT also dictates the number of active transporter molecules on the
presynaptic plasma membrane. The figure was obtained from Schmitt and Reith (2010).

21

Figure 1.4 Model of substrate translocation cycle for DAT. Binding of the ions primes
substrate-free (apo) DAT to fully stabilized outward-facing conformation with an open
extracellular gate to bind to the substrate DA. Substrate binding at the S1 binding site
promotes the formation of an occluded state and closure of the extracellular gate. Binding of
a second substrate molecule at the S2 site induces the opening of an intracellular gating
network leading to release of the S1-bound substrate from the inward-facing state of the
DAT. The image was taken from Schmitt et al. (2013).
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CHAPTER 2
MUTATION OF TYROSINE 470 OF HUMAN DOPAMINE TRANSPORTER IS CRITICAL
FOR HIV-1 TAT-INDUCED INHIBITION OF DOPAMINE TRANSPORT AND
TRANSPORTER CONFORMATIONAL TRANSITIONS1

ABSTRACT: HIV-1 Tat protein plays a crucial role in perturbations of the dopamine (DA)
system. Our previous studies have demonstrated that Tat decreases DA uptake, and
allosterically modulates DA transporter (DAT) function. In the present study, we have
found that Tat interacts directly with DAT, leading to inhibition of DAT function.
Through computational modeling and simulations, potential recognition binding site of
human DAT (hDAT) for Tat was predicted. Mutation of tyrosine470 (Y470H) attenuated
Tat-induced inhibition of DA transport, implicating the functional relevance of this
residue for Tat binding to hDAT. Y470H reduced the maximal velocity of [3H]DA uptake
without changes in the Km and IC50 values for DA inhibition of DA uptake but increased
DA uptake potency for cocaine and GBR12909, suggesting that this residue does not
overlap with the binding sites in hDAT for substrate but critical for these inhibitors.
Furthermore, Y470H also led to transporter conformational transitions by affecting zinc
modulation of DA uptake and WIN35,428 binding as well as enhancing basal DA efflux.
Midde NM, Huang X, Gomez AM, Booze RM, Zhan CG, Zhu J (2013) Mutation of tyrosine
470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine
transport and transporter conformational transitions. Journal of neuroimmune pharmacology : the
official journal of the Society on NeuroImmune Pharmacology 8:975-987. PMCID:PMC3740080
1
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Collectively, these findings demonstrated Tyr470 as a functional recognition residue in
hDAT for Tat-induced inhibition of DA transport and transporter conformational
transitions. The consequence of mutation at this residue is to block the functional binding
of Tat to hDAT without affecting physiological DA transport.
2.1 INTRODUCTION
The estimated prevalence of HIV-1-associated neurocognitive disorders (HAND)
is about 70% of HIV-1 positive individuals with antiretroviral therapy (Robertson et al.,
2007; Tozzi et al., 2007; Ernst et al., 2009). Cocaine has been shown to increase the
incidence and exacerbate the severity of HAND by enhancing viral replication (Nath et
al., 2001; Ferris et al., 2008). Antiretroviral agents cannot prevent the production of HIV1 viral proteins, such as Tat protein, in HIV-1 infected brains in the early stage of HIV-1
infection (McArthur et al., 2010; Nath and Clements, 2011). Tat has been detected in the
brains (Del Valle et al., 2000; Hudson et al., 2000; Lamers et al., 2010) and the sera
(Westendorp et al., 1995; Xiao et al., 2000) of HIV-1 infected patients. Furthermore, Tat
interacting with cocaine exacerbates the progression of the neurocognitive impairment
(Buch et al., 2011; Gannon et al., 2011).
Accumulating clinical evidence supported by imaging (Chang et al., 2008; Meade
et al., 2011a), neurocognitive (Kumar et al., 2011; Meade et al., 2011b), and postmortem
examinations (Kumar et al., 2009; Gelman et al., 2012), reveals that abnormal
neurocognitive function observed in HAND is associated with dysfunctions in dopamine
(DA) neurotransmission (Berger and Arendt, 2000; Purohit et al., 2011). The DA
transporter (DAT) terminates DA signaling and thus is central to control synaptic
dopaminergic tone (Torres and Amara, 2007). DAT activity is strikingly reduced in HIV24

1-infected patients with a history of cocaine use (Wang et al., 2004; Chang et al., 2008).
We have demonstrated that Tat allosterically modulates DAT function and reduces DAT
cell surface expression in rat striatal synaptosomes (Zhu et al., 2009; Zhu et al., 2011;
Midde et al., 2012).
Viral replication within HIV-1 infected brain regions results in Tat release, which
elevates DA levels via inhibiting DAT function (Gaskill et al., 2009). Exposure of HIV-1
infected patients to cocaine further impairs DAT function and increases synaptic DA
levels (Ferris et al., 2010). Importantly, the elevated DA induced by Tat and cocaine
stimulates viral replication and Tat release (Gaskill et al., 2009), which has been
implicated in the neuropathogenesis of HAND (Li et al., 2009). Considering oxidative
stress-induced damage to dopaminergic neurons, long lasting exposure to viral proteins
and elevated DA eventually lead to a DAT deficit that potentiates severity and accelerates
the progression of HAND (Purohit et al., 2011). To the best of our knowledge, the
mechanisms of Tat and cocaine interaction with hDAT have been virtually unexplored. In
order to explore the molecular mechanism(s) underlying the interplay of Tat with cocaine
in disrupting DAT-mediated DA neurotransmission, we performed computational
modeling and simulations to predict potential recognition binding sites of human DAT
(hDAT) for Tat. Identifying the functional recognition residues in hDAT for Tat may
provide therapeutic insights into HAND in concurrent cocaine abusers. Upon prediction
and validation of the functional relevance of tyrosine 470 (Tyr470) in hDAT, we
determined the mechanisms that underlie mutation of Tyr470 in Tat-induced inhibition of
DA transport and transporter conformational transitions.
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2.2 MATERIALS AND METHODS
2.2.1 CONSTRUCTION OF PLASMIDS
Plasmid pcDNA3.1+/Tat1-72 that encodes Tat1-72 protein was provided by Dr.
Avindra Nath (NINDS/NIH). Plasmid GFP-tagged Tat1-86 was a gift from by Dr. Mauro
Giacca (Molecular Medicine Laboratory, ICGEB, Italy). Plasmids pcDNA3.1+/Tat1-101
that encodes Tat1-101 protein was provided by NIH AIDS Reagent Program. Mutation in
hDAT (tyrosine to histidine, Y470H-hDAT) was generated based on WT hDAT sequence
(NCBI, cDNA clone MGC:164608 IMAGE:40146999) by site-directed mutagenesis.
Synthetic cDNA encoding hDAT subcloned into pcDNA3.1+ (provided by Dr. Haley E
Melikian, University of Massachusetts) was used as a template to generate Y470H-hDAT
using QuikChange™ site-directed mutagenesis Kit (Agilent Tech, Santa Clara CA). The
sequence of the mutant construct was confirmed by restriction enzyme mapping and
DNA sequencing.
2.2.2 CELL CULTURE AND DNA TRANSFECTION
CHO cells (ATCC #CCL-61) were maintained in F12 medium supplemented with
10% fetal bovine serum (FBS) and antibiotics (100 U/ml penicillin and 100 µg/mL
streptomycin) at 37°C in a 5% CO2 incubator. For hDAT transfection, cells were seeded
into 24 well plates at a density of 1×105 cells/cm2. After 24h, cells were transfected with
WT or mutant DAT plasmids using Lipofactamine 2000 (Life Tech, Carlsbad, CA). Cells
were used for the experiments after 24 h of transfection.
2.2.3 CO-IMMUNOPRECIPITATION (CO-IP) OF DAT AND TAT
To determine whether Tat directly binds to DAT, Co-IP of Tat and DAT assays
were performed in rat synaptosomes after exposure to recombinant Tat1-86 as described
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previously (Li et al., 2008). In brief, rat anti-DAT antibody (6 µg, MAB369, Millipore,
Temecula, CA) was incubated with 20 μl protein A/G agarose beads (SC2003, Santa
Cruz Biotechnology Inc., Santa Cruz, CA) for 5-6 h at 4°C with constant rotating and
were centrifuged at 8,000 g for 5 min. The agarose-anti DAT antibody complex was
washed five times with immunoprecipitation buffer (1% Triton X-100, 150 mM NaCl, 10
mM Tris, 1 mM EDTA, 1 mM EGTA, 0.2 mM sodium ortho-vanadate, 0.2 mM PMSF,
0.5% NP-40) to remove the unbound antibody. Rat synaptosomes from striatum and
cerebellum, and spleen homogenates were prepared as described previously (Zhu et al.,
2009) and adjusted to equal protein concentration (1.5 mg/ml) using the Bradford protein
assay (Bradford, 1976). Then, aliquots (500 µg) of synaptosomes or homogenates were
incubated in Krebs-Ringer-HEPES (KRH) buffer (final concentration in mM: 125 NaCl,
5 KCl, 1.5 MgSO4, 1.25 CaCl2, 1.5 KH2PO4, 10 D-glucose, 25 HEPES, 0.1 EDTA, 0.1
pargyline, and 0.1 L-ascorbic acid; pH 7.4) containing recombinant Tat1-86 (350 nM, final
concentration, Clade B, # REP0002a, DIATHEVIA, Fano, Italy) for 1 h at room
temperature and were then centrifuged at 8,000 g for 5 min. The resulting pellets were
washed 5 times with KRH buffer. The pellets were resuspended and added to the
agarose-antibody complex and incubated with agitation at 4°C overnight. These samples
(agarose-antibody-protein complex) were centrifuged at 8,000 g for 1 min and the
resulting pellets were washed with immunoprecipitation buffer for 5 times. These
samples were then mixed with 2 × Laemmli sample buffer and boiled for 5 min. To
detect immunoreactivity of DAT or Tat protein, the samples were then subjected to
Western blotting with either goat polyclonal DAT antibody (1:200, Cat # SC-1433, Santa
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Cruz Biotechnology Inc., Santa Cruz, CA) or mouse anti HIV-1 Tat (1:1000, Cat #
ab24778, Abcam, Cambridge, MA ) using our published method (Zhu et al., 2009).
2.2.4 GST-PULL-DOWN ASSAY
To confirm whether Tat interacts with DAT through a protein-protein interaction,
GST-Tat fusion protein was used as bait for pull-down DAT to show their interaction as
described previously (Li et al., 2008). In brief, BL21 E. coli expressing pGEX-Tat1-86
(obtained from Dr. Virginie W Gautier, University College Dublin, Ireland) and GST
only (as negative control) were grown in liquid culture media and induced GST protein
expression by 100 mM IPTG. These GST proteins were added to glutathione sepharose
beads (17-0756-01, GE Healthcare) and then incubated with the cell lysates from CHO
cells transfected with hDAT. The beads were washed with the immunoprecipitation
buffer described above and mixed with protein sample buffer. The eluted proteins were
subjected to immunoblotting with anti-DAT antibody (Cat # sc-1433, Santa Cruz
Biotechnology Inc., Santa Cruz, CA).
2.2.5 PREDICTING THE SITE FOR HDAT BINDING WITH TAT
The binding structure of hDAT with HIV-1 clade B type Tat was modeled and
simulated based on the nuclear magnetic resonance (NMR) structures of Tat (Peloponese
et al., 2000) and the constructed structure of DAT(DA), as reported previously (Huang
and Zhan, 2007; Huang et al., 2009). Briefly, Brownian dynamics (BD) simulations were
performed to obtain the initial binding structure of the hDAT-Tat complex. Starting from
the available 11 NMR structures of Tat, the BD simulations were launched from a
spherical surface around the extracellular side of hDAT, and the electrostatic interaction
energy was calculated for each BD trajectory by multiplying the electrostatic potential of
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hDAT with the atomic charges of Tat. The initial complex for hDAT binding with Tat
was identified from the BD trajectories, with the lowest interaction energy and the best
geometric matching quality. The identified initial hDAT-Tat complex structures were
energy-minimized in the same way as described in our previous studies on hDAT binding
with DA and cocaine (Huang and Zhan, 2007; Huang et al., 2009). Molecular dynamics
(MD) simulations were performed to further relax and equilibrate the energy-minimized
structure of the hDAT-Tat binding complex. Finally, the MD-simulated hDAT-Tat
binding structure was energy-minimized and analyzed.
2.2.6 PREPARATION OF RELEASED TAT FROM TAT-EXPRESSING CELLS
To generate released Tat from Tat-expressing cells, CHO cells were seeded into
60 mm plates at a density of 1 × 106/cm2. After 24 h, cells were transfected with different
amounts (5 and 10 µg) of plasmid DNAs for Tat1-72, GFP-tagged Tat1-86 and Tat1-101 using
Lipofactamine 2000. Cells transfected with pcDNA3.1+ were used as a negative control.
After transfection, culture media from Tat- transfected cells were collected at 24, 48 and
72 h.
2.2.7 [3H]DA UPTAKE ASSAY
Twenty four hours after transfection, [3H]DA uptake in CHO cells transfected
with wild type hDAT (WT hDAT) and Y470H-hDAT was performed in KRH buffer
using a modified procedure as reported previously (Zhu et al., 2009). To determine
whether mutated hDAT alters the maximal velocity (Vmax) or Michaelis-Menten constant
(Km) of [3H]DA uptake, kinetic analyses were conducted in WT hDAT versus Y470HhDAT in the presence or absence of recombinant Tat1-86. To generate saturation
isotherms, [3H]DA uptake was conducted in duplicate wells containing one of six
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concentrations of unlabeled DA (final DA concentrations, 1.0 nM–5 µM) and a fixed
concentration of [3H]DA (500,000 dpm/well, specific activity, 31 Ci/mmol; PerkinElmer
Life and Analytical Sciences, Boston, MA). In parallel, nonspecific uptake of each
concentration of [3H]DA (in the presence of 10 µM nomifensine, final concentration) was
subtracted from total uptake to calculate DAT-mediated uptake. To determine the effect
of Tat on DA uptake, cells transfected with WT or Y470H-hDAT were preincubated with
each concentration of [3H]DA in the presence or absence of the concentrations of
released Tat or Tat1-86 (350 nM). The reaction was terminated by washing twice with ice
cold uptake buffer. Cells were solubilized in 1% SDS and radioactivity was measured
using a liquid scintillation counter (model Tri-Carb 2900TR; PerkinElmer Life and
Analytical Sciences, Waltham, MA). Kinetic parameters (Vmax and Km) were determined
using Prism 5.0 (GraphPad Software Inc., San Diego, CA).
For the competitive inhibition experiment, assays were performed in duplicate in
a final volume of 500 µl. Cells in each well were incubated in 450 µl buffer containing 50
µl one of final concentrations of unlabeled DA (1 nM-1 mM), GBR12909 (1 nM-10 µM),
cocaine (1 nM-1 mM), and ZnCI2 (10 µM) at 37°C for 10 min and [3H]DA uptake was
determined by addition of 50 µl of [3H]DA (0.1 µM, final concentration) for an additional
5 min.
2.2.8 IMMUNODEPLETION
Released Tat was prepared as described above. Seventy-two hours after
transfection with Tat1-72 plasmid, aliquots (500 μl) of the conditioned media were
incubated with mouse anti-Tat antibody (1:200, # ab6539, Abcam, Cambridge, MA) at
4°C for 2 h on a shaking platform, followed by incubation with 20 μl of Protein A/G –
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PLUS Agarose beads (# SC2003, Santa Cruz Biotechnology Inc., Santa Cruz, CA) at 4°C
for 2 h. After incubation, the agarose-antibody-Tat complex was pelleted at 12,000g for
2 min at 4°C and supernatants were collected. For the immunodepletion assay, CHO cells
transfected with hDAT were incubated with either Tat-conditioned media or supernatant
at 37°C for 2 h, followed by [3H]DA uptake assay, as described above.

Anti-Tat

antibody specificity for the Tat protein was determined by using mouse IgG1 kappa
monoclonal antibody (1:200, # ab18447, Abcam, Cambridge, MA) as an isotype control.
2.2.9 CELL SURFACE BIOTINYLATION
To determine whether decreased DA uptake in Y470H-hDAT is due to a
reduction of cell surface DAT, biotinylation assays were performed, as described
previously (Zhu et al., 2005). CHO cells expressing hDAT and Y470H-hDAT were
plated on 6 well plates at a density of 105 cells/well. Cells were incubated with 1 ml of
1.5 mg/ml sulfo-NHS-SS biotin (Pierce, Rockford, IL) in PBS/Ca/Mg buffer (In mM:
138 NaCl, 2.7 KCl, 1.5 KH2PO4, 9.6 Na2HPO4, 1 MgCl2, 0.1 CaCl2, pH 7.3). After
incubation, cells were washed 3 times with 1 ml of ice-cold 100 mM glycine in
PBS/Ca/Mg buffer and incubated for 30 min at 4°C in 100 mM glycine in PBS/Ca/Mg
buffer. Cells were then washed 3 times with 1 ml of ice-cold PBS/Ca/Mg buffer and then
lysed by addition of 500 ml of Triton X-100, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM
pepstatin, 250 µM phenylmethysulfonyl fluoride), followed by incubation and continual
shaking for 20 min at 4 °C. Cells were transferred to 1.5 ml tubes and centrifuged at
20,000g for 20 min. The resulting pellets were discarded, and 100 µl of the supernatants
was stored at -20 °C for determination of immunoreactive total DAT. Remaining
supernatants were incubated with continuous shaking in the presence of monomeric
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avidin beads in Triton X-100 buffer (100 µl/tube) for 1 h at room temperature. Samples
were centrifuged subsequently at 17,000g for 4 min at 4°C, and supernatants (containing
the nonbiotinylated, intracellular protein fraction) were stored at -20°C. Resulting pellets
containing the avidin-absorbed biotinylated proteins (cell-surface fraction) were
resuspended in 1 ml of 1.0% Triton X-100 buffer and centrifuged at 17,000g for 4 min at
4°C, and pellets were resuspended and centrifuged twice. Final pellets consisted of the
biotinylated proteins adsorbed to monomeric avidin beads. Biotinylated proteins were
eluted by incubating with 50 µl of Laemmli sample buffer for 20 min at room
temperature. If further assay was not immediately conducted, samples were stored at -20
°C.
2.2.10 [3H]WIN 35,428 BINDING ASSAY
For the competitive inhibition experiment, cells transfected hDAT and Y470HhDAT were incubated in KRH buffer containing 50 µl of [3H]WIN 35,428 (5 nM, final
concentration, specific activity, 85 Ci/mmol) and ZnCI2 (10 µM) using our published
method (Zhu et al., 2009). The reaction was terminated by washing twice with ice cold
KRH buffer. Nonspecific binding at each concentration of [3H]WIN 35,428 was
determined in the presence of 30 µM cocaine (final concentration).

Cells were

solubilized in 1% SDS and radioactivity was measured using a liquid scintillation
counter.
2.2.11 DA EFFLUX ASSAY
Basal efflux from CHO cell transfected with hDAT or mutated hDAT was
measured, as described previously (Guptaroy et al., 2009). Cells were incubated in 24
well plates at a density of 105 cells/well for 24 h before assays were washed 3 times with
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KRH buffer and preloaded with [3H]DA (0.05 µM, final concentration) for 20 min at
room temperature. After loading, cells were washed 3 times with KRH buffer. To obtain
an estimate of the total amount of [3H]DA in the cells at the zero time point, cells from a
set of wells (four wells/sample) were lysed rapidly in 1% SDS after preloading with
[3H]DA. Buffer (500 µl) was added into separate set of cell wells and transferred to
scintillation vials after 1 min as fractional efflux at 1 min, and another 500 µl buffer was
added to the same wells (where the buffer was just removed for 1 min point) and
collected to vials after 10 min. Additional fractional efflux at 20, 30, 40 and 50 min,
respectively, was repeated under the same procedure. After 40 or 50 min, cells were lysed
and counted as total amount of [3H]DA remaining in the cells from each well. To
determine whether exposure to Tat alters basal DA efflux, CHO cells transfected with
hDAT were incubated with Tat- conditioned media from Tat-transfected cells collected at
72 h after transfection at 37°C for 2 h, followed by DA efflux assay.
2.2.12 DATA ANALYSIS
Descriptive statistics and graphical analyses were used as appropriate. Results are
presented as mean ± SEM, and n represents the number of independent experiments for
each experiment group. IC50 values for DA, cocaine and GBR12909 inhibiting specific
[3H]DA uptake were determined from inhibition curves by nonlinear regression analysis
using a one-site model with variable slope. Kinetic parameters (Vmax or Km) of [3H]DA
uptake were determined from saturation curves by nonlinear regression analysis using a
one-site model with variable slope. For experiments involving comparisons between
unpaired samples, unpaired Student’s t test was used to assess any difference in the
kinetic parameters (IC50, Vmax or Km) between WT and mutant; log-transformed values of
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IC50 or Km were used for the statistical comparisons. Significant differences between
samples were analyzed with separate ANOVAs followed by post-hoc tests, as indicated
in the results Section of each experiment. All statistical analyses were performed using
IBM SPSS Statistics version 20, and differences were considered significant at p, < 0.05.
2.3 RESULTS
2.3.1 TAT PROTEIN DIRECTLY BINDS TO hDAT
Exposure of rat striatal synaptosomes to Tat protein inhibits DA uptake (Zhu et
al., 2009). To determine whether Tat protein directly binds to DAT, we performed Co-IP
of hDAT and Tat assays. As depicted in Fig. 2.1A, recombinant Tat1-86 bound to Tat
antibody was able to immunoprecipitate hDAT in rat striatal synaptosomes but not in
spleen and cerebellum where the density of DAT was low. To confirm this finding, we
also used GST-Tat fusion protein (as bait) to pull down hDAT to show their interaction.
Figure 2.1B shows that GST-Tat1-86 bound to hDAT protein. These data strongly suggest
that the influence of Tat on DAT function involves a protein-protein interaction between
Tat and DAT, which provides an experimental base for us to perform the following
computational modeling analysis of the bindings between Tat and hDAT.
2.3.2 BINDING STRUCTURE OF hDAT WITH HIV-1 TAT
The energy-minimized binding structure of hDAT with Tat following the MD
trajectory was shown in Fig. 2.1C and 1D. Tat protein is located on the gate of the
vestibule of hDAT(DA). A loop (formed from residues #19 to #22) of Tat is plunged into
the vestibule of hDAT(DA), blocking the central pore of the substrate-entry tunnel of
hDAT(DA). Tat and DAT molecules bind with each other through both electrostatic
interactions and shape complementarity. Particularly, the side chain of Cys22 (C22) of
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Tat is located inside the vestibule of hDAT(DA), contacting closely with the side chain of
Tyr470 residue of hDAT and Lys19 (K19) side chain of Tat. The positively charged head
group of Lys19 side chain of Tat is hydrogen-bonded with the hydroxyl oxygen on
Tyr470 side chain of hDAT(DA). The positively charged side chain of Lys19 also
interacts with the aromatic side chain of Tyr470 through the cation-π interaction; the
modeled distance between the N atom of Lys19 side chain and the center of the aromatic
ring of Tyr470 side chain of hDAT(DA) is 4.55 Å. Based on the modeled hDAT-Tat
complex structure, we predicted that residue Tyr470 is critical for the hDAT binding for
Tat.
2.3.3 EXTRACELLULARLY RELEASED TAT IS MORE POTENT THAN RECOMBINANT TAT IN
INHIBITING hDAT FUNCTION
Most previous studies of Tat-induced inhibition of DAT function have been
performed using recombinant Tat. To mimic the nature of Tat released from HIV-1
infected cells, we have established a technique to ensure that clade B type Tat can be
released from Tat-expressing cells and the effects of released Tat on DA uptake were
examined. CHO cells were transfected with different amount of plasmid Tat1-72, GFPtagged Tat1-86, and Tat1-101 DNA, and subsequently the conditioned media from these
transfected cells were collected as a source of released Tat. The estimated amount (~1
ng/ml) of released Tat in culture media was measured by the density of immunoreactive
bands and quantitated by comparison to a known amount of recombinant Tat1-86.
To determine the effects of released Tat on DA uptake, we first performed the
concentration and time-dependent studies for released Tat. Different amounts of released
Tat from conditioned media collected at 24, 48 and 72 h were tested in [3H]DA uptake in
CHO expressing hDAT. A maximal effect of released Tat on DA uptake was observed
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when 100 µl conditioned media collected at 72 h were used (data not shown). As shown
in Fig. 2.2A, released Tat from cells transfected with Tat1-72, Tat1-86 or Tat1-101 produced a
similar magnitude of change from control in [3H]DA uptake (F(3, 12) = 29.6; p < 0.01, oneway ANOVA with Dunnett’s Multiple comparison test), suggesting that Tat1-72, Tat1-86
and full length Tat1-101 exhibit an equal ability in Tat-induced inhibitory effect on DA
transport. We next determined whether the inhibitory effect on DA uptake was specific
for released Tat by immunodepletion assay (Fig. 2.2B). Exposure to released Tat (1
ng/ml) produced a significant reduction (31 ± 2.7%) of specific [3H]DA uptake compared
to the control (media collected from cells transfected with vector alone). The released
Tat-induced decrease in DA uptake was diminished by immunodepletion with anti-Tat
antibody but not with an isotype control antibody (F(3,

12)

= 13.4; p<0.001, one-way

ANOVA with Tukey’s multiple comparison test). These data also confirmed that the
inhibitory effect of incubation with conditioned media on DA uptake was specific for
released Tat.
2.3.4 MUTATION OF TYR470 ALTERS DA UPTAKE KINETICS AND POTENCY OF SUBSTRATE AND
INHIBITORS
To validate the feasibility of the computational model of the DAT(DA)-Tat
complex, we determined whether a specific residue (Tyr470, which was predicted by the
computational modeling as one of favorable inter-molecular interactions between Tat and
hDAT) in hDAT is important for intermolecular interaction between Tat and DAT. A
mutation in hDAT (tyrosine to histidine, Y470H-hDAT) was generated by site-directed
mutagenesis. We first determined the pharmacological profiles of [3H]DA uptake in CHO
cells transfected with equal amount of plasmid DNA for WT hDAT and mutated hDAT.
As shown in Fig. 2.3A, the Y470H-hDAT displayed a decrease in the Vmax values (2.8 ±
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0.8 pmol/min/105 cells) compared with WT hDAT [15.7 ± 0.9 pmol/min/105 cells; t(3) =
15.6, p<0.001, unpaired Student’s t test]; no difference in the Km values was observed.
We have reported that Tat protein influences selective binding sites on the DAT,
with differential impact on binding to GBR12935, WIN35,428 and cocaine (Zhu et al.,
2009; Zhu et al., 2011). To explore the potential relationship between the binding sites of
Tat in DAT and the binding sites of DAT substrate and inhibitors, we also tested the
ability of DA, cocaine and GBR12909 to inhibit [3H]DA uptake in WT hDAT and
Y470H-hDAT (Table 1). The apparent affinity (IC50) for DA was not significantly
different between the WT hDAT (895 ± 80 nM) and Y470H-hDAT (737 ± 72 nM).
However, the potencies of cocaine and GBR12909 for inhibition of [3H]DA uptake were
~3.5-fold greater in Y470H-hDAT as compared with WT hDAT (unpaired Student’s t
test).
To assess whether the decreased Vmax in this mutant was caused by decreased
surface DAT expression, we determined DAT surface expression in CHO cells
transfected with WT or Y470H-hDAT using cell surface biotinylation. As shown in Fig.
2.3B, despite no difference in the ratio of surface DAT to total DAT between WT and
Y470-hDAT (biotinylated/total: WT, 0.70 ± 0.06; and Y479H, 0.68 ± 0.1; p >0.05, oneway ANOVA), the absolute surface DAT in the mutant hDAT was indeed decreased
compared to WT hDAT (unpaired Student’s t test). Thus, the reduction of available DAT
on the cell surface could contribute to the decreased DA uptake actually measured in
Y470H-hDAT, relative to WT DAT.
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2.3.5 MUTATION OF TYR470 ATTENUATES TAT-INDUCED INHIBITORY EFFECTS ON DA
TRANSPORT

To determine whether the mutation of Tyr470 alters inhibitory effects of Tat on
DA uptake, we examined the specific [3H]DA uptake in WT hDAT and Y470H-hDAT in
the presence or absence of released Tat1-72 (1 ng/ml) or recombinant Tat1-86 (350 nM). As
shown in Figure 2.4A, two-way ANOVA on the specific [3H]DA uptake in WT and
Y470H-hDAT revealed a significant main effect of mutation (F(1, 24) = 6.5; p < 0.05), Tat
treatment (F(1, 24) = 7.5; p < 0.05) and a significant mutation × Tat interaction (F(1, 24) =
8.9; p < 0.05). A subsequent simple effect analysis revealed a dramatic decrease (80%) in
[3H]DA uptake in Y470H-hDAT (F(1, 12) = 25; p < 0.001) compared to WT hDAT in the
absence of Tat. Exposure to Tat decreased [3H]DA uptake by 50% in hDAT (F(1, 12) =
16.1; p < 0.01; Fig. 2.4A); however, no effect of Tat was observed in Y470H-hDAT (F(1,
12)

= 0.05; p > 0.05), suggesting that mutation of Tyr470 in hDAT attenuates Tat-induced

reduction of hDAT function.
With regard to the effect of recombinant Tat1-86 on DA uptake (Fig. 2.4B), a
separate two-way ANOVA analysis revealed a significant main effect of mutation (F(1, 24)
= 7.4; p < 0.05) and Tat treatment (F(1,

24)

= 9.5; p < 0.05) as well as a significant

mutation × Tat interaction (F(1, 24) = 12.9; p < 0.05). [3H]DA uptake in Y470H-hDAT was
19% of that in WT hDAT in cells transfected with equal amount of plasmid DNA for WT
and mutated DAT, which is consistent with the low DAT expression observed in Fig.
2.3B. Exposure to Tat1-86 decreased [3H]DA uptake by 38% in WT hDAT (F(1, 12) = 12.8;
p < 0.01); however, no effect of Tat on [3H]DA uptake was observed in Y470H-hDAT.
Since DA uptake is linear with DAT expression, in order to rule out whether the lack of
effect of Tat on DA uptake in this mutant hDAT is due to a low DAT expression level in
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Y470H-hDAT relative to WT hDAT, we corrected Vmax value of Y470H-hDAT to 40%
of that in WT hDAT using 3x amount of plasmid Y470H DNA in transfection (Fig.
2.4C), as reported previously (Chen et al., 2004). A two-way ANOVA revealed a
significant main effect of mutation (F(1, 24) = 6.4; p < 0.05) and Tat treatment (F(1, 24) =
5.5; p < 0.05) as well as a significant mutation × Tat interaction (F(1, 24) = 11.2; p < 0.05).
Similarly, exposure to recombinant Tat1-86 decreased Vmax by 35% and 6% in WT hDAT
and Y470H-hDAT, respectively. Thus, this result supports the inference that Tyr470 in
hDAT is critical for HIV-1 Tat-induced inhibition of dopamine transport.
2.3.6 MUTATION OF TYR470 AFFECTS ZINC REGULATION OF DAT CONFORMATIONAL
TRANSITIONS AND BASAL DA EFFLUX
We hypothesize that Tat, via allosteric modulation sites, alters conformational
states of DAT, thereby decreasing DA transport. To test this possibility, we determined
whether mutation of Tyr470 affects zinc regulation of DAT conformational transitions
and basal DA efflux. In general, the conformational changes in DA transport process
involve conversions between outward- and inward-facing conformations (Zhao et al.,
2010). Occupancy of the endogenous Zn2+ binding site in WT hDAT (His193, His375,
and Glu396) stabilizes the transporter in an outward-facing conformation, which allows
DA to bind but inhibits its translocation, thereby increasing [3H]WIN 35,428 binding
(Norregaard et al., 1998; Moritz et al., 2013), but decreasing DA uptake (Loland et al.,
2003). Addition of Zn2+ is able to partially reverse an inward-facing state to an outwardfacing state (Norregaard et al., 1998; Loland et al., 2003). On the basis of this principle,
the addition of Zn2+ to WT hDAT would inhibit DA uptake, whereas in a functional
mutation in DAT Zn2+ might diminish the preference for the inward-facing conformation
and thus enhance DA uptake. To explore this possibility, we examined the effects of
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Tyr470 mutation on Zn2+ modulation of [3H]DA uptake and [3H]WIN35,428 binding that
are thought to reflect stabilization of outwardly facing transporter forms (Richfield, 1993;
Norregaard et al., 1998). For these experiments, CHO cells expressing WT and Y470HhDAT were treated with 10 µM ZnCI2 and assayed for both [3H]DA uptake and [3H]WIN
35,428 (Fig. 2.5A and 5B). As shown in Fig. 2.5A, two-way ANOVA on the specific
[3H]DA uptake in WT and Y470H-hDAT revealed a significant main effect of mutation
(F(1, 24) = 11.5; p < 0.05), zinc (F(1, 24) = 9.1; p < 0.05) and a significant mutation × zinc
interaction (F(1, 24) = 9.9; p < 0.05). The addition of Zn2+ decreased [3H]DA uptake in WT
and Y470H-hDAT by 89% versus 32%, respectively (Fig. 2.5A, p< 0.001 relative to
control, unpaired Student’s t test). A two-way ANOVA on the specific [3H]WIN35,428
binding in WT and Y470H-hDAT revealed a significant main effect of mutation (F(1, 24) =
6.5; p < 0.05), zinc (F(1, 24) = 4.3; p < 0.05) and a significant mutation × zinc interaction
(F(1, 24) = 4.2; p < 0.05). Zn2+ caused a 40% increase in [3H]WIN 35,428 binding in WT
but had no effect on Y470H-hDAT (Fig. 2.5B, p< 0.001 relative to control, unpaired
Student’s t test). The data suggest that Tyr 470 mutation disrupts an intermolecular
interaction key for maintenance of the outward‐facing conformation.
To further determine the role of Y470H-hDAT in the transition between outwardfacing and inward-facing states, we also examined basal DA efflux in WT hDAT and this
mutant. As shown in Fig. 2.5C, after preloading with 0.05 µM [3H]DA for 20 min at
room temperature, cells were washed and fractional DA efflux samples were collected at
the indicated times. A two-way ANOVA revealed significant main effects of mutation
(F(1, 14) = 170; p<0.001) and time (F(4, 56) = 145; p<0.001). A significant mutation × time
interaction (F(4,

56)

= 78; p<0.001) was also found. Post-hoc analysis revealed robust
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increases in DA efflux at 1, 10, 20, and 30 min compared to WT hDAT (p < 0.05,
Bonferroni t-test). To determine whether exposure to Tat represents similar results, basal
DA efflux in WT hDAT was determined in the presence or absence of released Tat1-72
(Fig. 2.5D). The fractional basal DA efflux data in WT hDAT were expressed as a
percentage change in the respective controls of total DA content in cells with or without
Tat. Analysis of two-way ANOVA revealed that a significant main effect of treatment
(F(1, 10) = 18.7; p < 0.01) and time (F(5, 50) = 291.9; p<0.001) as well as a significant
treatment × time interaction (F(5, 50) = 9.9; p<0.001). Although a lower magnitude of DA
efflux in response to Tat treatment was found in WT hDAT in comparison to DA efflux
in Y470H-hDAT (Fig. 2.5D), post-hoc analysis revealed that exposure to released Tat1-72
significantly increased basal DA efflux at 1, 10, 20 and 30 min compared to control (p <
0.05, Bonferroni t-test). These data further support the possibility that Tyr 470 mutation
causes a regional conformational change that affects hDAT associated with Tat.
2.4 DISCUSSION
In the current study, we used an integrated approach including computational
modeling and simulations, protein mutagenesis and molecular pharmacological function
assays to explore a key residue in the intermolecular interactions between HIV-1 Tat and
hDAT. Our data provide additional evidence showing a direct interaction between Tat
and hDAT as suggested in our previous report (Zhu et al., 2009). Through modeling and
simulations, the site for Tat interaction with DAT has predicted that residue Tyr470 in
hDAT is crucial for HIV-1 Tat-induced inhibition of DA transport. Tyr470 mutation did
not alter the affinity for DA uptake but increased DA uptake potency for cocaine and
GBR12909, suggesting that Tyr470 does not overlap with the substrate binding site but
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disrupts the binding sites on DAT for these inhibitors. Importantly, mutation of Tyr470
alters Zn2+ modulation of DAT and basal DA efflux, compared to WT hDAT, implying a
mechanistic context for the transporter conformational transitions by this mutant.
Collectively, our results provide a relatively comprehensive molecular insight into this
important residue for DA translocation and the underlying allosteric mechanism in DAT
for Tat binding.
In response to the fundamental question how Tat interacts with hDAT through
their recognition binding sites to interrupt DAT-mediated DA transmission, our
computational model has predicted Tyr470 of hDAT and Cys22 as well as Lys19 in Tat
as one of the favorable inter-molecular interactions between hDAT and Tat protein. Data
from Co-IP and GST pull-down experiments demonstrate a direct interaction between Tat
and DAT, which is consistent with the predictions from computational modeling and
simulations. This study, based on the computational prediction, demonstrated that
mutation of Tyr470 changes hDAT conformation and attenuates Tat-induced inhibition of
DA transport. Despite the importance of Tyr470, our computational modeling does not
anticipate that a single residue in hDAT is sufficient to control the interaction of Tat with
hDAT. Therefore, once all recognition residues in hDAT are identified, an essential task
in our future study will be to determine the influence of combined recognition residues on
Tat-DAT interaction. The computational prediction of the binding mode was based on a
series of computational modeling studies including homology modeling, Brownian
dynamics simulations (Gabdoulline and Wade, 1998), and molecular dynamics
simulations. Considering the fact that the Tat molecule has a large positive electrostatic
potential, and hDAT(DA) bears negative charge, the long-range electrostatic attraction
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can be viewed as the driving force for the association of Tat with hDAT. The binding
mode of hDAT with Tat demonstrates that the Tat molecule is associated with DAT
through inter-molecular electrostatic attractions and complementary hydrophobic
interactions. In support of our proposed model, the current study and our previous report
(Zhu et al., 2009) demonstrate that mutation of either Tyr470 in hDAT or Cys22 in Tat
leads to attenuation of WT Tat-induced inhibitory effects on DA transport, implicating a
structural and functional relationship between Tat and hDAT. Since Lys19 is also
predicted as a critical residue for Tat interacting with the Tyr470 residue in DAT, we will
also determine whether mutation of Lys19 produces a similar effect as mutation of Cys22
in Tat on DAT function in our future investigation. These data also qualitatively support
that our computationally simulated model of the hDAT(DA)-Tat complex is reliable to be
used to predict the intermolecular interactions between Tat and DAT.
Although both recombinant Tat and Tat released from cells expressing Tat
produced a strong inhibitory effect on DA transport, released Tat was ~4000-fold more
potent than recombinant Tat. This finding is consistent with a previous report showing
this form of Tat was more neurotoxic than recombinant Tat protein (Li et al., 2008). We
also found that Tat1-72, Tat1-86 and full length Tat1-101 exhibited an equivalent inhibitory
effect on DAT function, which is consistent with the previous studies showing that equal
ability of Tat protein in Tat-induced neurotoxicity (Li et al., 2008; Aksenov et al., 2009).
The concentration of released Tat (1 ng/ml) used in this study is similar to native HIV-1
Tat actually detected in the serum of patients with HIV infection (Westendorp et al.,
1995) and in the conditioned medium of HIV-infected cells (Albini et al., 1998). Thus,
our data support that physiologically secreted Tat is more neurotoxic to neuronal targets,
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such as DAT. The advantage of this approach is feasible for further determination of the
recognition sites of Tat (WT versus mutated) that functionally interact with hDAT.
The present results show that mutation of Tyr470 decreased the Vmax with no
changes in Km value and IC50 value for DA inhibiting DA uptake compared to WT
hDAT, demonstrating that the Tyr470 residue does not affect substrate transport
characteristics. These data are consistent with the aforementioned computational
prediction based on the modeled hDAT(DA)-Tat complex structure: Tat binding site in
hDAT(DA) complex does not overlap with the binding site of substrate DA (Fig. 2.2). In
contrast, the DA uptake potency of cocaine and GBR12909 was increased in Y470HhDAT compared to WT hDAT. While GBR12909 labels the classic DA uptake site in
rodent brain, binding to the piperazine acceptor site (Andersen et al., 1987) was affected
much less by mutation of hDAT than cocaine (Loland et al., 2002; Guptaroy et al., 2011),
consistent with the fact that cocaine preferentially stabilizes the hDAT in the outwardfacing conformational state, resulting in a reduction of DA uptake (Reith et al., 2001;
Loland et al., 2002). One interpretation of our finding is that Tat allosterically modulates
DA transport rather than overlaps DA uptake sites on DAT as previously suggested (Zhu
et al., 2011). However, the Tat binding site in hDAT may be close to the binding sites in
hDAT for cocaine and GBR12909, increasing their DA uptake potency. Thus, the results
may suggest synergistic influences of Tat and cocaine on DAT function: Tat, via
allosteric modulation of the DAT, enhances the inhibitory effects of cocaine on DA
transport. These findings also provide evidence to support our previous reports that Tat
and cocaine synergistically inhibit DAT function in vivo and in vitro (Harrod et al., 2008;
Ferris et al., 2010).
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Our previous work provides evidence that Tat allosterically modulates DAT
function (Zhu et al., 2009; Zhu et al., 2011). The allosteric modulation of DAT is
responsible for conformational transitions via substrate- and ligand-binding sites on DAT
(Zhao et al., 2010; Shan et al., 2011). In the present study, we found that mutation of
Tyr470 diminished Zn2+-induced inhibition of [3H]DA uptake and attenuated increased
[3H]WIN 35,428 binding compared to WT hDAT. The endogenous Zn2+ binding sites in
hDAT have been widely employed to investigate whether mutations of hDAT alter
transporter conformational transitions in DA transport (Norregaard et al., 1998). The
Zn2+-mediated inhibition of DA transport and stimulation of WIN35,428 binding to DAT
occur by stabilization of outwardly facing transporter conformations (Richfield, 1993;
Norregaard et al., 1998; Moritz et al., 2013). Although analysis of Zn2+ regulation of
DAT function only reflects one mechanistic aspect of DAT mutant-induced
conformational change, our data provide strong evidence for the context of an allosteric
mechanism responsible for conformational transitions in DAT. To explore the possible
mechanism, we also examined the effects of mutant hDAT on basal DA efflux and
observed extremely low accumulation of DA over time in Y470H-hDAT relative to WT
hDAT. One possible explanation for the low accumulation of DA is that basal DA efflux
can be elevated in this mutant, resulting in reduced accumulation of intracellular DA.
One caveat is that DA efflux data may reflect not only DA moving out of the cell through
the transporter, but also non-specific diffusion and reuptake. However, there is evidence
(Guptaroy et al., 2009; Guptaroy et al., 2011) that this measurement largely reflects basal
DA efflux through DAT because such basal DA efflux is consistent with amphetamineor voltage-stimulated efflux of intracellular DA in cells expressing hDAT and its mutant.
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Amphetamine, a substrate for DAT, competitively inhibits DA reuptake and elicits
outward transport of DA by reversal of the transporter (Sulzer et al., 2005). Thus, it is
possible that Y470H mutation shifts the conformation of DAT from physiologically
favored substrate influx mode to an efflux one; a conformational switch promoted by Tat
protein, and disturbs transition between inward- and outward-facing conformations.
Taken together, these findings infer a potential mechanism that mutation of Tyr470 alters
the transporter conformational transitions, which is consistent with our previous findings
that Tat mediates allosteric modulation of DAT (Zhu et al., 2011). Additionally, the
enhanced DA efflux was also observed in WT hDAT in the presence of Tat. Interestingly,
the magnitude of DA efflux in WT hDAT was lower in response to Tat compared to that
in Y470H-hDAT. One possible explanation for the discrepancy is that in addition to
residue Y470, other recognition residues of the DAT may be involved in the effects of
Tat on DA efflux. Therefore, to fully understand the mechanisms by which Tat inhibits
DAT function, future studies based on the combined experimental and computational
approaches will be necessary to further analyze the changes in the conformational
transition attributed to the identified residues in DAT (i.e. an outward-facing form and an
inward-facing form).
In conclusion, we have begun to identify the specific intermolecular interactions
between Tat and DAT and the molecular mechanism(s) that underlies how Tat, via the
recognition binding sites in DAT, interrupts DA transport. Particularly, our results
provide relatively a broad molecular validation of this important residue of DA
translocation and the underlying allosteric mechanism in DAT for Tat. We propose that
multiple recognition residues in the DAT are involved in the dynamic and complex
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interactions between Tat and DAT. Results obtained from Tyr470 only reflect the role of
this residue in DAT-Tat interaction. The current findings have shed light on further
mapping and validating the predicted sites for Tat interaction with DAT towards an
ultimate goal to develop compounds that specifically block Tat binding site(s) in DAT
without affecting physiological DA transport. Ideally, these compounds would be
therapeutic candidates for stabilizing physiological dopaminergic tone.
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Table 2.1 Summary of inhibitory activities in [3H]DA uptake in WT and mutated hDAT
in the presence of DA, cocaine or GBR12909
DA

cocaine

GBR12909

IC50 (nM)
WT hDAT

895 ± 80

370 ± 40

160 ± 30

Y470H-hDAT

737 ± 72

100 ± 30*

50 ± 10*

Data are calculated as a percentage of DA uptake in the absence of substrate or inhibitor
and analyzed by nonlinear regression. Data are presented as mean ± S.E.M. of IC50 values
from three to four independent experiments performed in duplicate. * p < 0.05 compared
with WT hDAT (unpaired Student’s t test).
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Figure 2.1 A direct interaction between Tat and DAT and the energy-minimized
hDAT(DA) binding complex following the MD simulation. Co-IP of DAT and Tat was
performed by immunoprecipitation (IP) with anti-DAT antibody as bait and immunoblot
(IB) with anti-Tat antibody. (A) Co-IP of DAT and Tat. Rat synaptosomes from spleen,
cerebellum, striatum were preincubated with (+, lanes 1, 2 and 4, from left) or without (-,
lane 3) 350 nM recombinant Tat1-86 (rTat1-86). Top panel: DAT immunoreactivity was
detected in striatum but not in spleen and cerebellum. Bottom panel: rTat1-86 bound to
agarose beads was able to immunoprecipitate DAT in rat striatum but not in spleen and
cerebellum. rTat1-86 (10 ng) was loaded in lane 5 as the positive control for Tat
immunoreactivity. (B) GST-Tat1-86 bound to WT hDAT protein. Top panel: The GSTTat1-86 fusion proteins were bound to glutathione-sepharose beads, and then incubated
with cell lysates from CHO cells transfected with WT hDAT at room temperature for 1h
following Western Blot using anti-DAT. GST-Tat fusion protein bound to glutathionesepharose was able to pull down DAT, but GST alone was not. Bottom panel: DAT
immunoreactivity in CHO cells expressing hDAT was shown in all lanes. (C) Side view
of the complex structure. Tat is shown as ribbon in cyan color and hDAT(DA) as ribbon
in gold color. Atoms of residue C22 (Cys22) of Tat are shown as overlapped balls in cyan
color. Atoms of substrate dopamine (DA) and the Cl- ion are shown as overlapped balls
in green color. 2 Na+ ions are shown as balls in blue color. The vestibule (colored in
purple) is represented as molecular surface calculated by using program HOLLOW (Ho
and Gruswitz, 2008). (D) Local view of the anchoring residues Lys 19 (K19) and Cys22
(C22) of Tat inside the vestibule of hDAT(DA). Residues K19 and C22 of Tat are shown
in ball-and-stick style, and colored by the atom types. Residue Tyr470 (Y470) of
hDAT(DA) is also shown in ball-and-stick style and colored by the atom types. The
hydrogen bonding between the K19 side chain of Tat and the hydroxyl oxygen atom on
Y470 side chain of hDAT(DA) is indicated with the dashed line. The non-polar hydrogen
atoms are not shown for clarity. The positions of trans membrane domain11 and 12
(TM11 and TM12) of hDAT(DA) are also labeled.
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Figure 2.2 Inhibition of DA uptake by released Tat from Tat-expressing cells. (A) CHO
cells transfected with WT hDAT were preincubated in KRH buffer including 100 µl
conditioned media collected at 72 h from cells transfected with plasmid Tat1-72, Tat1-86,
Tat1-101 DNAs and vector alone (Control) followed by addition of [3H]DA uptake. *p <
0.05 different from control (Dunnett’s Multiple comparison test). (B) Specificity of
released Tat in inhibition of [3H]DA uptake. Conditioned media collected at 72 h from
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cells transfected with Tat1-72 were preincubated with anti-Tat antibody or isotype control
IgG at 4°C for 3h, followed by incubation with protein A/G – Agarose beads 4°C for 2h.
Media collected at same time from cells transfected with vector alone was used as
control. Cells transfected with WT hDAT were preincubated in KRH buffer containing
supernatants from the agarose-antibody-medium-beads complex, followed by [3H]DA
uptake. Released Tat1-72 caused significant decrease in [3H]DA uptake, which was
attenuated by immunodepletion with anti-Tat antibody but not isotype control antibody
(one-way ANOVA followed by Tukey’s multiple comparison test). * p < 0.05 different
from control. # p < 0.05 different from Tat1-72 and Tat1-72 + Con IgG. (n = 4).

52

Specific [3H]DA uptake
(pmol/min/105 cells)

A
Vmax
WT-hDAT
15.7  0.9
Y470H-hDAT 2.8  0.8*

20

Km
1.2  0.1
1.4  0.1

15
10
5
0
0

1

2

3

4

5

DA concentration (uM)

B

DAT Immunoreactivity
(103  arbitrary units)

40
Total
Biotinylated

30

*

20

*

10
0

WT hDAT

Y470H-hDAT

Figure 2.3 [3H]DA uptake and DAT surface expression in WT hDAT and mutant. (A)
Kinetic analysis of [3H]DA uptake in WT hDAT and Y470H-hDAT. CHO cells
transfected with WT hDAT or Y470H-hDAT were incubated with one of six mixed
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concentrations of the [3H]DA as total rate of DA uptake. In parallel, nonspecific uptake
of each concentration of [3H]DA (in the presence of 10 µM nomifensine, final
concentration) was subtracted from total uptake to calculate DAT-mediated uptake. * p <
0.05 compared to control value (unpaired Student’s t test) (n = 5). (B) Cell surface of WT
hDAT (WT) or Y470H-hDAT (Y470H) was analyzed by biotinylation. Top panel:
representative immunoblots in CHO cells expressing WT hDAT or Y470H-hDAT.
Bottom panel: DAT immunoreactivity is expressed as mean ± S.E.M. densitometry units
from three independent experiments (n = 3). * p < 0.05 compared to WT hDAT (unpaired
Student’s t test).
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Figure 2.4 Effects of Tat on kinetic analysis of [3H]DA uptake in WT hDAT and mutant.
(A) CHO cells transfected with WT or Y470H-hDAT were preincubated with or without
released Tat1-72 (1.0 ng/ml) at room temperature for 20 min followed by the addition of
one of six mixed concentration of the [3H]DA. In parallel, nonspecific uptake at each
concentration of [3H]DA (in the presence of 10 µM nomifensine, final concentration) was
subtracted from total uptake to calculate DAT-mediated uptake. (B) [3H]DA uptake in
cells transfected with WT or Y470H-hDAT was determined in the presence or absence of
recombinant Tat1-86 (rTat1-86, 350 nM, final concentration). (C) [3H]DA uptake in cells
transfected with WT (0.8 µg plasmid cDNA) or Y470H-hDAT (2.4 µg plasmid cDNA)
was determined in the presence or absence of rTat1-86 (350 nM). Data are expressed as
means from three independent experiments ± S.E.M. * p < 0.05 compared with the
respective control values. # p < 0.05 compared to WT hDAT. (n = 5)
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Figure 2.5 Mutation of Tyr470 alters transporter conformational transitions. Tyr470
mutation of DAT affects zinc regulation of DA uptake (A) and [3H]WIN 35,428 binding
(B). CHO cells transfected with WT or Y470H-hDAT were incubated with assay buffer
alone (control) or ZnCl2 (10 µM, final concentration) followed by [3H]DA uptake or
[3H]WIN 35,428 binding (n = 4). The histogram shows [3H]DA uptake and [3H]WIN
35,428 binding expressed as mean ± S.E.M. of the respective controls set to 100% for the
mutant. * p < 0.05 compared to control. # p < 0.05 compared to WT hDAT with ZnCl2.
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(C) Functional DA efflux properties of WT hDAT and mutant. CHO cells transfected
WT or Y470H-hDAT were preincubated with [3H]DA (0.05 µM, final concentration) at
room temperature for 20 min. After incubation, cells were washed and incubated with
fresh buffer as indicated time points. Subsequently, the buffer was separated from cells,
and radioactivity in the buffer and remaining in the cells was counted. Each fractional
[3H]DA efflux in WT hDAT and Y470H-hDAT was expressed as percentage of total [3H]
in the cells at the start of the experiment. Fractional [3H]DA efflux at 1, 10, 20, 30 and 40
min are expressed as the percentage of total [3H]DA with preloading with 0.05 µM (WT
hDAT: 15379 ± 1800 dpm and Y470H-hDAT: 2488 ± 150 dpm) present in the cells at
the start of the experiment (n = 4). × p < 0.05 and ×× p < 0.01, compared to WT hDAT
(Bonferroni t-test). (D) Functional DA efflux properties of WT hDAT in the presence or
absence of Tat1-72. CHO cells transfected with WT hDAT were preincubated with
released Tat1-72 (1 ng/mg) followed by DA efflux assay. Fractional [3H]DA efflux at 1,
10, 20, 30, 40 and 50 min are expressed as the percentage of total [3H]DA with
preloading with 0.05 µM (control: 14200 ± 1448 dpm and released Tat: 10102 ± 1505
dpm) present in the cells at the start of the experiment (n = 6). ^ p < 0.05 and ^^ p < 0.01,
compared to WT hDAT in the absence of Tat (Bonferroni t-test).
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CHAPTER 3
POINT MUTATIONS AT TYR 88, LYSINE 92 AND TYR 470 OF THE HUMAN
DOPAMINE TRANSPORTER ATTENUATE TAT-INDUCED INHIBITION OF DOPAMINE
TRANSPORTER FUNCTION

ABSTRACT: HIV-1 transactivator of transcription (Tat) protein disrupts the dopamine (DA)
neurotransmission by inhibiting DA transporter (DAT) function, leading to increased
neurocognitive impairment in HIV-1 infected individuals. Through computational modeling
and simulations, three functional residues in human DAT (hDAT) were predicted as
potential recognition binding sites for Tat. We previously showed that mutation of
tyrosine470 (Y470H) of hDAT attenuates Tat-induced inhibition of DA uptake by changing
the transporter conformational transitions. In the present study we examined the functional
influences of other substitutions at tyrosine470 (Y470F and Y470A) and tyrosine88 (Y88F)
and lysine92 (K92M), two other predicted residues for Tat binding to hDAT, in Tat-induced
inhibitory effects on DA transport. Compared to wild type (WT) hDAT, K92M but not Y88F
reduced Vmax without changes in Km. Both Y88F and K92M did not alter IC50 values for DA
inhibition of [3H]DA uptake but increased [3H]DA uptake or [3H]WIN35,428 binding
potencies for cocaine and GBR12909, indicating that these residues do not overlap with the
binding sites in hDAT for DA transport but are critical for these inhibitors. Besides, Y88F,
K92M and Y470A attenuated Tat-induced inhibition of DA transport that is observed in WT
hDAT. Y470F, Y470A, Y88F and K92M mutants reversed the zinc-induced increase of
[3H]WIN35,428 binding but not the [3H]DA uptake. Moreover, Y470A and K92M mutants
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displayed enhanced DA basal efflux compared to WT hDAT. Taken together, these results
demonstrate that Tyr88 and Lys92 along with Tyr470 as functional recognition residues in
hDAT for Tat interaction-induced inhibition of DA transport and provide mechanistic
insights into identifying target residues on the DAT for Tat binding.
3.1 INTRODUCTION
HIV-associated neurocognitive disorder (HAND) that encompasses neurological and
psychiatric complications has been on the considerably rise in people living with HIV-1 and
AIDS even in the era of highly active antiretroviral therapy (HAART)(Heaton et al., 2010;
Simioni et al., 2010; Mothobi and Brew, 2012). The growing body of evidence indicates that
the HAND progression and severity is exacerbated by comorbid factors like widely abused
drugs, particularly cocaine (Buch et al., 2011; Nair and Samikkannu, 2012). Lower
adherence to medication regimen by HIV-1 positive people is also strongly associated with
the active cocaine use (Arnsten et al., 2002; Norman et al., 2009). HAND is highly correlated
with neurotoxic effects of HIV-1 viral proteins that are exuded from infected microglial cells
(Bansal et al., 2000; Kaul et al., 2001; Mattson et al., 2005; Kaul and Lipton, 2006). Tat, a
non-structural viral protein required for productive infection of virus, is one of the major
neurotoxins responsible for neurotoxicity and oxidative stress in the central nervous system
(Pocernich et al., 2005; Wallace et al., 2006). Studies have demonstrated that Tat protein and
cocaine interaction have deleterious effects in HIV-1 positive brains by altering viral
replication, neuropathogenesis and behavioral effects (Gandhi et al., 2010; Paris et al., 2013).
Dysregulation of dopamine (DA) neurotransmission in HIV-1 infected patients is
greatly associated to HAND pathophysiology and has been reviewed extensively elsewhere
(Koutsilieri et al., 2002; Ferris et al., 2008; Purohit et al., 2011). HIV-infection has been
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shown to deplete intracellular DA levels in postmortem brains (Scheller et al., 2005; Kumar
et al., 2009). Recently, enhanced DA levels were reported in cerebrospinal fluid of HIV-1
positive individuals with no treatment compared to normal subjects (Scheller et al., 2010).
An explanation for this elevated level of DA is possibly due to impairment of DA transporter
(DAT) function (Purohit et al., 2011). DAT is a presynaptic membrane protein that rapidly
clears extracellular DA via rapid reuptake and is a primary determinant for the regulation of
DA homeostasis in the brain (Vaughan and Foster, 2013). Clinical results using positron
emission tomography imaging have demonstrated that HIV-associated dementia patients
show a dramatic loss of DAT protein in the putamen and ventral striatum regions (Wang et
al., 2004; Chang et al., 2008). Likewise, previous animal and in vitro studies including
published data from our own laboratory indicated that the Tat manipulates the function of
DAT (Ferris et al., 2009b; Ferris et al., 2009a; Zhu et al., 2009; Perry et al., 2010).
Furthermore, we showed that Tat down regulates DAT function through allosteric
mechanism (Zhu et al., 2011); also it decreases DAT cell surface expression in rat striatal
synaptosomes (Midde et al., 2012). Therefore, it is expected that DAT would be a promising
clinical target for therapeutic interventions to curb the damage of DA system instigated by
the Tat protein.
It has been proposed that different ligands exert their actions on DAT by inducing
specific conformational changes in the transporter that can influence DA uptake and efflux
(Schmitt et al., 2013). DAT substrates and inhibitors initially recognize specific amino acids
and are likely followed by a series of molecular changes to modulate DAT function (Tanda
et al., 2009; Shan et al., 2011). Previous studies suggest that allosteric modulators of DAT
differentially regulate transporter uptake and efflux properties (Pariser et al., 2008; Rothman
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et al., 2009). Along these lines, our published report showed that Tat decreases DAT activity
via binding to allosteric sites and also alters cocaine binding sites (Zhu et al., 2011),
indicating different mode of Tat interaction that does not directly interfere with substrate
translocation. Likewise, computational and experimental studies have focused to identify the
binding mode and pocket of dopamine as well as cocaine (Li et al., 2002; Beuming et al.,
2008; Huang et al., 2009; Shan et al., 2011). Having emerging evidence for additive and/or
synergistic effects of Tat and cocaine (Gandhi et al., 2010; Paris et al., 2013), it is worth
noting that molecular relationship between Tat binding site and the binding site of cocaine on
the transporter remain unclear. Thus, in order to identify the binding pocket for Tat protein in
DAT, it is necessary to identify the residues forming the crevice and understand the
contribution of these recognition residues in substrate translocation, cocaine binding and
conformational rearrangements in the transporter.
In the process of understanding the combined effects of Tat and cocaine on down
regulation of DA transport through alteration of DAT function, using biophysical (Zhu et al.,
2009) and biochemical methods (Midde et al., 2013), we demonstrated that Tat directly
interacts with DAT. Based on predictions of computational modeling and simulations, as a
proof of principle study we showed evidence that mutating Y470 of human DAT (hDAT)
attenuates Tat-mediated inhibition of DA uptake but increases the potency of DAT inhibitor
cocaine (Midde et al., 2013). It has also been demonstrated that Tyr470His-hDAT (Y470HhDAT) mutant differentially modulates zinc-mediated regulation of DA uptake and
WIN35,428 binding, and basal DA efflux properties, suggesting a role of Tyr470 in
maintaining structural integrity of the transporter and mutating this amino acid resulted in a
transporter that favors an inward facing conformation. As a follow up to this published data,
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in the current study we investigated the role of additional substitutions at Tyr470 and other
predicted potential Tat binding residues, Tyr88 and Lys92 of hDAT in Tat-induced decrease
of DA translocation by generating points mutations Tyr470F (Y470F-hDAT), Tyr470AhDAT (Y470A-hDAT), Tyr88Phe (Y88F-hDAT), Lys92Met (K92M-hDAT) and assessing
their variability in function, surface expression, interaction with ligands and underlying
mechanism for these alterations.
3.2 MATERIALS AND METHODS
3.2.1 PREDICTING THE SITE FOR hDAT BINDING WITH TAT
The binding structure of hDAT with HIV-1 clade B type Tat was modeled and simulated
based on the nuclear magnetic resonance (NMR) structures of Tat (Peloponese et al., 2000)
and the constructed structure of hDAT-DA complex. According to D-Y470 site-directed
mutation experimental data as reported previously (Midde et al., 2013), Y470 of hDAT is a
functional recognition residue for Tat-induced inhibition of DAT transport cycle. Therefore,
Y470 of hDAT is expected to interact with Tat directly. The protein docking program
ZDOCK (Pierce et al., 2011) was applied for obtaining the initial binding structure of the
hDAT-Tat complex, with the constraint of contact between D-Y470 and Tat. Total 535
potential conformations were generated based on 11 NMR structures of Tat, then all of these
conformations were evaluated and ranked by ZRANK (Pierce and Weng, 2007). Top 107
conformations (top 20%) were selected for further investigation by MD simulation. Then
initial binding structure of the hDAT-Tat was identified from these simulations, with the best
geometric matching quality and rational interaction between D-Y470 and Tat. With further
relaxing and equilibrating the system, final MD-simulated hDAT-Tat binding structure was
energy-minimized and analyzed.
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3.2.2 CONSTRUCTION OF PLASMIDS
All point mutations of Tyr88, Lys92, and Tyr470 in hDAT were selected based on the
predictions of the 3D-computational modeling and simulations. Mutations in hDAT at Tyr88
and Tyr470 (tyrosine to phenylalanine, Y88F-hDAT and Y470F-hDAT) are expected to
destroy the hydrogen bond only. Since methionine is nearly isosteric with lysine, substitution
at Lys92 (lysine to methionine, K92M-hDAT) should abolish hydrogen bond with minimal
perturbations to the native structure of the transporter. Substitution of tyrosine at 470 with
alanine or tryptophan (Y470A-hDAT and Y470W-hDAT) is expected to eliminate both
hydrogen bond and cation-π interactions that is similar to Y470H-hDAT, but with different
spatial effects on structural organization of the transporter. All mutations in hDAT were
generated based on wild type human DAT (WT hDAT) sequence (NCBI, cDNA clone
MGC: 164608 IMAGE: 40146999) by site-directed mutagenesis. Synthetic cDNA encoding
hDAT subcloned into pcDNA3.1+ (provided by Dr. Haley E Melikian, University of
Massachusetts) was used as a template to generate mutants using QuikChange™ sitedirected mutagenesis Kit (Agilent Tech, Santa Clara CA). The sequence of the mutant
construct was confirmed by DNA sequencing at University of South Carolina EnGenCore
facility. Plasmid DNA were propagated and purified using plasmid isolation kit (Qiagen,
Valencia, CA, USA)
3.2.3 CELL CULTURE AND DNA TRANSFECTION
Chinese hamster ovary (CHO, ATCC #CCL-61) cells were maintained in F12 medium
supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 U/ml penicillin and
100 µg/mL streptomycin). Pheochromocytoma (PC12, ATCC #CRL-1721) cells were
maintained in Dulbecco’s modified eagle medium supplemented with 15 % horse serum, 2.5
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% bovine calf serum, 2 mM glutamine and antibiotics (100 U/ml penicillin and 100 µg/mL
streptomycin). Both cells were cultured at 37°C in a 5% CO2 incubator. For hDAT
transfection, cells were seeded into 24 well plates at a density of 1×105 cells/cm2. After 24h,
cells were transfected with WT or mutant DAT plasmids using Lipofectamine 2000 (Life
Tech, Carlsbad, CA). Cells were used for the experiments after 24 h of transfection.
3.2.4 [3H]DA UPTAKE ASSAY
Twenty four hours after transfection, [3H]DA uptake in PC12 cells transfected with WT
hDAT and mutants was performed as reported previously (Midde et al., 2013). To determine
whether mutated hDAT alters the maximal velocity (Vmax) or Michaelis-Menten constant
(Km) of [3H]DA uptake, kinetic analyses were conducted in WT hDAT and mutants. To
generate saturation isotherms, [3H]DA uptake was measured in Krebs-Ringer-HEPES (KRH)
buffer (final concentration in mM: 125 NaCl, 5 KCl, 1.5 MgSO4, 1.25 CaCl2, 1.5 KH2PO4,
10 D-glucose, 25 HEPES, 0.1 EDTA, 0.1 pargyline, and 0.1 L-ascorbic acid; pH 7.4)
containing one of six concentrations of unlabeled DA (final DA concentrations, 1.0 nM–5
µM) and a fixed concentration of [3H]DA (500,000 dpm/well, specific activity, 21.2
Ci/mmol; PerkinElmer Life and Analytical Sciences, Boston, MA). In parallel, nonspecific
uptake of each concentration of [3H]DA (in the presence of 10 µM nomifensine, final
concentration) was subtracted from total uptake to calculate DAT-mediated uptake. The
reaction was conducted at room temperature for 8 min and terminated by washing twice with
ice cold uptake buffer. Cells were lysed in 500 μl of 1% SDS for an hour and radioactivity
was measured using a liquid scintillation counter (model Tri-Carb 2900TR; PerkinElmer
Life and Analytical Sciences, Waltham, MA). Kinetic parameters (Vmax and Km) were
determined using Prism 5.0 (GraphPad Software Inc., San Diego, CA). To determine the
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inhibitory effects of Tat on [3H]DA uptake, cells transfected with WT hDAT or mutants
were preincubated with Tat1-86 or Tat Cys22 (500 nM, final concentration) for 20 min. Tat
Cyc22 was used as a negative control because our previous study shows that Tat Cyc22 has
no effect on DA uptake (Zhu et al., 2009).
The competitive inhibition DA uptake experiments were performed in duplicate in a
final volume of 500 µl. Cells in each well were incubated in 450 µl KRH buffer containing
50 µl one of final concentrations of unlabeled DA (1 nM-1 mM), GBR12909 (1 nM-10 µM),
cocaine (1 nM-1 mM), WIN 35,428 (1 nM-1 mM) or ZnCI2 (10 µM) at room temperature for
10 min and [3H]DA uptake was determined by addition of 50 µl of [3H]DA (0.1 µM, final
concentration) for an additional 8 min.
3.2.5 [3H]WIN 35,428 BINDING ASSAY
Binding assays were conducted to determine whether mutated hDAT alters the
kinetic parameters (Bmax or Kd) of [3H]WIN 35,428 binding in PC12 cells transfected with
WT hDAT and mutants. Twenty four hours after transfection, PC12 cells were dissociated
with trypsin/EDTA (0.25%/0.1%, 1 mL for 100 mm dish) and resuspended in growth
medium. After 10 min incubation at room temperature, the dissociated cells were harvested
by centrifugation at 3000 rpm for 5 min and washed once with phosphate-buffered saline
(PBS). The resulted cell pellets were resuspended in sucrose-phosphate buffer (final
concentration in mM: 2.1 NaH2PO4, 7.3 Na2HPO47H2O, and 320 sucrose, pH 7.4) for
binding assay.
To generate saturation isotherms, aliquots of cell suspensions (100 µl) were incubated
with one of the eight concentrations of [3H]WIN 35,428 (84 Ci/mmol, PerkinElmer, 0.5 – 30
nM final concentrations) in a final volume of 250 μl on ice for 2 h. In parallel, nonspecific
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binding at each concentration of [3H]WIN 35,428 (in the presence of 30 µM cocaine, final
concentration) was subtracted from total binding to calculate the specific binding. For the
competitive inhibition experiment, assays were performed in duplicate in a final volume of
500 μl. Aliquots of the cell suspensions (50 μl) were added to the assay tubes containing 50
μl of [3H]WIN 35,428 (final concentration, 5 nM) and one of seven concentrations of
unlabeled substrate DA (1 nM – 100 μM), inhibitors cocaine (1 nM – 100 μM) or GBR12909
(0.01 nM – 1 μM) and incubated on ice for 2 h. Assays were terminated by rapid filtration
onto Whatman GF/B glass fiber filters, presoaked for 2 h with assay buffer containing 0.5%
polyethylenimine, using a Brandel cell harvester. Filters were rinsed three times with 3 ml of
ice-cold assay buffer. Radioactivity remaining on the filters was determined by liquid
scintillation spectrometry (model Tri-Carb 2900TR; PerkinElmer Life and Analytical
Sciences, Waltham).
3.2.6 CELL SURFACE BIOTINYLATION
To determine whether DAT mutations alter DAT surface expression, biotinylation
assays were performed as described previously (Zhu et al., 2005). CHO cells transfected with
hDAT and mutants were plated on 6 well plates at a density of 105 cells/well. Cells were
incubated with 1 ml of 1.5 mg/ml sulfo-NHS-SS biotin (Pierce, Rockford, IL) in PBS/Ca/Mg
buffer (In mM: 138 NaCl, 2.7 KCl, 1.5 KH2PO4, 9.6 Na2HPO4, 1 MgCl2, 0.1 CaCl2, pH 7.3).
After incubation, cells were washed 3 times with 1 ml of ice-cold 100 mM glycine in
PBS/Ca/Mg buffer and incubated for 30 min at 4°C in 100 mM glycine in PBS/Ca/Mg
buffer. Cells were then washed 3 times with 1 ml of ice-cold PBS/Ca/Mg buffer and then
lysed by addition of 500 ml of Triton X-100, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM
pepstatin, 250 µM phenylmethysulfonyl fluoride), followed by incubation and continual
shaking for 20 min at 4 °C. Cells were transferred to 1.5 ml tubes and centrifuged at 20,000g
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for 20 min. The resulting pellets were discarded, and 100 µl of the supernatants was stored at
-20 °C for determination of immunoreactive total DAT. Remaining supernatants were
incubated with continuous shaking in the presence of monomeric avidin beads in Triton X100 buffer (100 µl/tube) for 1 h at room temperature. Samples were centrifuged subsequently
at 17,000g for 4 min at 4°C, and supernatants (containing the nonbiotinylated, intracellular
protein fraction) were stored at -20°C. Resulting pellets containing the avidin-absorbed
biotinylated proteins (cell-surface fraction) were resuspended in 1 ml of 1.0% Triton X-100
buffer and centrifuged at 17,000g for 4 min at 4°C, and pellets were resuspended and
centrifuged twice. Final pellets consisted of the biotinylated proteins adsorbed to monomeric
avidin beads. Biotinylated proteins were eluted by incubating with 75 µl of Laemmli sample
buffer for 20 min at room temperature. If further assay was not immediately conducted,
samples were stored at -20 °C.
3.2.7 BASAL EFFLUX ASSAY
DAT-mediated basal substrate efflux was carried out, as described previously
(Guptaroy et al., 2009). We have reported that Y470H-hDAT significantly increased DA
efflux compared to WT hDAT (Midde et al., 2013). In this study, we compared the effects of
two types of substrates, DA or MPP+ on basal efflux in WT hDAT and mutants. The MPP+
was chosen because MPP+ has less diffusive properties than DA in heterologous expression
systems (Scholze et al., 2001). CHO cells were seeded into 24 well plates and transfected
with WT hDAT and mutants. Twenty four hours after transfection cells at a density of 105
cells/well were washed 3 times with KRH buffer and preloaded with [3H]DA (50 nM, final
concentration) or 5 nM final concentrations of [3H]1-methyl-4-phenylpyridinium
([3H]MPP+, 5 nM, final concentration, specific activity, 83.9 Ci/mmol; PerkinElmer Life and
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Analytical Sciences, Boston, MA) at room temperature for 20 or 30 min, respectively. After
incubation, cells were washed 3 times with KRH buffer. To obtain an estimate of the total
amount of [3H]DA or [3H]MPP+ in the cells at the zero time point, cells from a set of wells
(four wells/sample) were lysed rapidly in 1% SDS. To determine the time course of the
fractional basal efflux, fresh buffer (500 µl) was added into separate set of cell wells (four
wells/sample) and transferred to scintillation vials after 1 min as initial fractional efflux at 1
min, and another 500 µl buffer was added to the same wells (where the buffer was just
removed for 1 min point) and collected to vials after 10 min. Additional fractional efflux at
20, 30, 40 and 50 min, respectively, was repeated under the same procedure. After last time
point (50 min), cells were lysed in 1% SDS and counted as total amount of [3H]DA
remaining in the cells from each well.
3.2.8 DATA ANALYSES
Descriptive statistics and graphical analyses were used as appropriate. Results are
presented as mean ± SEM, and n represents the number of independent experiments for each
experiment group. Kinetic parameters (Vmax,

Km,

Bmax, and Kd) were determined from

saturation curves by nonlinear regression analysis using a one-site model with variable slope.
IC50 values for substrate and inhibitors inhibiting [3H]DA uptake or [3H]WIN 35,428 were
determined from inhibition curves by nonlinear regression analysis using a one-site model
with variable slope. For experiments involving comparisons between unpaired samples,
unpaired Student’s t test was used to assess any difference in the kinetic parameters (Vmax,
Km, Bmax, Kd or IC50) between WT and mutant; log-transformed values of IC50, Km or Kd
were used for the statistical comparisons. Significant differences between samples were
analyzed with separate ANOVAs followed by post-hoc tests, as indicated in the results
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Section of each experiment. All statistical analyses were performed using IBM SPSS
Statistics version 20, and differences were considered significant at p < 0.05.
3.3 RESULTS
3.3.1 STRUCTURAL INDICATIONS FROM MOLECULAR MODELING AND DYNAMICS SIMULATIONS
The transporting process of dopamine by DAT involves the conformational changes of DAT,
typically from outward-open DAT (Figure 3.1A) bound with ions (2Na+, and Cl-) to
outward-occluded DAT bound with both ions and substrate dopamine, and then to the
inward-open DAT bound with Cl- (Figure 3.1C). The mode of intra-molecular interactions
guarantees the smooth conformational change of DAT during dopamine transporting. We
could assume that the transporter is optimized via natural evolution and energy barrier of
conformation change is relatively low for an efficient transporting process. Therefore any
mutation of key residues that make the structure incline to certain state may decrease the
efficiency of dopamine transporting process. Based on the results of molecular modeling and
molecular dynamics simulations, we found that the Y470 is the key component of a
hydrophobic core, which is critical to stabilize the compact structure of DAT and then reduce
the barrier of conformation change between outward-open and outward-occlude state of
DAT (Figure 3.1B). In addition, residues Y88, K92 and D313 also help to stabilize TM1b
and TM6a through hydrophobic or electrostatic intra-molecular interactions, which make the
outward-open and outward-occlude state of DAT keep compact and be ready for
conformation changing. The hydroxyl group at the aromatic side chain of Y88 reduces the
hydrophobicity and makes the hydrophobic core nearby Y88 less stable than Y88F mutation,
as a result, the Y88F mutation is expected to make the TM1b and EL4 more compact and
bring about positive effect on the transporting kinetics of dopamine, i.e. increasing the
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Vmax. However, the compact conformation of TM1b also squeeze the vacant of dopamine
binding site, which may bring about negative effect of binding affinity of dopamine, i.e.,
increasing the Kmax. Specifically, the positive charged side chain of K92 could interact with
the negative charged side chain of residue D313 through electrostatic interaction, and
hydrogen bonding which is mediated by surrounding water molecules. As observed in our
simulation, TM1b and TM6a move together during the conformation change of transporting,
therefore K92-D313 interaction could stabilize the connection between TM1b and TM6a and
consequently decrease the energy barrier of conformation change. It can be expected that the
K92M mutation would bring about negative effects on the transporting kinetics of dopamine,
i.e. decreasing the Vmax. Moreover, the carboxyl of D79 in TM1b and carbonyl in main
chain of F320 in TM6a interact directly with dopamine, so the K92M would pull away
TM1b and TM6a, and these associated hydrogen bonding groups, which brings about
negative effect of binding affinity of dopamine, i.e., increasing the Kmax (Figure 3.1D).
Besides, as shown in the binding structure of HIV-1 TAT-DAT complex (Figure 3.2), the DY470 interacts with the positive charged N-terminal of T-M1 through cation- interaction.
Hydroxyl of D-Y88 forms hydrogen bond with side chain of T-K19. Side chain of D-K92 of
DAT forms hydrogen bond with carbonyl of main chain of T-P18. Based on the mode of
interaction between DAT and HIV-1 TAT, it could be expected that the mutating of residues
Y88 and K92 into residues without hydrogen-bonding capacity will weaken the interaction
between DAT and TAT. This is why that the mutations of Y88F and K92M decrease the
inhibitory potency of HIV-1 TAT against the function of dopamine uptake by DAT.
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3.3.2 MUTATIONS OF TYR88 AND LYS92 ALTER DA UPTAKE KINETICS AND POTENCY OF
SUBSTRATE AND INHIBITORS

To examine the functional relevance of Tyr88 and Lys92 residues of hDAT in
intermolecular interaction between Tat and DAT, mutations in Tyr88 and Lys92 residues of
hDAT (tyrosine to phenylalanine, Y88F-hDAT and lysine to methionine, K92M-hDAT)
were generated by site-directed mutagenesis. We first determined the pharmacological
profiles of [3H]DA uptake in CHO cells transfected with WT hDAT or mutated hDAT. As
shown in Table 3.1 and Fig. 3.4A, compared to WT hDAT (15.7 ± 0.9 pmol/min/105 cells),
the Y88F-hDAT did not alter the Vmax values, whereas the K92M-hDAT displayed a
decrease in the Vmax values (4.5 ± 1.7 pmol/min/105 cells, t(3) = 3.7, p<0.05, unpaired
Student’s t test); no difference in the Km values was observed. WIN 35,428 binding site
shares pharmacological identity with the DA uptake carrier and is part of the cocaine binding
domain (Pristupa et al., 1994). We also determined the effects of these mutants on possible
relationship between the binding site of Tat on DAT and the WIN 35,428 binding site. As
shown in Table 3.1, the Bmax values were not altered in Y88F-hDAT (5.8 ± 0.9 pmol/105
cells, t(8) = 2.1, p=0.07, unpaired Student’s t test) but decreased in K92M-hDAT (2.4 ± 0.4
pmol/105 cells, t(8) = 4.4, p<0.01, unpaired Student’s t test) compared with WT hDAT (9.7 ±
1.6 pmol/105 cells). However, the Kd values were significantly decreased in both in Y88FhDAT (4.0 ± 0.6 nM, t(8) = 3.6, p<0.01, unpaired Student’s t test) and K92M-hDAT (3.5 ±
1.1 nM, t(8) = 3.2, p<0.01, unpaired Student’s t test) compared with WT hDAT (8.6 ± 1.1
nM).
We tested the ability of substrate and DAT inhibitors to inhibit [3H]DA uptake in WT
hDAT and its mutants (Table 3.2). The apparent affinity (IC50) for DA was not significantly
different among the WT hDAT (1730 ± 82 nM), Y88F-hDAT (3010 ± 60 nM) and K92M72

hDAT (2870 ± 48 nM). However, the potencies of cocaine and GBR12909 for inhibition of
[3H]DA uptake were 1.4 ~4.0-fold greater in Y88F-hDAT (Cocaine: 160 ± 9 nM and
GBR12909: 95 ± 7 nM) and K92M-hDAT (Cocaine: 69 ± 4 nM and GBR12909: 101 ± 12
nM) as compared with WT hDAT (Cocaine: 285 ± 49 nM and GBR12909: 224 ± 41 nM).
The apparent affinity (IC50) for WIN 35,428 was not significantly different in Y88F-hDAT
(20 ± 2 nM) but more potent in K92M-hDAT (10 ± 1.0 nM) compared to WT hDAT (39 ±
10 nM). The ability of substrate and DAT inhibitors to inhibit [3H]WIN 35,428 binding in
WT hDAT and its mutants was also examined (Table 3.2). The apparent affinity (IC50) for
DA was significantly lower in Y88F-hDAT (2071 ± 340 nM) and K92M-hDAT (4211 ± 118
nM) than the WT hDAT (827 ± 120 nM). In addition, the IC50 for cocaine was increased in
Y88F-hDAT (85 ± 60 nM, t(8)=5.8, p<0.01) but not K92M-hDAT compared to WT hDAT
(150 ± 8.6 nM).
To validate the relationship between the Vmax values and surface DAT expression in
these mutants, we determined DAT surface expression in CHO cells transfected with WT or
Y88F-hDAT or K92M-hDAT using biotinylation assay. As shown in Fig. 3.4B, despite no
difference in the ratio of surface DAT (biotinylated DAT) to total DAT between WT (1.0 ±
0.05), Y88F-hDAT (1.13 ± 0.13; p >0.05, one-way ANOVA) and K92M-hDAT (1.09 ±
0.09; p >0.05, one-way ANOVA). The biotinylated DAT was not altered but total DAT was
significantly decreased in K92M-hDAT compared to WT hDAT (t(8) = 4.6, p<0.01,
unpaired Student’s t test). Thus, the decreased DA uptake in K92M-hDAT is not due to
alteration of the available DAT on the cell surface.
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3.3.3 MUTATIONS OF TYR88, LYS92 AND TYR470 DIFFERENTIALLY INFLUENCE TAT-INDUCED
INHIBITORY EFFECTS ON DA TRANSPORT
We have recently reported that mutation of either Tyr470 in hDAT or Cys22 in Tat
attenuated Tat-induced decrease in DA uptake (Zhu et al., 2009; Midde et al., 2013). To
determine whether other substitutions at Tyr470 residue show differential effects on Tatinduced decrease in DA uptake, we generated two mutations in Tyr470 residue of hDAT
(tyrosine to phenylalanine, Y470F-hDAT and tyrosine to alanine, Y470A-hDAT) based on
the predictions from computational modeling. We examined the specific [3H]DA uptake in
WT hDAT and mutants in the presence or absence of recombinant Tat1-86 (500 nM) or
recombinant Tat Cys22 (500 nM).
As shown in Fig. 3.5A, two-way ANOVA on the specific [3H]DA uptake in WT
hDAT and Tyr470 mutants revealed a significant main effect of mutation (F(2, 36) = 88.1; p <
0.001) and Tat treatment (F(2, 36) = 15.5; p < 0.05), as well as a significant mutation × Tat
interaction (F(4, 36) = 5.2; p< 0.01). The DA uptake was gradually decreased as Y470F (42%)
> Y470H (72%) > Y470A (92%) compared to WT hDAT in the absence of Tat. Exposure to
Tat decreased [3H]DA uptake by 32% in WT hDAT (F(1, 8) = 23.6; p < 0.01) and Y470FhDAT (47%, F(1, 8) = 15.4; p < 0.01); however, no effect of Tat was observed in Y470HhDAT (p > 0.05) and Y470A-hDAT (p > 0.05), suggesting that the different substitutions at
Tyr470 residue in hDAT differentially influence Tat-induced down regulation of DA uptake.
We have demonstrated that mutation of Cys22 in Tat shows no inhibitory effect on [3H]DA
uptake (Zhu et al., 2009). As illustrated in Figure 3.5A, Tat Cyc22 did not alter DA uptake in
WT hDAT and three Tyr470 mutants compared to respective controls, suggesting that Cyc22
residue in Tat plays a critical role in Tat-induced regulation DAT function.
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As shown in Figure 3.5B, two-way ANOVA on the specific [3H]DA uptake in WT
and mutants revealed a significant main effect of mutation (F(2, 54) = 124; p < 0.001) and Tat
treatment (F(2, 54) = 4.7; p < 0.05), however, mutation × Tat interaction (F(4, 54) = 1.9; p >
0.05) was not significant. In control group, a subsequent simple effect analysis revealed
decreased [3H]DA uptake in Y88F-hDAT (40%, p<0.05) and K92M-hDAT (72%, p<0.05)
compared to WT hDAT in the absence of Tat. Exposure to Tat decreased [3H]DA uptake by
32% in WT hDAT (F(1,

12)

= 8.0; p < 0.05; Fig. 3.5B); however, no effect of Tat was

observed in Y88F-hDAT (F(1, 12) = 1.1; p > 0.05) and K92M-hDAT (F(1, 12) = 1.4; p > 0.05),
suggesting that mutation of either Tyr88 or Lys92 in hDAT attenuates Tat-induced reduction
of hDAT function. With regard to the effect of recombinant Tat Cys22 on DA uptake (Fig.
3.5B), exposure to Tat Cyc22 did not alter DA uptake in Y88F-hDAT and K92M-hDAT
compared to WT hDAT.
3.3.4 EFFECTS OF TYR88, LYS92, AND TYR470 MUTANTS ON ZINC REGULATION OF DAT
CONFORMATIONAL TRANSITIONS AND BASAL DA EFFLUX
In general, occupancy of the endogenous Zn2+ binding site in WT hDAT (His193,
His375, and Glu396) stabilizes the transporter in an outward-facing conformation, which
allows DA to bind but inhibits its translocation, thereby increasing [3H]WIN 35,428 binding
(Norregaard et al., 1998; Moritz et al., 2013), but decreasing [3H]DA uptake (Loland et al.,
2003) . Addition of Zn2+ is able to partially reverse an inward-facing state to an outwardfacing state (Norregaard et al., 1998; Loland et al., 2003). On the basis of this principle, the
addition of Zn2+ to WT hDAT would inhibit DA uptake, whereas in a functional mutation in
DAT Zn2+ might diminish the preference for the inward-facing conformation and thus
enhance DA uptake. We recently reported that Y470H-hDAT exhibit an attenuation of Zn2+mediated decreased [3H]DA uptake and increased [3H]WIN35,428 binding observed in WT
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hDAT, which demonstrates a preference for the inward-facing conformation of the
transporter (Midde et al., 2013).
To investigate the role of additional substitutions at Tyr470 and Tyr88, Lys92
residues in DAT conformational transitions, we examined the effects of respective mutations
on Zn2+ modulation of [3H]DA uptake and [3H]WIN35,428 binding. As described in Fig.
3.6A, two-way ANOVA on the specific [3H]DA uptake in WT and Y470F-hDAT and
Y470A-hDAT revealed a significant main effect of mutation (F(2, 24) = 99; p < 0.001), zinc
(F(1, 24) = 40; p < 0.001) and a significant mutation × zinc interaction (F(2, 24) = 8.9; p < 0.02).
The addition of Zn2+ decreased [3H]DA uptake in WT and Y470F-hDAT and Y470A-hDAT
by 47%, 49% and 72% respectively (Fig. 3.6A, p< 0.01 relative to control, unpaired
Student’s t test). A two-way ANOVA on the specific [3H]WIN35,428 binding in WT and
Y470F-hDAT and Y470A-hDAT revealed a significant main effect of mutation (F(2, 44) = 38;
p < 0.01), zinc (F(1, 44) = 5; p < 0.04); however, no significant mutation × zinc interaction (F(2,
44) = 2; p > 0.13) was observed. Moreover, as presented in Fig. 3.6B. compared to respective

control (in the absence of Zn2+), Zn2+ caused a 48% increase in [3H]WIN 35,428 binding in
WT but 17% and 7% in Y470F-hDAT and Y470A-hDAT, respectively (p< 0.05 relative to
control, unpaired Student’s t test). Additionally, as shown in Fig. 3.7A, two-way ANOVA on
the specific [3H]DA uptake in WT and Y88F-hDAT and K92M-hDAT revealed a significant
main effect of mutation (F(1, 24) = 170; p < 0.001), zinc (F(1, 24) = 102; p < 0.001) and a
significant mutation × zinc interaction (F(2,

24)

= 8.3; p < 0.01). The addition of Zn2+

decreased [3H]DA uptake in WT and Y88F-hDAT and K92M-hDAT by 48%, 73% and 81%,
respectively (Fig. 3.6A, p< 0.001 relative to control, unpaired Student’s t test). A two-way
ANOVA on the specific [3H]WIN35,428 binding in WT and Y88F-hDAT and K92M-hDAT
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revealed a significant main effect of mutation (F(1, 18) = 7.8; p < 0.01), zinc (F(1, 18) = 26; p <
0.001); however, no significant mutation × zinc interaction (F(2, 18) = 0.9; p > 0.05) was
observed. As displayed in Fig. 3.7B. compared to respective control (in the absence of
Zn2+), Zn2+ caused a 54% increase in [3H]WIN 35,428 binding in WT but 22% and 19% in
Y88F-hDAT and K92M-hDAT respectively (p< 0.001 relative to control, unpaired Student’s
t test). These results suggest that Y88F, K92M, Y470F and Y470A mutants attenuate zinc
modulation of [3H]WIN 35,428 binding sites but not [3H]DA uptake.
To further evaluate the effects of mutations on transporter conformational transitions,
we examined the fractional efflux levels of [3H]DA and [3H]MPP+ in WT hDAT and these
mutants. As shown in Fig. 3.6C, after preloading with 0.05 µM [3H]DA for 20 min at room
temperature, cells were washed and fractional DA efflux samples were collected at the
indicated times. A two-way ANOVA revealed significant main effects of mutation (F(2, 9) =
10; p<0.05), time (F(5, 45) = 175; p<0.001) and significant mutation × time interaction (F(10,45)
= 13; p<0.001) for Y470F-hDAT and Y470A-hDAT compared to WT. Post-hoc analysis
showed that compared to WT hDAT, DA efflux levels were elevated at 1 and 10 min in
Y470A-hDAT only (Figure 3.6C; p < 0.05, Bonferroni t-test). Similarly, a two-way ANOVA
revealed significant main effects of mutation (F(3, 13) = 45; p<0.001) and time (F(5, 65) = 75;
p<0.001) for Y88F-hDAT and K92M-hDAT compared to WT. A significant mutation × time
interaction (F(15, 65) = 24; p<0.001) was also found. Post-hoc analysis revealed that compared
to WT hDAT, DA efflux levels were at 1 and 10 min in K92M-hDAT (Figure 3.7C; p <
0.05, Bonferroni t-test) but not in Y88F-hDAT. With regarding to MPP+ efflux, a two-way
ANOVA revealed significant main effects of mutation (F(2, 9) = 19; p<0.05), time (F(5, 45) =
253; p<0.001) and significant mutation × time interaction (F(10, 45) = 10; p<0.001) for Y470F-

77

hDAT and Y470A-hDAT compared to WT. Post-hoc analysis displayed that compared to
WT hDAT, MPP efflux levels were elevated at 1, 10, 20, 30, 40 and 50 min in Y470AhDAT only (Figure 3.6D; p < 0.05, Bonferroni t-test). Taken together, this data suggest that
Tyr470, Tyr88 and Lys92 residues differentially affect the basal efflux levels of either DA or
MPP+.
3.4 DISCUSSION
Recently, we have demonstrated that Tyr470 in hDAT is a key residue in the
intermolecular interaction between Tat and hDAT (Midde et al., 2013). In the current study,
we extended characterization of Tyr470 by additional substitution mutations. Further, we
pursued to characterize other predicted amino acids Tyr88 and Lys92 in the interaction of
Tat with DAT. Tyr470 mutants exhibited differential impact on DAT uptake capacity and
Tat-induced inhibition of DAT function, indicating the importance of Tyr470 in DAT
interaction with Tat protein through cation- interaction. Mutations at Tyr88 and Lys92
exhibited increased potencies for inhibitors to inhibit [3H]DA uptake and [3H]WIN 35,428
binding with less impact on potencies for DA substrate to inhibit [3H]DA uptake and
[3H]WIN 35,428 binding, suggesting the influence of Tat interaction on inhibitors binding to
DAT without interfering the DA uptake site. Notably, Y470F, Y470A, Y88F and K92M
mutants did not reverse the Zn2+-facilitated inhibition of DA uptake but decreased the zincmediated potentiation of WIN35,428 binding. In addition, Y470A and K92M displayed
significant elevation in DA basal efflux compared to WT, suggesting the involvement of
these residues in maintenance of conformational states of the transporter. Overall, our
experimental evidence shows that Tyr88, Lys92 and Tyr470 play an essential role in
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imparting Tat-induced conformational alterations in DAT and thereby inhibiting DA
translocation process.
The current results show that K92M decreases Vmax but not the Y88F, and both
mutants failed to show appreciable change in Km values compared to WT, reflecting that
K92M indirectly involve in DA transport but not the Y88F. The likely reasons for impaired
translocation in K92M would be either loss of transporter density on the membrane or
alteration of DA turnover rate. Because of surface biotinylation data revealed similar
amounts of WT and K92M mutant in the plasma membrane (Fig 3.4B) and Km value for DA
uptake was not changed, the turnover for DA is possibly decreased in this mutant.
Furthermore, decreased binding capacity and increased affinity for [3H]WIN35,428 binding
(Table 3.2) were noted in both mutants. These observations indicate that Tat binding sites,
Y88 and K92 are localized close to WIN35,428 binding site. Remarkably, our previous work
showed that Tat protein decreases Bmax for [3H]WIN35,428 binding in dose dependent
manner (Zhu et al., 2009). In addition, IC50 values for DA inhibiting [3H]DA uptake were not
significantly altered in both mutants supporting the view that Y88 and K92 residues do not
manipulate the DA binding affinities for the transporter. In contrary, IC50 values for
inhibitors cocaine, GBR12909 inhibiting [3H]DA uptake are considerably decreased in both
mutants compared to WT (Table 3.1), suggesting that increased potency for inhibitors
observed in these mutants is a consequence of influence of Y88 and 92 on inhibitors binding
sites. Similarly, this interpretation was further supported by increased potencies for inhibitors
to inhibit [3H]WIN35,428 binding in these mutants (Table 3.2). Cocaine and its analog
WIN35,428, and atypical inhibitor GBR12909 represent different classes of DAT inhibitors.
While cocaine-like compounds exhibit increased binding affinity, GBR12909 shows weaker
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binding affinity for DAT mutants (W84L, D313N and Y335A) that influence the
conformational states of the transporter (Chen et al., 2001; Loland et al., 2002; Chen et al.,
2004). Unlike these reported mutants, Y88F and K92M displayed enhanced potencies for
both cocaine and GBR12909, revealing that Tat may increase the effectiveness of cocaine
through interaction at Tat binding sites. Furthermore, cocaine-like compounds were shown to
interact with TM1 and TM6 of DAT, in the vicinity of substrate binding site (Beuming et al.,
2008; Parnas et al., 2008). As our computational modeling data indicated Tat impacts TM1b
and TM6a helices movement through interacting with Tyr 88, Lys 92 and Tyr 470 (Figure
3.2), it is conceivable that Tat and cocaine may have synergistic or additive effects on DAT
function. In support of this interpretation, a recent study demonstrated that Tat expression in
brain potentiates cocaine behavioral effects in mice (Paris et al., 2013) . Thus, these results
support the idea of interactive effects of Tat and cocaine on DAT function.
We demonstrated that mutating Tyr470 to His attenuates the inhibitory effects of Tat
on DA uptake by eliminating both hydrogen bond and cation- interactions with Tat (Midde
et al., 2013). To further validate Tyr470 residue, substitution mutants Y470A, Y470W and
Y470F were generated with the expectation that Y470A and Y470W show characteristics
similar to Y470H but with different sizes. Y470F mutant abolishes only hydrogen but not the
cation- interactions (Figure 3.3). We did not characterize Y470W mutant because our
efforts failed to improve basal uptake in this mutant irrespective of increased DNA for
transfections or protein concentration for assays. Y470A displayed mitigation of Tat
inhibitory effects on DA translocation (Figure 3.5A), which is similar to our reported mutant
Y470H (Midde et al., 2013). Interestingly, other mutant Y470F failed to diminish Tatmediated effects on DA transport, indicating the important role of aromatic ring of Y470 in
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DAT and Tat interaction. Moreover, Y88F and K92M mutants clearly showed attenuation of
Tat-induced inhibition of DA uptake (Figure 3.5B) which is in line with Y470H and Y470A.
Importantly, Tat Cys22 protein inhibitory effect was evidently attenuated by the mutant
transporters irrespective of substitution, signifying the importance of physical interaction of
Tat with DAT on transporter function. However, other residues of Tat protein that are
involved in this interaction are needed to be evaluated. Taken together, this data demonstrate
that Tat exploits Y470, Y88 and K92 amino acids of DAT to induce inhibitory effects on
transporter function.
In our recent report we revealed that Y470H mutant transporter prefers inward-facing
conformational state (Midde et al., 2013). Zinc, a DAT modulator that stabilizes the
transporter in outward conformation by loosely binding to the transporter, is extensively used
to study the conformational effects of mutants on transporter function (Loland et al., 2003).
Accordingly, studies show that Zn2+ inhibits DA uptake and increases WIN35,428 binding in
WT. In the present study, we showed that Y88F, K92M, Y470F and Y470A mutants do not
attenuate Zn2+-mediated inhibition of [3H]DA transporter but decrease potentiation of
[3H]WIN 35,428 binding compared to WT. Established evidence indicate that transporters
that prefer inward facing state reverse Zn2+ inhibitory effects on DA uptake and decrease
Zn2+ -mediated WIN35,428 binding (Loland et al., 2002; Loland et al., 2004; Guptaroy et al.,
2009; Liang et al., 2009; Midde et al., 2013). A possible explanation for Y88F, K92M,
Y470F and Y470A mutants failing to reverse Zn2+ influence on DA uptake could be that
these particular mutants induce an aberrant structure of the DAT that may not be suitable for
Zn2+ inhibitory effects on DA translocation because Zn2+ binding require strict geometrical
structural constraints (Alberts et al., 1998). However, our data strongly supports a modified
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conformational change in the mutant transporters by attenuation of Zn2+ induced [3H]WIN
35,428 binding (Figure 3.6B, 3.7B) and by showing increased inhibitor potency values for
inhibiting [3H]WIN 35,428 binding (Table 3.2). The effect of mutations on conformational
states of DAT was further probed by measuring substrate basal efflux. We used both DA and
MPP+ for efflux studies to produce more accurate outcomes as MPP+ has less diffusive
properties than DA. In our recent study we showed that Y470H mutant robustly increases
DA efflux compared to WT (Midde et al., 2013). In the present study, we found that Y470A
exhibits increased efflux of both DA and MPP+ but not the Y470F mutant. The likely
explanation for normal efflux in Y470F would be due to less impact of this substitution on
the structural integrity of the transporter. Interestingly, K92M displayed increased DA efflux
at two initial time points but failed to retain this ability when MPP+ efflux was measured.
The possible reason for K92M not replicating elevated efflux levels in [3H]MPP+ efflux
assay as in [3H]DA efflux may be due to assuming a putative conformation that is not
favorable to MPP+ binding (Liang et al., 2009). This conformation may favor slower
transition between inward and outward facing states and less effective at inducing DATmediated efflux at least for substrate MPP+. The alternative explanation would be quick loss
of substrate DA but not MPP+ by diffusion after short period of accumulation. Taken
together these findings infer that Y470A and K92M disrupt the inter-molecular interaction
required to maintain transporter outward facing conformation. Nevertheless, we proposed
that Tat promotes alterations in transporter conformation through allosteric regulation (Zhu
et al., 2009; Zhu et al., 2011). Intriguingly, this mechanism is similar to the exogenous full
substrates like amphetamines action on DAT (Robertson et al., 2009; Rothman et al., 2009).
Therefore, it is important that systemic identification and characterization of all Tat binding
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sites in DAT are required in order to pin point the mode of action of Tat on rearrangements
of DAT conformational cycle.
In summary, we have evaluated different substitutions at 470 (Y470F and Y470A)
and identified additional residues (Y88 and K92) in DAT that are predicted to be interact
with Tat. All mutants attenuated the inhibitory action of Tat on DA translocation except
Y470F and we reasoned that these alterations are the result of disruption of critical
intramolecular interactions in DAT by Tat binding. As different substitutions at 470
consistently favored against Tat-induced decrease in DA uptake it is apparent that Tyr 470 of
DAT plays central role in Tat and DAT interaction, and Tyr 88 and Lys 92 may work as
supporting residues along with other unidentified residues. Because Tat-driven allosteric
mechanism down regulates DA uptake (Zhu et al., 2011) and mutations at predicted amino
acids show alterations in conformational distribution of DAT, future investigations that
identify and validate other recognition residues will certainly improve our understanding of
functional relevance of Tat binding sites on DAT. This information would be useful to
develop therapeutics that alleviate imbalances of the DA system in HIV-infected individuals.

83

Table 3.1 Summary of kinetic properties and inhibitory activities in [3H]DA uptake in
CHO cells expressing WT and mutated hDATs.
IC50 (nM)

Vmax
(pmol/105
cells)

Km (µM)

WThDAT

12.4 ± 4.6

Y88FhDAT
K92MhDAT

DA

Cocaine

GBR12909 WIN35,428

1.2 ± 0.4

1730 ±
82

285 ± 49

224 ± 41

39 ± 10

14.8 ± 3.7

1.9 ± 0.3

2010 ±
60

160 ± 9*

95 ± 7*

20 ± 2

4.5 ± 1.7*

1.9 ± 0.4

2870 ±
48

69 ± 4*

101 ± 12*

10 ± 1*

Data are presented as mean ± S.E.M. values from 5-7 independent experiments performed in
duplicate. * p < 0.05 compared with WT hDAT (unpaired Student’s t test).
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Table 3.2 Summary of kinetic properties and inhibitory activities in [3H]WIN 35,428
binding in PC12 cells expressing WT and mutated hDATs.
IC50 (nM)

Bmax
(pmol/105
cells)

Kd (nM)

WT-hDAT

9.7 ± 1.6

Y88F-hDAT
K92M-hDAT

DA

Cocaine

GBR12909

8.6 ± 1.1

827 ± 102

150 ± 8.6

20.7 ± 6.3

5.8 ± 0.9

4.0 ± 0.6*

2071 ± 340*

85 ± 6.9

15.1 ± 5.1

2.4 ± 0.4*

3.5 ± 1.1*

4211 ± 118*

106 ± 31.5

12.8 ± 14.3

Data are presented as mean ± S.E.M. of IC50 values from five independent experiments
performed in duplicate. * p < 0.05 compared with WT hDAT (unpaired Student’s t test).
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Figure 3.1 MD simulated structure of outward-open DAT (A and B) and structure of
inward-open DAT (C and D). (A) Side view of outward-open state of DAT structure shown
as cyan-colored ribbon. 2 Na+ ions and 1 Cl- ion are shown as spheres. (B) Local view of the
residues around the mouth of the vestibule of outward-open state of DAT. These residues are
R85, Y88, K92, D313, Y470 and D476 shown in stick-style. Hydrogen bond between K92
and D313 are represented as dashed lines with labeled distances (between hydrogen bond
donor and acceptor, unit in Å), which stabilized the TM1b and TM6a. (C) Side view of
inward-open state of DAT structure shown as colored ribbon. 1 Cl- ion is shown as sphere.
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(D) Local view of residues around the mouth of the vestibule of inward-open state of DAT.
We also found that the salt bridge formed by the positive side chain of residue R85 and the
negative side chain of D476 act as the gate for the entry of substrate dopamine into its biding
pocket. The R85-D476 salt bridge are also labeled, which stabilized the inward-open state of
DAT.
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Figure 3.2 MD simulated structure of HIV-1 Tat-DAT binding complex. (A) HIV-1 Tat protein is shown as ribbon and colored in golden,
and DAT is represented as cyan ribbon. Residues T-M1, T-P18 and T-K19 of HIV-1 Tat are represented as sticks and colored by atom
types. Dopamine is shown as green spheres. One Cl- ion is shown as a green sphere, and two Na+ ions as blue spheres. (B) Atomic

interactions between HIV-1 Tat and DAT as observed from the binding structure. Critical residues of inter-molecular interactions from
HIV-1 Tat and DAT are shown in stick style and colored by atom types. Two dashed lines on the left represent inter-molecular hydrogen
bonds with labeled distances. The orange ball indicates the center of aromatic ring, and the dashed line pointing to the orange ball
represents the cation-π interaction with labeled distance.
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Figure 3.3 Interaction between TAT-M1 and DAT-Y470 mutations. (A) Residues T-M1 and
D-Y470 are represented as sticks and colored by atom types. The orange ball indicates the
center of aromatic ring, and the dashed line pointing to the orange ball represents the cationπ interaction with labeled distance. (B) Y470F mutation retains the cation-π interaction
between T-M1 and D-Y470. It can be expected Y470F would bring little influence on the
TAT effect, which is consist with experimental data. (C) Y470W would eliminate the cationπ interaction because of the unfavorable van der Waals interaction, which is expected to
exhibit attenuation on DAT-TAT binding affinity. (D) Y470A would eliminate the cation-π
interaction between T-M1 and D-Y470, which is also expected to exhibit attenuation on
DAT-TAT binding affinity.
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Figure 3.4 [3H]DA uptake and DAT surface expression in WT hDAT and mutants. (A)
Kinetic analysis of [3H]DA uptake in WT hDAT, Y88F-hDAT and K92M-hDAT. CHO cells
transfected with WT hDAT, Y88F-hDAT or K92M-hDAT were incubated with one of six
mixed concentrations of the [3H]DA as total rate of DA uptake. In parallel, nonspecific
uptake of each concentration of [3H]DA (in the presence of 10 µM nomifensine, final
concentration) was subtracted from total uptake to calculate DAT-mediated uptake. * p <
0.05 compared to control value (unpaired Student’s t test) (n = 5). (B) Cell surface
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expression of WT hDAT (WT), Y88F-hDAT (Y88F) and K92M-hDAT (K92M) was
analyzed by biotinylation assay. Top panel: representative immunoblots in CHO cells
expressing WT hDAT, Y88F-hDAT or K92M-hDAT. Bottom panel: DAT immunoreactivity
is expressed as mean ± S.E.M. densitometry units from three independent experiments (n =
3). * p < 0.05 compared to WT hDAT (unpaired Student’s t test).
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Figure 3.5 Effects of Tat or Tat Cys22 on [3H]DA uptake in WT hDAT and mutants. (A)
PC12 cells transfected with WT, Y470F-hDAT (Y470F), Y470H-hDAT (Y470H) or
Y470A-hDAT (Y470A) were preincubated with or without recombinant Tat Cys22 or Tat1-86
(rTat1-86) at 500 nM final concentration at room temperature for 20 min followed by the
addition of 0.05 μM final concentration of the [3H]DA. Nonspecific uptake was determined
in the presence of 10 µM final concentration of nomifensine. (B) [3H]DA uptake in cells
transfected with WT hDAT (WT), Y88F-hDAT (Y88F) and K92M-hDAT (K92M) was
determined in the presence or absence of Tat Cys22 or rTat1-86 (500 nM, final concentration).
Data are expressed as means from seven independent experiments ± S.E.M. * p < 0.05
compared with the respective control values. # p < 0.05 compared to WT hDAT. (n = 5)
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Figure 3.6 Effects of Y470F, Y470A and Y470H mutants on transporter conformational
transitions. Mutations of Tyr470 affect zinc regulation of [3H]DA uptake (A) and [3H]WIN
35,428 binding (B). CHO cells transfected with WT hDAT (WT), Y470F-hDAT (Y470F)
and Y470A-hDAT (Y470A) were incubated with assay buffer alone (control) or ZnCl2 (10
µM, final concentration) followed by [3H]DA uptake or [3H]WIN 35,428 binding (n = 6).
The histogram shows [3H]DA uptake and [3H]WIN 35,428 binding expressed as mean ±
S.E.M. of the respective controls set to 100% for the mutant. * p < 0.05 compared to control.
#
p < 0.05 compared to WT hDAT with ZnCl2. Functional efflux of (C) DA and (D) MPP+
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was determined in WT hDAT and mutants. CHO cells transfected with WT hDAT or
mutants were preincubated with [3H]DA (0.05 µM, final concentration) or [3H]MPP+ (5 nM,
final concentration) at room temperature for 20 or 30 min, respectively. After incubation,
cells were washed and incubated with fresh buffer as indicated time points. Subsequently,
the buffer was separated from cells, and radioactivity in the buffer and remaining in the cells
was counted. Each fractional efflux of [3H]DA or [3H]MPP+ in WT hDAT (WT), Y470FhDAT (Y470F), Y470A-hDAT (Y470A) or Y470H-hDAT was expressed as percentage of
total [3H]DA or [3H]MPP+ in the cells at the start of the experiment. Fractional [3H]DA
efflux at 1, 10, 20, 30, 40 and 50 min are expressed as the percentage of total [3H]DA with
preloading with 0.05 µM (WT hDAT: 26837 ± 5089 dpm, Y470F-hDAT: 20908 ± 4209
dpm, Y470A-hDAT: 1158 ± 123 dpm and Y470H-hDAT: 2488 ± 150 dpm) present in the
cells at the start of the experiment (n = 3). ×× p < 0.05 compared to WT hDAT (Bonferroni ttest). Fractional [3H]MPP+ efflux at 1, 10, 20, 30, 40 and 50 min are expressed as the
percentage of total [3H]MPP+ with preloading with 0.05 µM (WT hDAT: 12120 ± 397 dpm,
Y470F-hDAT: 7399 ± 359 dpm, Y470A-hDAT: 460 ± 46 dpm and Y470H-hDAT: 602 ±
28 dpm) present in the cells at the start of the experiment (n = 3). ×× p < 0.05, compared to
WT hDAT (Bonferroni t-test).
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Figure 3.7 Effects of Y88F and K92M mutants on transporter conformational transitions.
Mutations of Tyr88 and Lys92 affect zinc regulation of [3H]DA uptake (A) and [3H]WIN
35,428 binding (B). The histogram shows [3H]DA uptake and [3H]WIN 35,428 binding
expressed as mean ± S.E.M. of the respective controls set to 100% for the mutant. * p < 0.05
compared to control. # p < 0.05 compared to WT hDAT with ZnCl2. Functional efflux of
(C) DA and (D) MPP+ was determined in WT hDAT and mutants. Each fractional efflux of
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[3H]DA or [3H]MPP+ in WT hDAT (WT), Y88F-hDAT (Y88F) or K92M-hDAT (K92M)
was expressed as percentage of total [3H]DA or [3H]MPP+ in the cells at the start of the
experiment. Fractional [3H]DA efflux at 1, 10, 20, 30, 40 and 50 min are expressed as the
percentage of total [3H]DA with preloading with 0.05 µM (WT hDAT: 70082 ± 8256 dpm,
Y88F-hDAT: 41805 ± 6887 dpm and K92M-hDAT: 9655 ± 2160 dpm) present in the cells at
the start of the experiment (n = 3). ×× p < 0.05 compared to WT hDAT (Bonferroni t-test).
Fractional [3H]MPP+ efflux at 1, 10, 20, 30, 40 and 50 min are expressed as the percentage
of total [3H]MPP+ with preloading with 0.05 µM (WT hDAT: 15516 ± 920 dpm, Y88FhDAT: 5695 ± 450 dpm and K92M-hDAT: 967 ± 121 dpm) present in the cells at the start
of the experiment (n = 3).
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CHAPTER 4
HIV-1 TAT PROTEIN DECREASES DOPAMINE TRANSPORTER CELL SURFACE
EXPRESSION AND VESICULAR MONOAMINE TRANSPORTER-2 FUNCTION IN RAT
STRIATAL SYNAPTOSOMES2

ABSTRACT: The dopamine (DA) transporter (DAT) and vesicular monoamine transporter
(VMAT2) proteins interact as a biochemical complex to regulate dopaminergic
neurotransmission. We have reported that HIV-1 Tat1-86 decreases the specific [3H]DA
uptake and [3H]WIN 35,428 binding sites without a change in total DAT immunoreactivity
in rat striatum (Zhu et al., 2009b). The present study determined the effects of Tat on DAT
phosphorylation and trafficking, and vesicular [3H]DA uptake. Pre-incubation of rat striatal
synaptosomes with the protein kinase C (PKC) inhibitor bisindolylmaleimide I (1 µM)
completely blocked Tat1-86 -induced reduction of [3H]DA uptake, indicating that Tat
regulates DAT function through a PKC-dependent mechanism. After exposure of
synaptosomes to Tat1-86 (1 µM), DAT immunoreactivity was decreased in plasma membrane
enriched fractions (P3) and increased in vesicle-enriched fractions (P4) relative to controls
without change in total synaptosomal fractions (P2), suggesting that Tat-induced inhibition
of DA uptake is attributable to DAT internalization. Although both DAT and VMAT2
proteins are essential for the regulation of DA disposition in synapse and cytosol, Tat
Midde NM, Gomez AM, Zhu J (2012) HIV-1 Tat Protein Decreases Dopamine Transporter Cell
Surface Expression and Vesicular Monoamine Transporter-2 Function in Rat Striatal Synaptosomes.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune
Pharmacology. PMCID: PMC3688268
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inhibited the specific [3H]DA uptake into vesicles (P4) and synaptosomes (P2) by 35% and
26%, respectively, inferring that the inhibitory effect of Tat was more profound in VMAT2
protein than in DAT protein. Taken together, the current study reveals that Tat inhibits DAT
function through a PKC and trafficking-dependent mechanism and that Tat impacts the
dopaminergic tone by regulating both DAT and VMAT2 proteins. These findings provide
new insight into understanding the pharmacological mechanisms of HIV-1 viral proteininduced dysfunction of DA neurotransmission in HIV-infected patients.
4.1 INTRODUCTION
The prevalence of HIV-1-associated neurocognitive disorders (HAND) in HIV-1
positive individuals remains high (~50%), regardless of the success with treatments of antiretroviral agents effectively controlling viral replication and dramatically improving
longevity (Robertson et al., 2007; Tozzi et al., 2007; Ernst et al., 2009). Notably, the
incidence and severity of HAND are greatly enhanced (~70%) due to concomitant use of
drugs of abuse such as cocaine (Norman et al., 2009), which has been postulated as a comorbid factor in the susceptibility and progression of HAND (Larrat and Zierler, 1993; Fiala
et al., 1998; Webber et al., 1999; Buch et al., 2011). While HIV-1 virus enters the brain and
produces proviral DNA in the early stage of HIV-1 infection (Nath and Clements, 2011),
anti-retroviral agents cannot prevent the production of HIV-1 viral proteins in infected brain
cells (McArthur et al., 2010; Nath and Clements, 2011). HIV-1 viral proteins, such as Tat,
have been detected in brains of patients with HIV-1 infection (Del Valle et al., 2000; Hudson
et al., 2000; Lamers et al., 2010), and have been implicated in the pathophysiology of HAND
(Li et al., 2009). Moreover, Tat protein has been found to synergize with psychostimulant
drugs in producing profound neural and behavioral impairments in preclinical models (Ferris
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et al., 2008), consistent with the findings in the human HIV-1 positive drug abusing
population (Larrat and Zierler, 1993). Unfortunately, there are no promising therapeutic
approaches for such HIV-1-associated neurocognitive impairments.
The development of neurocognitive dysfunction in HAND patients is associated with
perturbations of the central dopamine (DA) neurotransmission (Kumar et al., 2011; Meade et
al., 2011a). The DA system is a clinically relevant HAND target as evidenced by recent
human imaging (Chang et al., 2008; Meade et al., 2011a), neurocognitive (Kumar et al.,
2011; Meade et al., 2011b), and post-mortem examinations (Silvers et al., 2007; Kumar et
al., 2009), that HAND is associated with vulnerability of the DA system. Limited studies
have reported that DA levels are decreased in DA-rich brain area (Sardar et al., 1996; Kumar
et al., 2009), but increased in the CSF (Scheller et al., 2010) of HAND patients. The DA
transporter (DAT) is critical for DA homeostasis, which is critical for neurocognitive
function (Chudasama and Robbins, 2006). DAT is a target for HIV-1 viral proteins (Hu et
al., 2009; Zhu et al., 2009b) and cocaine to impact the DA system (Zhu and Reith, 2008).
We have demonstrated that Tat inhibits DA uptake in rat striatal synaptosomes and that
influence of Tat on DAT ligand binding sites involves a protein-protein interaction (Zhu et
al., 2009b). In particular, we have shown that Tat allosterically inhibits DAT function and
modulates cocaine binding sites on DAT in rat striatal synaptosomes and heterologous cells
expressing human DAT (Zhu et al., 2011).
The dynamic regulation of DAT function and cell surface localization of DAT are
under the control of complex processes involving phosphorylation, protein-protein
interaction, substrate pretreatment, and interaction with presynaptic receptors (Zhu and
Reith, 2008). For example, activation of protein kinase C (PKC) results in reduced DA
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transport activity, decreased transporter recycling and DAT cell surface expression, thereby
causing reduced DA uptake (Daniels and Amara, 1999; Melikian, 2004; Zahniser and
Sorkin, 2004). On one hand, dynamic cell surface localization of DAT is regulated by
cellular signaling pathways and endocytotic trafficking (Zhu and Reith, 2008). On the other
hand, the DAT and vesicular monoamine transporter (VMAT2) proteins interact as a
biochemical complex to regulate dopaminergic tone in response to motivationally relevant
stimuli, including abused drugs (Vergo et al., 2007; Zhu and Reith, 2008; Egana et al., 2009).
This study was aimed to understand the molecular mechanisms underlying Tatinduced decrease in DAT reuptake activity. The primary hypothesis tested here was that Tatinduced reduction of DA transport is attributable to acceleration of DAT endocytosis through
the dynamic-trafficking and phosphorylation-dependent mechanisms and that both DAT and
VMAT-2 function contribute to Tat-induced impairment of DA neurotransmission.
4.2 MATERIAL AND METHODS
4.2.1 ANIMALS
Adult male Sprague – Dawley rats (225-250g body weight) were obtained from
Harlan Laboratories, Inc. (Indianapolis, IN). Rats were housed in standard polyurethane
cages and provided normal rodent food (ProLab Rat/Mouse/Hamster Chow 3000) and water
ad libitum. The colony was maintained at 21±2 °C, 50±10% relative humidity and a 12L:
12D cycle with lights on at 0700 h (EST).The animals were maintained according to the
National Institute of Health (NIH) guidelines in AAALAC accredited facilities. The
experimental protocol was approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of South Carolina.
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4.2.2 DRUGS AND CHEMICALS
[3H]DA (3,4-ethyl-2[N-3H]dihydroxyphenylethylamine; specific activity, 31
Ci/mmol) and [3H]WIN 35,428 (specific activity, 85 Ci/mmol) were purchased from
PerkinElmer Life and Analytical Sciences (Boston, MA). Recombinant HIV-1 transactivator
of transcription (Tat1–86, Clade B, REP0002a) protein and its mutant protein Tat Cys22
(cysteine 22 was substituted to glycine, REP0032) were purchased from Diatheva (Fano,
Italy). D-amphetamine, cocaine and Bisindolylmaleimide-I (BIM-I) were purchased from
Tocris Biosciences (Ellisville, MO). Tetrabenazine (TBZ) was provided by NIMH Chemical
Synthesis and Drug Supply Program (Bethesda, MD). Antibodies recognizing rat DAT (C20; goat polyclonal antibody) and actin (C-2; mouse monoclonal antibody) were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-goat IgG horseradish
peroxidase was purchased from Jackson ImmunoResearch Laboratories Inc. (West Grove,
PA). Goat anti-mouse IgG-horseradish peroxidase was purchased from Santa Cruz
Biotechnology, Inc. D-Glucose, L-ascorbic acid, WIN35,428, L-leucine, L-lysine, bovine
serum albumin, pyrocatechol, EDC, HEPES, isopropanol, nomifensine maleate, pargyline
hydrochloride, polyethylene glycol, sucrose, and Tween 20 were purchased from SigmaAldrich (St. Louis, MO).
4.2.3 PREPARATION OF SYNAPTOSOMES, SUBFRACTIONS AND SYNAPTIC VESICLES
Striata from individual rats were homogenized in 20 ml of ice-cold 0.32 M sucrose
containing 5 mM NaHCO3, pH 7.4, with 16 up-and-down strokes using a Teflon pestle
homogenizer (clearance, approximately 0.003 in.). Crude synaptosomal preparation was
centrifuged at 2000g for 10 min at 4°C, and the resulting supernatants were then centrifuged
at 20,000g for 15 min at 4°C. The resulting pellets (P2 fractions) were resuspended in 5 ml
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of ice-cold Krebs-Ringer-HEPES assay buffer (final concentration in mM: 125 NaCl, 5 KCl,
1.5 MgSO4, 1.25 CaCl2, 1.5 KH2PO4, 10 D-glucose, 25 HEPES, 0.1 EDTA, 0.1pargyline,
and 0.1 L-ascorbic acid, saturated with 95% O2, 5% CO2; pH 7.4) for the synaptosomal
[3H]DA uptake. To determine the distribution of DATs in subcellular fractions after
exposure to Tat, striata from every two rats were pooled to achieve sufficient vesicles and the
subcellular fractions were prepared using a previously published method with minor
modifications (Middleton et al., 2007). Striata were homogenized in ice-cold 0.32 M sucrose
buffer using a Teflon pestle homogenizer and then centrifuged at 800g for 12 min, 4°C. The
resulting supernatant (S1) was centrifuged at 22,000g for 15 min at 4°C to yield a crude
synaptosomal pellet (P2). The P2 pellet was then resuspended in DA uptake assay to obtain
synaptosomes. In order to determine whether Tat (1 µM)-induced decreases of [3H]DA
uptake, as observed in our previous report (Zhu et al., 2009b), was associated with a
reduction of DAT expression in plasma membrane, half of the synaptosomes were
preincubated with Tat1–86 (1 µM), and the other half were preincubated without Tat1–86 as
control at 34°C for 15 min. This concentration of Tat1–86 was chosen based on our previous
report showing that the inhibitory effect of Tat (1 µM) on DA uptake was reversible (Zhu et
al., 2009b). Subsequently, the synaptosomal samples were centrifuged at 22,000g for 15 min
at 4°C and synaptosomes in the pellets (P2) were then lysed in ice-cold 25 mM HEPES, pH
7.5, and 100 mM potassium tartrate (pH 7.4) plus phosphatase inhibitor cocktails I (P2850,
Sigma-Aldrich, St. Louis, MO) and protease inhibitor cocktail (P8340, Sigma-Aldrich, St.
Louis, MO). After thorough mixing of all contents, the resulting mixture was centrifuged at
20,000g for 15 min at 4°C to get the plasma membrane enriched (P3) and vesicle-enriched
supernatant (S3). The S3 was then centrifuged at 100,000g for 45 min at 4°C to yield the

103

cytoplasmic vesicles pellet (P4). The three fractions (P2, P3, and P4) were used for Western
blot assay. Protein concentrations were determined by the Bradford protein assay (Bradford,
1976) using bovine serum albumin as the standard (Bio-Rad Laboratories, Hercules, CA).
4.2.4 SYNAPTOSOMAL [3H]DA UPTAKE
[3H]DA uptake was determined using previously described methods (Zhu et al.,
2009b). Assays were performed in triplicate with a final volume of 1 mL. Aliquots of striatal
synaptosomes were preincubated in assay buffer containing BIM-I (100 µM, final
concentration) at 34 °C for 5 min in an oxygenated metabolic shaker, and then incubated
with amphetamine (20 µM, final concentration) or Tat (0.7 µM) for an additional 15 min.
The concentration of BIM-I was chosen based on the previous report showing that BIM-I
(100 µM) alone did not show inhibitory effect on [3H]DA into rat striatal synaptosomes
(Richards and Zahniser, 2009). A low concentration of Tat (0.7 µM) was chosen because
our previously published study (Zhu et al., 2009b) has demonstrated that Tat at both 0.7 and
1.0 µM concentrations significantly decreases [3H]DA uptake by 21% and 26%, respectively.
The purpose of the experiment was to determine whether Tat-induced decrease in DAT
function is PKC-dependent. We selected the low concentration because it was sufficient to
elicit a significant decrease in DA uptake for the PKC experiment. Subsequently, the
synaptosomes were centrifuged at 20,000g for 15 min and the resulting pellets were
resuspended with ice cold assay buffer. Aliquots of the well-washed synaptosomes were
incubated with 5 nM [3H]DA (final concentration) at 34 °C for 10 min. The reactions were
terminated by the addition of 3 ml of ice-cold assay buffer. Nonspecific uptake was
determined in duplicate at each [3H]DA concentration by including 10 µM nomifensine in
the assay buffer. Samples were filtered through Whatman GF/B glass fiber filters (Whatman,
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Maidstone, UK), presoaked with assay buffer containing 1 mM pyrocatechol. Filters were
washed three times with 3 ml of ice-cold assay buffer containing 1 mM pyrocatechol using a
Brandel cell harvester (model M-48; Biochemical Research and Development Laboratories
Inc., Gaithersburg, MD). Pyrocatechol (catechol) is a catechol-O-methyltransferase inhibitor.
In the current study, pyrocatechol (1 mM) was included in the DA uptake assay buffer to
prevent the degradation of [3H]DA during the processes of washes and harvesting (Zhu et al.,
2004). Radioactivity was determined using liquid scintillation spectrometry (model Tri-Carb
2900TR; PerkinElmer Life and Analytical Sciences).
4.2.5 VESICULAR [3H]DA UPTAKE
To determine inhibitory effects of Tat on VMAT-2 function, vesicular [3H]DA
uptake was measured using previously described methods (Volz et al., 2007). In brief,
assays were performed in duplicate with a final volume of 250 µl. For the competitive
inhibition experiment, aliquots of P4 suspensions were preincubated in VMAT-2 assay
buffer (final concentration in mM: 25 HEPES, 100 potassium tartrate, 0.05 EGTA, and 0.1
EDTA, 1.7 ascorbic acid, and 2 ATP-Mg2+, pH 7.5) containing Tat, Tat Cys22 or TBZ (final
concentration, 0.1 nM-10 µM) at 34 ºC for 15 min in an oxygenated metabolic shaker and
subsequently incubated with a fixed concentration of [3H]DA (1 µM, final concentration) at
34 ºC for additional 8 min. To determine if Tat differentially inhibits DAT and VMAT-2
function, in a separate experiment, synaptosomes were preincubated with 1 µM Tat at 34 ºC
for 15 min. Subsequently the synaptosomes were washed with fresh ice-cold assay buffer,
and P2 and P4 fractions were then separated as described above. Aliquots of P4 fractions
were incubated in the assay buffer with 1 to 8 concentrations of [3H]DA (0.03-5 µM) at 34
ºC for 8 min. Nonspecific uptake was determined in the presence of 10 µM TBZ. Reactions
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were terminated by addition of 1 ml of cold wash buffer (assay buffer containing 2 mM
MgSO4 substituted for the ATP-Mg2+, pH 7.5) and rapid filtration through Whatman GF/B
filters soaked previously in 0.5% polyethylenimine. Filters were washed 3 times with the
VMAT-2 assay buffer and radioactivity was measured using a liquid scintillation counter.
4.2.6 WESTERN BLOTS
Proteins were extracted from each fraction (P2, P3 and P4) as described above with
the Laemmli sample buffer (Sigma-Aldrich, St. Louis, MO) containing phosphatase
inhibitor cocktail 1 (P2850, Sigma-Aldrich, St. Louis, MO) and protease inhibitors (P8340,
Sigma-Aldrich, St. Louis, MO) and boiled for 5 min. To detect the immunoreactive DAT
protein in these fractions, samples were subjected to gel electrophoresis and Western
blotting. Proteins were separated by 10% SDS-polyacrylamide gel electrophoresis for 90 min
at 150 V and transferred to Immobilon-P transfer membranes (Millipore, Billerica, MA) in
transfer buffer (50 mM Tris, 250 mM glycine, and 3.5 mM SDS) using a Mini Trans-Blot
Electrophoretic Transfer Cell (Bio-Rad Laboratories) for 110 min at 72 V. Transfer
membranes were incubated with blocking buffer (5% dry milk powder in phosphate-buffered
saline containing 0.5% Tween 20) for 1 h at room temperature, followed by incubation with
goat polyclonal DAT antibody (1 µg/ml in blocking buffer) overnight at 4°C. Transfer
membranes were washed five times with wash buffer (phosphate-buffered saline containing
0.5% Tween 20) at room temperature and then incubated with rabbit anti-goat DAT antibody
(1:2500 dilution in blocking buffer) for 1 h at 22°C. Blots on transfer membranes were
detected using enhanced chemiluminescence and developed on Hyperfilm ECL-Plus (GE
Healthcare, Chalfont St. Giles, Buckinghamshire, UK). After detection and quantification of
the DAT protein, each blot was stripped in 10% Re-blot plus mild antibody stripping
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solution (Millipore Bioscience Research Reagents, Temecula, CA) for 20 min at room
temperature and reprobed for detection of actin. Actin was used as an intracellular control
protein to monitor protein loading between samples and determined using a mouse
monoclonal antibody (1:1000 dilution in blocking buffer). Multiple autoradiographs were
obtained using different exposure time, and immunoreactive bands within the linear range of
detection were quantified with densitometric scanning (Scion Image software; Scion
Corporation, Frederick, MD). Band density measurements, expressed as relative optical
density, were used to determine levels of the DAT immunoreactivity in synaptosomes.
4.2.7 [3H]WIN 35,428 BINDING ASSAY
To determine whether Tat-induced inhibition of [3H]DA uptake was the result of
alterations in the maximal number of binding sites (Bmax) or affinity (Kd) for [3H]WIN
35,428 binding in P3 fraction, kinetic analysis of [3H]WIN 35,428 binding was determined
using a previously described method (Zhu et al., 2009b). After exposure of synaptosomes to
Tat (1 µM) or vehicle (control) as described above, the P3 pellets were resuspended in icecold sodium-phosphate buffer (2.1 mM NaH2PO4, 7.3 mM Na2HPO47H2O, and 320 mM
sucrose, pH 7.4). Aliquots of P3 fractions were incubated with one of the eight
concentrations of [3H]WIN 35,428 (final concentration, 0.5–30 nM) on ice for 2 h. In
parallel, nonspecific binding at each concentration of [3H]WIN 35,428 (in the presence of 30
µM cocaine, final concentration) was subtracted from total binding to calculate the specific
binding. Assays were terminated by rapid filtration onto Whatman GF/B glass fiber filters,
presoaked for 2 h with the assay buffer containing 0.5% polyethylenimine, using a Brandel
cell harvester. Filters were rinsed three times with 3 ml of ice-cold assay buffer.
Radioactivity remaining on the filters was determined by liquid scintillation spectrometry.
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4.2.8 DATA ANALYSIS
Data are presented as mean ± S.E.M., and n represents the number of independent
experiments for each experiment. The effect of BIM-I on Tat-induced changes in DA uptake
was analyzed by one-way ANOVA. Student-Newman-Keuls comparisons were made for
post hoc analyses. Separate paired Student’s t test was conducted on DAT immunoreactivity
for comparisons between control and Tat treated samples. Kinetic parameters (Bmax and Kd)
of [3H]WIN 35,428 binding were determined from saturation curves by nonlinear regression
analysis using a one-site model with variable slope. For experiments involving comparisons
between two paired samples, paired Student’s t test was used to determine the ability of Tat
to alter the kinetic parameters [Km and Vmax for [3H]DA uptake; Kd and Bmax for [3H]WIN
35,428 compared with control (the absence of Tat)]; log-transformed values of Km or Kd
were used for these statistical comparisons. IC50 values for Tat-induced inhibition in specific
vesicular [3H]DA uptake were determined from inhibition curves by nonlinear regression
analysis using a one-site model with variable slope. All statistical analyses were performed
using SPSS, standard version 19.0 (SPSS Inc., Chicago, IL), and differences were considered
significant at p < 0.05.
4.3 RESULTS
4.3.1 INVOLVEMENT OF PKC IN TAT-INDUCED DOWN-REGULATION OF DAT FUNCTION IN RAT
STRIATAL SYNAPTOSOMES
To determine whether the Tat-induced down-regulation of DAT function was
mediated by activation of PKC, synaptosomes were preincubated with the PKC inhibitor
BIM-I (1 µM) for 5 min prior to preincubation with Tat (0.7 µM) or amphetamine (20 µM)
for additional 15 min. Amphetamine was used as a positive control, because the previous
report has shown that amphetamine-induced down-regulation of DAT activity was blocked
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by preincubation of BIM-I (Richards and Zahniser, 2009). As shown in Figure 4.1,
amphetamine (F(3, 15) = 8.83, p < 0.01) or Tat (F(3, 15) = 8.28, p < 0.05) alone significantly
reduced [3H]DA uptake, and preincubation of BIM-I completely blocked both amphetamineand Tat-induced reductions.
4.3.2 TAT PROTEIN DECREASED CELL SURFACE DAT EXPRESSION IN RAT STRIATAL
SYNAPTOSOMES
To determine if the Tat-induced decrease in [3H]DA uptake of DAT function was
attributed to a reduction in the plasma membrane of the DATs, DAT expression in
subfractions was examined. As shown in Figure 4.2, after exposure of synaptosomes to Tat
(1 µM), DAT immunoreactivity was decreased by 46% in P3 fractions (t(3) = 3.22, p<0.05)
and increased by 49% in P4 fractions (t(3) = 5.64, p<0.05) without changes in P2 fractions.
To verify the Tat-induced decreases in P3 fractions, the Bmax of [3H]WIN 35,428 in P3
fractions was determined. Figure 4.3 shows that 15 min preincubation of synaptosomes with
Tat (1 µM) led to a significant decrease of the Bmax value by 64% (3.99 ± 0.6 pmol/mg
protein) compared with the control [11.2 ± 1.3 pmol/mg protein; t(3) = 5.6, p<0.05, paired
Student’s t test]. There was no change in the Kd value between Tat-treated and control
samples (38.9 ± 8.7 and 33.9 ± 11.4 nM).
4.3.3 INHIBITORY EFFECTS OF TAT ON VMAT-2 AND DAT FUNCTION
To determine whether Tat differentially inhibited DAT and VMAT-2 function, the
ability of Tat protein to inhibit vesicular [3H]DA uptake or synaptosomal [3H]DA uptake was
measured. As shown in Figure 4.4, 15 min preincubation of synaptosomes with Tat (1 µM)
caused a 35 ± 1.8 and 26 ± 1.5% reduction in [3H]DA uptake into vesicles and
synaptosomes, respectively.
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To determine the concentration-dependent inhibitory effect of Tat on specific [3H]DA
uptake into striatal vesicles, vesicular [3H]DA uptake was examined in the presence of
various concentrations of Tat. Specific [3H]DA uptake was substantially inhibited by Tat
(IC50 = 210 ± 19 nM; Figure 4.5). TBZ was used as a positive control for the [3H]DA uptake
assay and had a IC50 value of 9.8 ± 0.7 nM. Tat Cys22 was a negative control for the assay,
which showed no inhibitory effect on vesicular [3H]DA uptake across the concentration
range from 0.1 nM to 10 µM.
4.4 DISCUSSION
We have reported previously that Tat protein induced decrease of [3H]DA uptake in
rat striatal synaptosomes (Zhu et al., 2009b). The current study investigated the mechanism
of this Tat-induced impairment of DAT activity. This study also determined the effect of Tat
on VMAT-2 function. The results provide evidence that the Tat-induced decrease in DA
uptake is ascribed to a DAT trafficking- and phosphorylation-dependent mechanism. Further,
we demonstrated that Tat inhibited not only DAT activity but also VMAT-2 function. These
findings provide new insight into understanding the molecular mechanisms of HIV-1 viral
protein-induced dysfunction of DA neurotransmission in HIV-1 infected patients.
The present results are in agreement with previous work showing that in vitro
exposure of rat striatal synaptosomes to Tat protein leads to a decrease in DAT uptake
function (Wallace et al., 2006; Zhu et al., 2009b). In this study, while a PKC inhibitor, BIMI, alone had no effect on DA uptake, Tat (0.7 µM)-induced decrease (21%) in specific
[3H]DA uptake was ablated by BIM-I. Similarly, preincubation of the synaptosomes with
BIM-I completely blocked amphetamine-induced decrease (31%) in [3H]DA uptake, which
is consistent with a previous report (Richards and Zahniser, 2009). Therefore, compared to
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amphetamine, Tat produces a similar regulatory effect on DAT uptake function through a
PKC-dependent mechanism. It has been well documented that exposure to amphetamine
results in DAT internalization or reduced DA uptake in cell lines expressing DAT and
synaptosomes (Chen et al., 2010). Also, DAT shows a time-dependent, biphasic trafficking
pattern in vitro and in vivo upon short- and long-exposure to amphetamine (Chen et al.,
2010). For example, rapid treatment (less than 1 min) of rat striatal synaptosomes with
amphetamine increased DAT surface expression (Furman et al., 2009), whereas a prolonged
stimulation (30-60 min) led to reductions of surface DAT (Gulley et al., 2002; Johnson et al.,
2005; Thwar et al., 2007), indicating that rapid amphetamine-induced DAT surface
expression may contribute to amphetamine-induced DA efflux. While the current results and
previous studies (Cervinski et al., 2005; Gorentla and Vaughan, 2005; Richards and
Zahniser, 2009) have demonstrated that amphetamine-induced reduction of DA uptake can
be blocked by pretreatment of BIM-I, it was reported that amphetamine-induced reduction in
surface DAT in human DAT-PC12 cells was not inhibited by BIM-I (Boudanova et al.,
2008), suggesting that amphetamine regulates DAT activity through a PKC-independent
pathway. In contrast, this study shows that Tat decreased DA uptake via activation of PKC
pathway. Importantly, we have demonstrated that the influence of Tat on DAT function
involves a protein-protein interaction between Tat and DAT (Zhu et al., 2009b) and that Tat
acts as an allosteric modulator of DAT rather than as either a reuptake inhibitor (e.g. cocaine)
or a substrate releaser (e.g. amphetamine) (Zhu et al., 2011). Allosterism has been shown to
be responsible for the conformational transitions via substrate- and ligand-binding sites on
the DAT (Shan et al., 2011). Tat-induced inhibition of DA transporting may involve a
change in the DAT conformation that requires DAT phosphorylation. Previous studies
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suggest that Tat protein and amphetamine synergistically impair DAT function in vitro (Cass
et al., 2003; Theodore et al., 2006) and in vivo (Kass et al., 2010); however, underlying
mechanism(s) are unclear. To investigate the synergistic effects of Tat and amphetamine on
DAT function and trafficking will be an essential task in our future study.
In the current study, exposure to Tat (0.7 µM) for 15 min decreased [3H]DA uptake
activity in rat synaptosomes. In general, Tat-induced decrease of DA transport could be
accomplished in several manners: increased DAT protein degradation, decreased turnover
rates of DAT, or changes in DAT trafficking on the cell surface expression without changes
in total DAT immunoreactivity. To validate these potential mechanisms, first, we have
demonstrated that a 15-min exposure to Tat1-86 induced a rapid and reversible decrease in
Vmax of [3H]DA uptake without changes in total DAT levels (Zhu et al., 2009b), suggesting
that Tat-induced reduction in Vmax of DA uptake is not caused by DAT degradation. Second,
transporter turnover rate, which reflects the number of DA molecules transported per second
per site (Lin et al., 2000), was determined and shown that 15-min exposure of synaptosomes
to 1 µM Tat did not alter the ratio of Vmax for [3H]DA uptake/Bmax for [3H]WIN 35,428
binding. This result provides evidence that Tat does not decrease the turnover rates of DAT
(Zhu et al., 2009b). The current results display that the levels of DAT immunoreactivity
were increased by 49% in vesicle-enriched fractions (P4) and decreased by 46% in plasma
membrane enriched fractions (P3) without changes in total synaptosomal fractions (P2) in
Tat-exposed samples compared to the respective controls. These data indicate that exposure
to Tat results in a redistribution of DAT from the cell surface to intracellular compartments
(i.e. internalization) and that loss of DAT from the plasma membrane is responsible for the
decrease in Vmax observed after Tat exposure.
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The efficiency of DA transport depends on the number of DAT molecules expressed
on the plasma membrane, which is regulated by a dynamic-trafficking mechanism (Zhu and
Reith, 2008). This has been consistently reported in a number of studies using cells
expressing DAT (Saunders et al., 2000; Chi and Reith, 2003) and rat striatal synaptosomes
(Chi and Reith, 2003; Zhu et al., 2005; Zhu et al., 2009a). Changes in DAT dynamics in
plasma membranes can be detected using either biotinylation assay (Zhu et al., 2005; Zhu et
al., 2009a) or subfractionation method (Middleton et al., 2007). In the current study, a 49%
decrease in DAT surface expression (P3) was not comparable to the magnitude (26%) of the
decrease in Vmax for [3H]DA uptake in rat striatal synaptosomes demonstrated in our
previous report (Zhu et al., 2009b). This result is also supported by [3H]WIN 35,428 binding
experiment showing that the Bmax was decreased in P3 of Tat-treated samples compared to
controls. As reported in our previous studies, levels of the changes in DAT cell surface
expression were less than (Zhu et al., 2009a) or similar (Zhu et al., 2005) to the magnitude of
the changes in Vmax for [3H]DA uptake. Trafficking of plasma membrane transporters is
associated with changes in posttranslational modifications of the DAT protein, including
phosphorylation states and protein-protein interactions (Sager and Torres, 2011). Therefore,
the current results infer that Tat-induced great decrease of DAT expression in plasma
membranes could be regulated by both phosphorylation (i.e. PKC-dependent mechanism)
and protein-protein interactions (e.g. allosteric modulation). In contradiction with our
results, 30-min exposure of PC12 cells expressing human DAT to 120 nM Tat1-86 increased
(24%) DA uptake using measurement of the fluorescence ASP+, which was accompanied by
a profound increase (177%) in plasma membranes and a minor decrease (14%) in
cytoplasmic membranes compared to respective controls (Perry et al., 2010).

113

The

contrasting results might be due to differences in DAT expression models (rat synaptosomes
versus a human DAT cell line), Tat concentration, exposure time and methodology. Tatinduced changes in DAT surface levels could arise from increased PKC-mediated
endocytosis, decreased DAT recycling rates, or both. Rat synaptosomes express DAT
endogenously and have less surface DAT expression compared to DAT expressed in
heterologous cells such as PC12 cells (Johnson et al., 2005; Boudanova et al., 2008). In
addition, synaptosomes exhibit fast DAT recycling rates for basal DAT levels in plasma
membranes, whereas the PC12 cells overexpressing DAT have slow DAT recycling rates
(Johnson et al., 2005; Boudanova et al., 2008). These differences may, at least in part,
contribute to the contrasting results between the current study and the previous report (Perry
et al., 2010). Nevertheless, the results from Perry et al’s study demonstrate that increased
membrane DAT may be a compensatory response to decreased transporting efficiency of
individual DAT (Perry et al., 2010).
Another important finding from this study is that Tat inhibited not only DAT function
and trafficking but also VMAT-2 function. Although both DAT and VMAT-2 proteins are
essential for the regulation of DA disposition in the synapse and cytosol, our data show that
the inhibitory effects of Tat are more profound in VMAT2 protein than in DAT protein.
Moreover, the potency of Tat for inhibiting synaptosomal [3H]DA uptake (IC50 = 3.1 µM)
(Zhu et al., 2009b) is 15-fold higher than that for inhibiting vesicular [3H]DA uptake (IC50 =
0.21 µM). Thus, VMAT-2 protein may play a more critical role in Tat-induced alterations of
extracellular DA concentrations. In the current study, the affinity of TBZ, a highly selective
compound for VMAT-2 (Erickson et al., 1996) was about 20-fold greater than that of Tat
protein. Interestingly, our recent study shows that the influence of Tat on DAT ligand
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binding sites involves a protein-protein interaction and that a mutation of Tat (Cys22Gly)
significantly attenuates Tat-induced inhibitory effects on DA transport (Zhu et al., 2009b).
In addition to influencing DAT function, the current study demonstrates that this mutant of
Tat (Cys22Gly) also attenuates Tat-induced decrease in VMAT-2 function. Together, these
findings suggest that the residue (Cys22) of Tat may share a favorable inter-molecular
interaction between Tat protein and human DAT (or VMAT-2). Furthermore, this result also
suggests that Tat protein may cause synergistic effects on impairing DA neurotransmission
by inhibition of both DAT and VMAT-2 proteins. At the functional level, plasma membrane
DAT translocates substrates through a sodium- and chloride-dependent mechanism (Rudnick
and Clark, 1993; Gu et al., 1994), whereas vesicular transporters use the proton
electrochemical gradient across the vesicular membrane to transport monoamines (Johnson,
1988). Many DAT inhibitors have an ability to rapidly regulate VMAT-2 localization and
function (Fleckenstein et al., 2009). For example, methamphetamine leads to releases of DA
from synaptic vesicles into the cytosol via an interaction with the VMAT2 and by disruption
of the vesicular proton gradient (Sulzer et al., 1995; Fleckenstein et al., 2007). Subsequently,
available cytosolic DA is reversely transported by the DAT into the extracellular space
(Sulzer et al., 1995). Co-exposure to Tat and methamphetamine produces synergistic effects
on impairing DA terminals (Theodore et al., 2006) and methamphetamine-mediated behavior
(Kass et al., 2010). Thus, the current results provide a mechanistic basis to interpret the
synergistic effects of Tat and methamphetamine.
HIV-1 associated dementia and neurocognitive disorder progress gradually over
months or years. Such long time intervals are not practical or feasible for in vitro
determination of long-term alteration of DAT function. Hence, we investigated acute effects
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of Tat exposure on DAT dynamics. Using this in vitro model, we have found that 15-min
exposure of synaptosomes to Tat (1 µM) caused a reversible reduction of DA uptake,
whereas 60-min Tat exposure greatly inhibited DA uptake that was not reversible (Zhu et al.,
2009b). It is possible that reduction of DA uptake and plasma membrane DAT in response to
a short-term Tat exposure is a protective mechanism against the build-up of toxic levels of
DA, whereas a long-term Tat exposure accelerates DAT degradation. Excessive levels of
cytosolic DA and its oxidative products can be toxic to dopaminergic neurons and are
postulated to contribute to the development of HIV-associated dementia and neurocognitive
disorders (Mosharov et al., 2009). HIV-1 infection causes the hallmark decrease in CD4+ T
cells, which results from programmed cell death, apoptosis (McCune, 2001). Tat protein
released from infected cells can induce apoptosis in uninfected bystander T cells (Ma and
Nath, 1997) or neurons (New et al., 1997) and these cells subsequently become toxic cells
and can destroy other bystander cells (Campbell and Loret, 2009). While the present study
has provided evidence that in vitro exposure of rat synaptosomes to Tat functionally
regulates DAT function and trafficking, it also indicates potential roles of Tat in dynamic
regulation of DAT in vivo. Given that Tat can be absorbed by non-infected neurons, our
results infer that Tat-induced decrease in DAT function and cell surface expression in this in
vitro model may continue to produce long-term impairments of dopaminergic terminals in in
vivo models. Several studies have reported that continued presence of HIV-1 viral proteins
may be not required for Tat-induced long-term process of neurotoxicity. For example, an
exposure to Tat for a few minutes was sufficient for sustained releases of cytokines for
several hours (Nath et al., 1999); following a single intraventricular injection of Tat in rats,
progressive glial activation and macrophage infiltration could maintain for several days,
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whereas Tat was undetectable in the brain a few hours after the injection (Jones et al., 1998).
Further, an exposure of Tat for only milliseconds is adequate to induce prolonged
depolarization in neurons (Magnuson et al., 1995). Therefore, it is possible that a transient
exposure to Tat in dopaminergic target proteins, such as DAT, may share a similar “hit and
run” phenomenon to initiate a cascade of events, leading to progressive neuropathogenesis,
such as HIV-1 associated dementia (Wang et al., 2004).
In conclusion, Tat protein exposure led to changes of DAT and VMAT2 function and
expression in rat striatal synaptosomes. The Tat-induced reduction of DAT uptake function
is mediated by DAT trafficking- and PKC-dependent mechanisms. These findings may have
important implication for preclinical studies of the role of DAT and VMAT-2 in drugs of
abuse in HIV-1 infected individuals. Future studies will be necessary to investigate how
DAT interacts with VMAT-2 to promote Tat-induced dysfunction of DA neurotransmission
and which DAT residues are required for interactions of Tat and DAT.
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Figure 4.1 PKC inhibition attenuated Tat- and d-amphetamine (AMPH)-induced reduction
of [3H]DA uptake in rat striatal synaptosomes. After pre-incubation of synaptosomes with 1
µM BIM-I for 5 min, Tat (0.7 µM, A) or AMPH (20 µM, B) were added for another 15 min
and subsequently all reagents were washed off, specific uptake of 5 nM [3H]DA uptake was
measured. * P < 0.05 versus Tat or AMPH only.
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Figure 4.2 Tat protein decreased DAT cell surface expression. Rat striatal synaptosomes
were incubated with or without Tat (1 µM). Subsequently, total synaptosomal fractions (P2),
plasma membrane enriched fractions (P3), and vesicle-enriched fractions (P4) were prepared
for western blot analysis. The same portion of P3 fraction were used in [3H]WIN 35,428
binding assay (see Figure 4.3). The levels of DAT immunoreactivity are increased in P4 and
decreased in P3 without changes in P2 in Tat-exposed samples compared to the respective
controls. * P < 0.05, paired Student’s t-test.
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Figure 4.3 Tat protein decreased the specific [3H]WIN35,428 binding in plasma membrane
enriched fraction. Rat striatal synaptosomes were incubated with or without Tat (1 µM), and
then total synaptosomal fractions (P2), plasma membrane enriched fractions (P3) and
vesicle-enriched fractions (P4) were prepared and used for the specific [3H]WIN35,428
binding. * P <0.05, paired Student’s t-test.

120

A

*

100

50
25
0

125

S3 (VMAT2)

B

*

100
75
50
25
0

Tat

Synaptosomal [ 3H]DA Uptake
(% of control)

Tat

Control

75

Control

Vesicular [ 3H]DA Uptake
(% of control)

125

P2 (DAT)

Figure 4.4 Inhibitory effects of Tat on synaptosomal [3H]DA uptake and vesicular [3H]DA
uptake in rat striatum. Rat striatal synaptosomes were preincubated with or without Tat (1
µM) for 15 min. Drug was then washed off, and specific synaptosomal and vesicular uptake
of 0.1 µM [3H]DA uptake were measured. Tat inhibited the specific [3H]DA uptake into
vesicles (A; via VMAT2) and synaptosomes (B; via DAT) by 35% and 26%, respectively,
compared to the respective control values (*P <0.05, paired Student’s t-test).
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Figure 4.5 Pharmacological profiles of vesicular [3H]DA uptake in rat striatum in the
presence of Tat1–86, Tat Cys22, or tetrabenazine (TBZ, a VMAT2 inhibitor). Striatal
synaptosomes were preincubated with various concentrations of Tat1–86, Tat Cys22, or TBZ
(0.1 nM–10 µM) at 34°C for 15 min followed by the addition of [3H]DA (final
concentration, 0.1 µM) for 8 min. Tat Cys22 and TBZ were used as negative and positive
controls, respectively. Data are expressed as mean ± S.E.M. as percentage of control (CON)
values (28,205 ± 1965 dpm) from five independent experiments performed in duplicate.
Nonspecific [3H]DA uptake was determined in the presence of 10 µM nomifensine. All
curves were best fit to a single class of binding site and generated by nonlinear regression.
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CHAPTER 5
GENETICALLY EXPRESSED HIV-1 VIRAL PROTEINS ATTENUATE NICOTINEINDUCED BEHAVIORAL SENSITIZATION AND ALTER MESOCORTICOLIMBIC ERK
AND CREB SIGNALING IN RATS3
Abstract: The prevalence of tobacco smoking in HIV-1 positive individuals is 3-fold greater
than that in the HIV-1 negative population; however, whether HIV-1 viral proteins and
nicotine together produce molecular changes in mesolimbic structures that mediate
psychomotor behavior has not been studied. This study determined whether HIV-1 viral
proteins changed nicotine-induced behavioral sensitization in HIV-1 transgenic (HIV-1Tg)
rats. Further, we examined cAMP response element binding protein (CREB) and
extracellular regulated kinase (ERK1/2) signaling in the prefrontal cortex (PFC), nucleus
accumbens (NAc) and ventral tegmental area (VTA). HIV-1Tg rats exhibited a transient
decrease of activity during habituation, but showed attenuated nicotine (0.35 mg/kg, s.c.)induced behavioral sensitization compared to Fisher 344 (F344) rats. The basal levels of
phosphorylated CREB and ERK2 were lower in the PFC of HIV-1Tg rats, but not in the
NAc and VTA, relative to the controls. In the nicotine-treated groups, the levels of
phosphorylated CREB and ERK2 in the PFC were increased in HIV-1Tg rats, but decreased
in F344 animals. Moreover, repeated nicotine administration reduced phosphorylated ERK2
in VTA of HIV-1Tg rats and in the NAc of F344 rats, but had no effect on phosphorylated
Midde NM, Gomez AM, Harrod SB, Zhu J (2011) Genetically expressed HIV-1 viral proteins
attenuate nicotine-induced behavioral sensitization and alter mesocorticolimbic ERK and CREB
signaling in rats. Pharmacology, Biochemistry, and Behavior 98:587-597. PMCID: PMC3091851
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CREB, indicating a region-specific change of intracellular signaling.

These results

demonstrate that HIV-1 viral proteins produce differences in basal and nicotine-induced
alterations in CREB and ERK signaling that may contribute to the alteration in psychomotor
sensitization. Thus, HIV-1 positive smokers are possibly more vulnerable to alterations in
CREB and ERK signaling and this has implications for motivated behavior, including
tobacco smoking, in HIV-1 individuals who self-administer nicotine.
5.1 INTRODUCTION
Tobacco smoking prevalence among HIV-1 positive population is 3-fold greater than
that in HIV-1 negative population, according to Centers for Disease Control and Prevention
(2007). HIV-1 infected patients are more likely to become dependent on nicotine, and less
likely to quit than HIV-1 negative individuals (Hershberger et al., 2004; Fuster et al., 2009;
Nahvi and Cooperman, 2009). There is an increasing body of clinical and experimental
evidence that tobacco smoking is associated with a more rapid progression to AIDS (Nieman
et al., 1993; Crothers et al., 2005; Furber et al., 2007; Zhao et al., 2010) and HIV-1
associated dementia (Burns et al., 1996; Manda et al., 2010). Considering that the HIV-1
positive population exhibits a greater risk for tobacco-associated morbidity and mortality
(Palella et al., 2006; Triant et al., 2007), there is a critical need to define the molecular
mechanisms underlying the enhanced susceptibility to nicotine dependence in this
population.
HIV-1 infection is associated with a variety of neurological impairments that result,
in part, from the presence of HIV-1 viral proteins, such as Tat and gp120. Some of the
neurological deficits caused by these viral proteins reflect an apparent dysfunction of the
mesocorticolimbic dopamine (DA) system (Nath et al., 1987; Berger and Arendt, 2000;
125

Koutsilieri et al., 2002), the motivation pathway of the brain (Wise and Bozarth, 1987;
Everitt and Robbins, 2005; Berridge, 2007). Indeed, long-term viral protein exposure can
accelerate damage in this DA system (Del Valle et al., 2000; Ferris et al., 2008; Hudson et
al., 2010; Nath, 2010). For example, a significant reduction in DA transporter (DAT)
density in striatum was observed in HIV-1 positive patients (Wang et al., 2004; Chang et al.,
2008), and in vitro Tat and gp120 in vitro decreased the specific [3H]DA uptake in rat
striatum (Wallace et al., 2006; Zhu et al., 2009). Importantly, the use of addictive drugs by
HIV-1 positive individuals results in greater neurological impairments relative to individuals
who are infected with HIV-1 but do not abuse drugs (Del Valle et al., 2000; Ferris et al.,
2008; Hudson et al., 2010; Nath, 2010). Furthermore, the mesocorticolimbic DA pathway is
compromised in HIV-1 positive individuals that exhibit co-morbid drug abuse (Kumar et al.,
2009; Norman et al., 2009; Obermann et al., 2009). The extent to which HIV-1 related viral
proteins and drugs of abuse alter motivation in humans is not well understood.
Our laboratory uses a rodent model to investigate the neurobehavioral and
neurochemical changes induced by the combination of HIV-1 viral proteins and abused
drugs. Several approaches are utilized to study these viral proteins because experimental
rodents cannot be infected with HIV-1: 1) in vitro exposure to Tat (Zhu et al., 2009), 2)
direct microinjection of Tat into rat brain (Fitting et al., 2008; Harrod et al., 2008), 3)
transgenic mice that express Tat protein (Kim et al., 2003; Duncan et al., 2008), and 4) HIV1 transgenic (HIV-1Tg) rats, which express HIV-1 viral proteins (Reid et al., 2001). These
models mimic different aspects of viral protein-induced neurotoxicity, although none of
these models fully represent the spectrum of HIV-1 viral protein insult in humans (Nath,
2010). We are using the HIV-1Tg model in combination with basic behaviors that are
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mediated by the mesocorticolimbic system. This pathway organizes motivated behaviors
that range various levels of complexity. For example, psychomotor behavior, such as
locomotor/exploratory activity, represents the integration of sensory and motor information
(Wise and Bozarth, 1987; Berridge, 2007), whereas drug maintained responding is a
combination of Pavlovian and operant conditioning processes (Rescorla, 1991; Robinson and
Berridge, 2003; Everitt and Robbins, 2005), and is a relatively more complex form of
motivated behavior. Insult to this pathway produces significant changes in both types of
responding (Kelly and Iversen, 1976; Roberts et al., 1977; Fink and Smith, 1980; Joyce and
Koob, 1981; Koob et al., 1981; Kubos et al., 1987; Corrigall et al., 1992).
Nicotine activates nicotinic acetylcholine receptors (nAChRs) located throughout the
mesocorticolimbic DA system, specifically in the prefrontal cortex (PFC), nucleus
accumbens (NAc) and ventral tegmental area (VTA) (Kita et al., 1992; Panagis and Spyraki,
1996; Mansvelder et al., 2002; Laviolette and van der Kooy, 2004). Nicotine increases DA
levels in the NAc (Nisell et al., 1994b, a), and repeated nicotine treatment induces a
progressive increase in psychomotor behavior, which represents the initiation of behavioral
sensitization (Post, 1980; Clarke and Kumar, 1983b, a; Kalivas, 1995). Accordingly, the
locomotor stimulant properties of nicotine are blocked by lesion of mesolimbic DA neurons
(Louis and Clarke, 1998) or by nicotinic receptor antagonists (Clarke and Kumar, 1983b;
Corrigall et al., 1994). The behavioral sensitization procedure is sensitive to behavioral
changes produced by the psychostimulant effects of abused drugs, however, it is not a
measure of drug reward (Wise and Bozarth, 1987; Robinson and Berridge, 1993; Berridge
and Robinson, 1998). This procedure was used in the present experiment to determine
whether HIV-1 Tg rats exhibited deficits in locomotor sensitization to nicotine.
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Furthermore, HIV-1 viral proteins alter dopaminergic pathways that medaite behavioral
sensitization. For example, intra-accumbal or striatal Tat rats show decreased DAT activity
in striatum (Maragos et al., 2002), decreased DA levels (Cass et al., 2003), and attenuated
behavioral sensitization to cocaine (Harrod et al., 2008). Moreover, HIV-1Tg rats show
enhanced behavioral sensitization to methamphetamine (Liu et al., 2009; Kass et al., 2010).
However, whether the combination of nicotine and HIV-1 viral proteins alters psychomotor
behavior has not been investigated.
The extracellular regulated protein kinase (ERK) and its downstream transcriptional
signaling protein, the cyclic AMP response element-binding protein (CREB), appear critical
for long-term adaptations in individuals who exhibit drug abuse (Berhow et al., 1996;
Carlezon et al., 1998; Nestler, 2001; Girault et al., 2007). ERK is one of the mitogenactivated protein kinases involved in numerous cellular processes, including long-term
neuronal plasticity and survival (Hetman and Gozdz, 2004; Subramaniam and Unsicker,
2010). Abundant evidence suggests that ERK is an essential component of the signaling
pathways involved in synaptic plasticity and the long-term effects of drugs of abuse (Berhow
et al., 1996; Valjent et al., 2006; Girault et al., 2007; Lu et al., 2009). Two major isoforms of
ERK, ERK1 and ERK2, are very similar in sequence (Yoon and Seger, 2006), but have
distinct functions (Lloyd, 2006; Lu et al., 2009). It has implicated that ERK2 is more
strikingly changed than ERK1 in the long-term effects of drugs of abuse (Valjent et al.,
2005; Girault et al., 2007; Iniguez et al., 2010). Moreover, acute nicotine treatment increases
CREB phosphorylation in the NAc, striatum and VTA (Walters et al., 2005; Jackson et al.,
2009). Chronic nicotine exposure in mice decreases CREB phosphorylation in the NAc,
whereas nicotine withdrawal increases CREB phosphorylation in the VTA (Brunzell et al.,
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2003). In addition, the levels of CREB and phosphorylated CREB are decreased in the
cortex and amygdala after withdrawal from repeated nicotine administration (Pandey et al.,
2001). Thus, long-term nicotine exposure leads to neural adaptations in intracellular
signaling through the changes of ERK and CREB signaling (Brunzell et al., 2003; Brunzell
et al., 2009; Mineur et al., 2009). To date, the effects of HIV-1 viral proteins on ERK and
CREB signaling are unknown.
It was hypothesized that the combination of HIV-1 viral proteins and nicotine would
alter nicotine-induced behavioral sensitization, and would also produce changes in the
expression of intracellular signaling proteins. To test these hypotheses, HIV-1Tg rats and
Fischer 344/NHsd (F344) non-transgenic, wild-type control rats were used to determine if
genetically expressed HIV-1 viral proteins produce altered nicotine-induced behavioral
sensitization. To investigate a potential mechanism, the modulation of ERK and CREB
signaling following repeated nicotine exposure was determined in the PFC, NAc and VTA
regions of the mesocorticolimbic DA system.
5.2 MATERIALS AND METHODS
5.2.1 SUBJECTS
Male HIV-1Tg Fisher 344/NHsd rats and age-matched male nontransgenic Fisher
344/NHsd rats were obtained from Harlan Laboratories, Inc. (Indianapolis, IN). The HIV1Tg rat model carries a gag-pol-deleted HIV-1 provirus regulated by the viral promoter
expressing seven of the nine HIV-1 viral proteins (Reid et al., 2001). Since the HIV-1Tg rat
model is developed from F344 strain, F344 rats were used as the control animals. Rats at
age of 7-9 weeks arrived in the animal care facilities and were pair housed throughout the
experiment. Rodent food (Pro-Lab Rat, Mouse Hamster Chow #3000) and water were
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provided ad libitum. The colony was maintained at 21 ± 2 °C, 50 ± 10% relative humidity
and a 12L:12D cycle with lights on at 0700 h (EST). The animals were weighed daily. The
animals were maintained according to the National Institute of Health (NIH) guidelines in
AAALAC accredited facilities. The experimental protocol was approved by the Institutional
Animal Care and Use Committee (IACUC) at the University of South Carolina.
5.2.2 DRUGS
Nicotine hydrogen tartrate salt was purchased from Sigma-Aldrich (St. Louis, MO,
USA) and dissolved in sterile saline (0.9% sodium chloride). Nicotine was prepared
immediately prior to injection. The nicotine solution was neutralized to pH 7.0 with
NaHCO3. Nicotine (0.35 mg/kg, freebase) was administered subcutaneously (s.c.) in a
volume of 1 ml/kg once daily for 20 days.
5.2.3 LOCOMOTOR ACTIVITY PROCEDURE
5.2.3.1 BEHAVIORAL APPARATUS
The activity monitors were square (40 × 40 cm) locomotor activity chambers
(Hamilton-Kinder Inc., Poway, CA) that detect free movement of animals by infrared
photocell interruptions. This equipment uses an infrared photocell grid (32 emitter/ detector
pairs) to measure locomotor activity. The chambers were converted into round (~ 40 cm in
diameter) compartments by adding clear Plexiglas inserts; photocell emitter/detector pairs
were tuned by the manufacturer to handle the extra perspex width. Total horizontal activity
represents all beam breaks in the horizontal plane. All activity monitors were located in an
isolated room.
5.2.3.2 HABITUATION
Rats in the HIV-1Tg-Saline (HIV1Tg-Sal; n = 8/group), HIV-1Tg-Nicotine (HIV1Tg-Nic; n = 8/group), F344-Saline (F344-Sal; n = 8/group) and the F344-Nicotine (F344130

Nic; n = 8/group) groups were habituated to the locomotor activity chambers for two 60-min
sessions, once/day. No injections were administered on the habituation days. Twenty four
hours after the second habituation session, all rats were habituated to the chambers for 30
min prior to injection, and then injected (s.c.) with saline and placed into the activity
chambers for 60-min to measure baseline activity.
5.2.3.3 PRE-INJECTION HABITUATION AND NICOTINE-INDUCED BEHAVIORAL SENSITIZATION
The behavioral sensitization procedure began 24 hours after the saline baseline
measurement. First, all rats received a 30-minute habituation period in the testing chamber
prior to nicotine (0.35 mg/kg) or saline injection as previously reported (Addy et al., 2007).
This was done so that the onset of nicotine’s effects did not overlap with the period that rats
showed the most exploratory behavior in the chamber, which was during the first 15 min.
Previous research indicates that control rats exhibit asymptotic levels of within-session
habituation by 20 to 30 min, according to similar procedures and use of the same automated
chambers (Harrod et al., 2008; Harrod and Van Horn, 2009). Rats were administered
nicotine or saline subcutaneously every day for a total of 20 days. Locomotor activity was
assessed every other day, i.e., on days 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, for 60 min. On
alternate days, nicotine and saline administered in the home cage.
5.2.4 WESTERN BLOT ANALYSIS
Following completion of the behavioral study, brains were removed by rapid
decapitation 4 hours after the last injection on day 20. Brains were placed in ice-cold PBS
and dissected in a chilled matrix. PFC, NAc and VTA were dissected and immediately
sonicated on ice in a homogenization buffer containing 20 mM HEPES, 0.5 mM EDTA, 0.1
mM EGTA, 0.4 M NaCI, 5 mM MgCI2, 20% glycerol, 1 mM PMSF, phosphatase inhibitor
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cocktails I (Sigma, P2850) and protease inhibitors (Sigma, P8340).

Samples were

centrifuged at 12000 g for 15 min. The supernatant was stored at -80°C.

Protein

concentrations were determined in duplicate using Bio-Rad DC protein detection reagent.
Proteins (30, 10 or 15 µg per sample in the PFC, NAc or VTA) were loaded for ERK,
phosphorylated ERK (pERK), CREB, phosphorylated CREB (pCREB) and Tyrosine
Hydroxylase (TH) immunoreactivity.
Proteins were separated by 10% SDS-polyacrylamide gel electrophoresis (SDSPAGE) for 90 min at 150 V, and subsequently transferred to Immobilon-P transfer
membranes (Cat # IPVH00010, 0.45 µm pore size; Millipore Co., Bedford, MA) in transfer
buffer (50 mM Tris, 250 mM glycine, 3.5 mM SDS) using a Mini Trans-Blot Electrophoretic
Transfer Cell (Bio-Rad, Hercules, CA) for 110 min at 72 V. Transfer membranes were
incubated with blocking buffer (5% dry milk powder in PBS containing 0.5% Tween 20) for
1 h at room temperature followed by incubation with primary antibodies diluted in blocking
buffer overnight at 4 ºC. Antisera against ERK½ (V114A, Promega, Madison, WI) and
pERK½ (SC-16982R, Santa cruz biotechnology, inc, Santa Cruz, CA) were used at a
dilution of 1:2000 and 1:1000, respectively. Anti-CREB (9104, Cell signaling, Danvers,
MA) and anti-pCREB (9196, Cell signaling, Danvers, MA) antibodies were used at a
dilution of 1:1000 and 1:500, respectively. Anti-TH (2792) was diluted 1:2000 (Cell
signaling, Danvers, MA). Blots were washed 5 min × 5 times with wash buffer (PBS
containing 0.5% Tween 20) at room temperature, and then incubated for 1 h in affinitypurified, peroxidase-labeled, anti-rabbit IgG (1:10000 for ERK½, 1:5000 for pERK½,
1:20000 for TH, Jackson ImmunoResearch, West Grove, PA) and 1:2000 anti-mouse IgG
(7076, Bio-Rad, Hercules, CA) in blocking buffer for 1 h at room temperature. Blots on the
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transfer membranes were detected using enhanced chemiluminescence and developed on
Hyperfilm (ECL-plus; Amersham Biosciences UK Ltd., Little Chalfont Buckinghamshire
UK). After detection and quantification of these proteins, each blot was stripped in 10% of
Re-blot plus mild antibody stripping solution (CHEMICON, Temecula, CA) for 20 min at
room temperature and reprobed for detection of β-tubulin (sc-9104, Santa cruz
biotechnology, inc, Santa Cruz, CA). β-tubulin was used to monitor protein loading among
samples. Multiple autoradiographs were obtained using different exposure times, and
immunoreactive bands within the linear range of detection were quantified by densitometric
scanning using Scion image software (Scion Corp., Frederick, MD).
5.2.5 DATA ANALYSES
The data are presented as mean values ± standard error of the mean (S.E.M.). In
order to analyze the effects of nicotine exposure on body weight gain, the body weights of
the rats were expressed as a percentage of the body weights on the day prior to nicotine
injection. The effect of nicotine administration on body weight gain was analyzed with a (2
× 2 × 20) mixed factorial analysis of variance (ANOVA), with genotype (HIV1-Tg or F344)
and treatment (nicotine or saline) as the between-subjects factors, and day as the withinsubjects factor. A genotype × day × time (2 × 2 × 12) mixed factorial ANOVA was used to
analyze data from the 2 habituation days, and a genotype x time (2 × 12) factorial ANOVA
was conducted on the saline baseline day. The pre-injection habituation part of the
experiment was analyzed using a genotype × treatment × day × time (2 × 2 × 10 × 12)
ANOVA. The effect of repeated nicotine injection on total horizontal activity was analyzed
using a genotype × treatment × day × time (2 × 2 × 10 × 12) factorial ANOVA, with
genotype and treatment as between-subjects factors, and day and time as within-subjects
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factors. To determine the effects of repeated nicotine administration on the activity of
signaling proteins (ERK, CREB and TH), separate genotype x treatment (2 × 2) factorial
ANOVAs were performed on the data from the PFC, NAc, and VTA. Simple effect
comparisons were made for post hoc analyses. All statistical analyses were performed using
SPSS (standard version 18.0, Chicago, IL) and differences were considered significant at p <
0.05.
5.3 RESULTS
5.3.1 EFFECT OF NICOTINE ON BODY WEIGHT
Daily body weights were analyzed using a genotype × treatment × day ANOVA.
There were significant main effects of genotype (F(1,28) = 25.71; p < 0.001) and day
(F(19,532) = 384.28; p < 0.001), indicating that HIV-1Tg rats weighed less than F344
controls, and that all animals gained weight over days. Body weight gain across days was
not different between HIV-1Tg rats and F344 rats (F(19,532) = 1.24; p = 0.22): these groups
showed 11 and 12% increase in weight gain from day 1 to day 20, respectively (Figure 5.1).
5.3.2 HABITUATION, PRE-INJECTION HABITUATION, AND NICOTINE-INDUCED LOCOMOTOR
ACTIVITY IN HIV-1TG AND F344 RATS
Habituation and Saline Baseline
Animals were habituated to the chambers for two days, 60 min per day. The total
horizontal activity that occurred during the two habituation days is shown on Figures 5.2A
and 2B. A genotype × day × time ANOVA (2 × 2 × 12) revealed main effects of day (F(1,
30) = 55.95, p < 0.001) and time (F(11, 330) = 147.6, p < 0.001), and a significant genotype
× day × time interaction (F(11, 330) = 2.14, p < 0.05). Both genotypes showed the most
activity at the beginning of the habituation session, and the activity decreased over the 30min period, and both groups of rats were at asymptote for the remaining 30 min of the
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session. HIV-1Tg rats exhibited less locomotor activity than did F344 rats in the first 30 min
of the first habituation session (p < 0.01 Bonferroni t-test), and this is observed as a
downward, and leftward shift in the habituation curve (Figure 5.2B). No significant
differences in total horizontal activity during second habituation session were detected (Fig.
5.2B). On the third day, total horizontal activity was recorded for all groups after a saline
injection to determine baseline activity prior to the induction of sensitization phase of the
experiment. The genotype × time ANOVA revealed a main effect of time (F(11, 330) =
41.77, p < 0.001), and a genotype × time interaction (F(11, 330) = 2.41, p < 0.05). No main
effect of genotype was found. In general, both genotypes showed lower activity during the
first 5 min of the saline baseline day, acquired asymptotic levels of activity more quickly,
and showed a lower asymptote compared to that of the habituation sessions (Fig. 5.2C).
Within the first 30 min period, the F344 habituation curve crosses and slightly goes below
that of the HIV-1Tg curve. The habituation curve crosses again at minute 30, and this was
observed again at the end of the session within the last 30 min (data not shown). None of the
comparisons indicated differences between the HIV-1Tg and F344 rats (all p >.05).
Pre-injection habituation
Animals were placed into locomotor chambers for 30 min prior to the activity
measurement to produce within-session habituation of activity prior to nicotine or saline
injection. Total horizontal activity during the 30 min habituation period across the 19-day
treatment was recorded and is shown in Figure 5.3A. A mixed-factor genotype × treatment ×
day × time ANOVA (2 × 2 × 10 × 12) revealed main effects of treatment (F(1, 28) = 4.76, p
< 0.05), day (F(9, 252) = 9.15, p < 0.05), time (F(5, 140) = 705.56, p < 0.05) and a
significant day × treatment interaction (F(9, 252) = 2.74, p < 0.01). There was no main
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effect of genotype and there were no significant interactions containing this factor. The
treatment × day interaction indicates that, regardless of genotype, animals treated with
nicotine show increased activity during the pre-injection habituation measures as the number
of habituation/injection days increased. To test this, activity from the first and last preinjection habituation days were compared using a within-subjects comparison of the saline
(HIV-1Tg Sal and F344 Sal) and nicotine (HIV-1Tg Nic and F344 Nic) treated groups. The
saline treated rats showed activity counts of 652.6 (± 39.3) and 586.4 (± 20.3) on days 1 and
19, respectively; no change in pre-injection habituation activity was observed (F(1, 15) =
2.6, p > 0.05). The nicotine treated animals exhibited 640.3 (± 29.9) and 764.6 (± 35.5)
activity counts on days 1 and 19, respectively, and this increase in locomotor activity during
pre-injection habituation sessions was significant (F(1, 15) = 25.0, p < 0.001). These data
indicate that animals injected with nicotine, but not saline, exhibit a significant increase in
activity during the pre-injection observation.
Nicotine-induced behavioral sensitization
To determine the effect of HIV-1 viral proteins on nicotine-mediated locomotor
sensitization, we measured horizontal activity following administration of nicotine (0.35
mg/kg, s.c.) or saline in HIV-1Tg and F344 rats (Fig. 5.3B). A genotype × treatment × day ×
time ANOVA revealed significant main effects of genotype (F(1, 27) = 4.37, p < 0.05),
treatment (F(1, 27) = 965.71, p < 0.001), day (F(9, 243) = 23.52, p < 0.001) and time (F(11,
297) = 536.04, p < 0.001). A significant treatment × day interaction (F(9, 243) = 37.40, p <
0.05) was found, indicating that repeated nicotine injection produced behavioral
sensitization. Rats treated with saline exhibited decreased activity across treatment days,
from a mean (±S.E.M.) of 357 (±27) activity counts on day 1, to 245 (±32) on day 19.
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Nicotine treated rats exhibited 763 (±28) activity counts on day 1, but showed increased
locomotor counts of 1287 (±33) on day 19. The genotype × treatment (F(1, 27) = 4.40, p <
0.05) and genotype × day (F(9, 243) = 2.76, p < 0.05) interactions indicate that genotype
significantly interacted with the effects of repeated nicotine administration. The pattern of
nicotine-induced sensitization was similar for the HIV-1Tg and F344 rats following the first
ten nicotine injections; however, the nicotine-induced behavioral sensitization was attenuated
in HIV-1Tg rats compared to F344 rats during treatment days 11-19. The HIV-1Tg rats
showed decreased nicotine-induced activity on four of the remaining five nicotine behavioral
assessments, thus suggesting that transgenic animals do not acquire the same magnitude of
nicotine-induced behavioral sensitization.
A genotype × treatment × day ANOVA was conducted on the first and final
injection days to determine if HIV-1Tg rats exhibited attenuated nicotine-induced behavioral
sensitization (Figures. 5.4A and 4B). There were significant main effects of genotype
(F(1,28) = 6.27; p < 0.05), treatment (F(1,28) = 192.05; p < 0.001) and day (F(1,28) = 14.97;
p < 0.01). A significant genotype × day interaction (F(1,28) = 5.29; p < 0.05) and a
significant treatment × day interaction (F(1,28) = 40.96; p < 0.001) were found. On day 1,
the HIV-1Tg and F344 rats in nicotine-treated groups exhibited more activity than their
saline controls (p < 0.001; p < 0.001, Bonferroni t-test, respectively). No differences
between the HIV-1Tg-Nic and F344-Nic groups were observed (p > 0.05). Similarly, there
were no differences between HIV-1Tg-Sal and F344-Sal groups on day 1 (p > 0.05). On day
19, HIV-1Tg and F344 rats injected with nicotine displayed greater activity compared to
their saline controls (p < 0.001), however, both groups showed enhanced activity following
repeated nicotine injection relative to day 1 (F(1,6) = 136.5; p< 0.001), and day 19 (F(1,7) =
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98.8; p < 0.001, respectively). The HIV-1Tg-Nic group, however, exhibited less locomotor
activity relative to the F344-Nic group (p < 0.01), suggesting that the HIV-1Tg rats exhibited
attenuated psychomotor sensitization relative to the F344 rats.
The time course data from Day 1 and Day 19 are illustrated in Figures 5.4C and 4D.
Figure 5.4C shows that rats treated with nicotine and saline had the same amount of activity
in the first five min of the session, and that nicotine injected rats showed more activity than
did the rats administered saline. Figure 5.4D, which represents day 19, clearly shows that
animals treated with nicotine exhibited higher activity counts in the first 5 min relative to the
saline groups, and although both groups showed within-session habitua-tion, animals in the
nicotine conditions exhibited higher activity counts throughout the remainder of the hour.
Furthermore, HIV-1Tg rats treated with nicotine showed less activity than the F344 rats
treated with nicotine throughout the remainder of the hour measurement.
5.3.3 LEVELS AND ACTIVITY OF ERK AND CREB SIGNALING PROTEINS IN HIV-1TG AND
F344 RATS
To determine whether the nicotine-induced behavioral change is associated with
mesocorticolimbic DA signaling, we examined the effects of repeated nicotine
administration on the levels and the phosphorylation state of CREB and ERK in the PFC,
NAc and VTA from the HIV-1Tg and F344 rats used in the behavioral experiment.
Prefrontal Cortex (PFC)
Separate two-way ANOVAs were performed to determine the effect of nicotine on
the levels and phosphorylation state of the signaling proteins. As shown in Figure 5.5, no
significant differences in total CREB, ERK1, ERK2 and TH were found in the PFC among
the groups. With respect to the ratio of pCREB /β-tubulin, a main effect of genotype (F(1,
27) = 4.34, p < 0.05) and a significant genotype × treatment interaction (F(1, 27) = 9.47, p <
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0.05) were found. Post hoc analysis revealed that the ratio of pCREB /β-tubulin was lower
in the HIV-1Tg rats than that in the F344 rats in saline-control groups (F(1, 13) = 5.64, p <
0.05). The level of pCREB was greater in the nicotine-treated HIV-1Tg group than that in
the saline-treated HIV-1Tg group (F(1, 13) = 4.69, p < 0.05). In contrast, pCREB levels
were decreased in the nicotine-treated F344 group compared to the saline-treated F344 group
(F(1, 13) = 4.31, p < 0.05).
With respect to the ratio of pERK2/β-tubulin in the PFC, a main effect of genotype
(F(1, 27) = 4.32, p < 0.05) and a significant genotype × treatment interaction were found
(F(1, 27) = 8.81, p < 0.05). Post hoc analysis revealed that the ratio of pERK2/β-tubulin in
the PFC was lower in HIV-1Tg rats than that in F344 rats in saline-treated group (F(1, 13) =
13.2, p < 0.05). Nicotine increased the ratio in HIV-1Tg rats compared to the saline-treated
group (F(1, 13) = 6.64, p < 0.05). There was a trend toward a decrease in the ratio of
pERK2/β-tubulin in F344 rats after repeated nicotine injection (F(1,13) = 3.31; p = 0.07).
The ratio of pERK2/β-tubulin was greater in HIV-1Tg-Nic group than that in F344-Nic
group (p < 0.05).
Nucleus Accumbens (NAc)
There were no changes in total and phosphorylated CREB, in total ERK and pERK1,
or in the levels of TH observed in NAc of HIV-1Tg and F344 rats following nicotine or
saline injection. With respect to ratio of pERK2/β-tubulin, the two-way ANOVA revealed a
significant main effect of treatment (F(1, 27) = 5.31, p < 0.05), but neither the main effect of
genotype nor the genotype × treatment interaction was significant (Fig. 5.6). Repeated
nicotine administration decreased the ratio of pERK2/β-tubulin in F344 rats (F(1, 14) = 7.05,
p < 0.05), but not in the HIV-1Tg rats (F(1.14) = 0.51, p > 0.05).
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Ventral Tegmental Area (VTA)
There was no change in total and phosphorylated ERK and CREB, or in the levels of TH
observed in the VTA following nicotine administration. Regarding the ratio of pERK2/βtubulin, two-way ANOVA revealed a significant main effect of treatment (F(1, 27) = 4.45, p
< 0.05), but neither the main effect of genotype nor the genotype × treatment interaction was
not significant (Fig. 5.7). Repeated nicotine administration produced a decreased ratio of
pERK2/β-tubulin in HIV-1Tg rats (F(1, 14) = 6.74, p < 0.05), but not in the F344 rats
(F(1.14) = 0.34, p > 0.05).
5.4 DISCUSSION
The present findings demonstrate that genetically expressed HIV-1 viral proteins alter
the sensitivity of the locomotor effects of repeated nicotine administration. HIV-1Tg rats
exhibited diminished locomotor activity during habituation to a novel context and showed an
attenuation of nicotine-induced behavioral sensitization. Importantly, the basal levels of
pCREB and pERK2 in the PFC were lower in the HIV-1Tg saline group compared to F344
saline controls. Following repeated nicotine administration, the levels of pCREB and
pERK2 in PFC were decreased in F344 rats, but increased in HIV-1Tg rats, suggesting
opposite effects of nicotine on these phosphorylated signaling proteins. In addition, repeated
nicotine administration decreased pERK2 levels in the NAc of F344 rats and this effect was
also observed in the VTA of HIV-1Tg rats. Thus, HIV-1 viral protein-induced alterations in
the CREB and ERK signaling pathway in the mesocorticolimbic DA system appear to have
played a role in the locomotor effects of repeated nicotine in HIV-1Tg rats.
Regarding the behavioral portion of the experiment, we observed that HIV-1Tg rats
exhibited alterations in locomotor activity during both the habituation and behavioral
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sensitization phases of the experiment. First, the transgenic rats showed less activity during
day 1 of habituation compared to F344 rats, indicating that the novelty of the initial context
exposure produced less activity in the transgenics relative to control rats. This difference in
habituation between the HIV-1Tg and F344 rats was transient, as the transgenic rats did not
continue to exhibit the blunted locomotor response, relative to F344 controls, on either day 2
of habituation or on the saline baseline measure. A recent study reported HIV-1Tg rats
exhibited less rearing and head movement activity compared to F344 rats following repeated
saline injections (Liu et al., 2009), but these differences did not reach significance in another
report (Kass et al., 2010). The lower baseline activity exhibited by HIV-1Tg rats in the
present study and reported by Liu et al. (2009) appear to be the result of manipulation of
dopaminergic system by genetically expressed viral proteins (Fink and Smith, 1980).
Indeed, HIV-1Tg rats exhibited increased expression of D1 receptors in the PFC (Liu et al.,
2009) and a decrease in DAT mRNA (Webb et al., 2010). These studies are consistent with
clinical studies showing a significant reduction of DAT density in the putamen and ventral
striatum in HIV-1 infected patients (Wang et al., 2004; Chang et al., 2008). In addition, D1
expression has been reported to be negatively correlated with baseline locomotor activity
observed in D1 receptor-deficient mice (El-Ghundi et al., 2010). Thus, our behavioral data
indicate that the attenuated habituation curve in HIV-1Tg rats is related to neural adaptations
produced by HIV-1 viral proteins, and that this transient effect represents an attenuation of
activity in response to the novelty of the locomotor activity chambers.
The induction of nicotine-induced behavioral sensitization was altered in transgenic
rats as well. In this study, enhanced locomotor activity was observed in both genotypes
across days following repeated nicotine administration. Although no difference in acute
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nicotine-induced activity between the two genotypes was observed on day 1, the HIV-1Tg
group displayed reduced nicotine-induced locomotor activity during the later days, i.e., 1319, relative to the nicotine-treated F344 group. Thus, although transgenic rats showed a
blunted response to repeated nicotine exposure during the induction of sensitization, those
animals did not exhibit a deficit in developing behavioral sensitization. Rather, HIV-1Tg
rats exhibited less sensitivity to the repeated effects of nicotine, and this deficit may
contribute to an alteration in nAChR-mediated dopamine neurotransmission. In accord with
these behavioral data, we recently found that HIV-1Tg rats had lower IC50 values for
[3H]nicotine binding with 5-fold rightward shift of the nicotine concentration curve,
compared to F344 controls (unpublished data). Similarly, previous research showed that
intra-accumbal Tat infusion attenuated cocaine-induced behavioral sensitization in rats
(Harrod et al., 2008), suggesting that the viral protein Tat is involved in the altered
behavioral response to psychostimulant drugs. Together, the results indicate that the HIV1Tg rats are a pertinent model to investigate how chronic exposure to viral proteins and
nicotine alter dopaminergic pathways that mediate motivated behavior.
Notably, although behavioral sensitization is a sensitive measure for the influence of
psychostimulants on the mesocorticolimbic system (Berridge, 2007), it does not measure
drug reward. Thus, predictions regarding cigarette smoking in HIV-1 positive individuals
are limited. Given that two behavioral models of viral protein exposure produced diminished
psychostimulant-induced behavioral sensitization (Harrod et al., 2008), it is suggested that
cigarette smoking by HIV-1 positive individuals will produce alterations in motivated
behavior due to the interplay of nicotine exposure and HIV viral proteins within the
mesocorticolimbic DA system.
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Previous research suggests the possibility that the sensitization of one type of
behavior, like rearing, could result in the decrease of another behavior, such as horizontal
activity (Iwamoto, 1984; Jerome and Sanberg, 1987; Ksir, 1994; Reid et al., 1998). That the
attenuation of total horizontal activity exhibited by the HIV-1Tg rats was diminished in
response to the emergence of a competing behavior like rearing or stereotypy, however, is
not likely. First, our automated activity chambers measure rearing as all beam breaks in the
vertical plane. In the present experiment, there were no effects or interactions with the factor
of genotype so the data are not shown; however, animals progressively exhibited
sensitization and both genotypes showed asymptotic levels by day 7. Thus, rearing did not
emerge on days 11-19, which corresponds to the treatment days that transgenic rats exhibited
less nicotine-induced total horizontal activity. Although nicotine-induced sensitization of
stereotypy has been reported (Reid et al., 1998), it is not a consistent finding (Jerome and
Sanberg, 1987; Ksir, 1994; Harrod et al., 2004; Harrod et al., 2008). We did not use
observational procedures in the present experiment, so the levels of nicotine-induced
stereotypy were not determined. Our previous studies, which used a combination of
automated and observational procedures, show that repeated nicotine or cocaine injection
induced sensitization of horizontal activity and rearing incidence, but not of stereotypy
(Harrod et al., 2004; Harrod et al., 2008). It is unlikely that the attenuation of total horizontal
activity observed for the HIV-1Tg rats is attributable to an emergence of stereotypic
behavior.
The present results show that animals injected with nicotine, regardless of genotype,
exhibited increased locomotor activity during pre-injection habituation, which was
particularly evident on days 13-15. Rats in the saline control groups showed steady activity
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across the 19 day period. The increase in activity in the nicotine treated groups likely
represents drug-induced conditioned hyperactivity, which is well documented to be mediated
by Pavlovian conditioning processes (Anagnostaras and Robinson, 1996; Bevins and
Palmatier, 2003). Repeated psychostimulant injection within the same context allows for
contextual cues to function as a conditional stimulus, and the drug effect, e.g., hyperactivity,
to act as an unconditional stimulus (Anagnostaras and Robinson, 1996). In the present
experiment, repeated context-nicotine pairings support the standard associative model
described above, and exposure to the chamber prior to daily drug injection represents
presentation of the conditional stimulus, or the context alone, without the influence of the
unconditional stimulus.

Our results indicate that after being placed in the context,

hyperactivity, which is similar to the unconditional stimulus effects of repeated nicotine, was
observed and there were no effects of genotype on this effect.
The second part of the experiment determined levels of transcriptional factors
throughout the mesocorticolimbic DA system in nicotine sensitized HIV-1 rats relative to
F344 controls. First, HIV-1Tg-saline rats exhibited lower basal levels of pCREB and
pERK2 in the PFC, but not in the VTA or NAc, compared to F344-saline controls. These
findings suggest that viral proteins produced a neurobiological adaptation in ERK and CREB
signaling in the PFC. The observed changes in signaling have implications for the
functionality of the mesocorticolimbic DA system. For example, neuronal firing elicits ERK
activity in the brain of rats (Davis et al., 2000; Thiels et al., 2002; Ying et al., 2002), whereas
blocking ERK activity decreases the firing rate of DA neurons (Iniguez et al., 2010).
Increased tonic release of DA enhances ERK activity, which is attenuated in DA D1 receptor
mutant mice (Chen and Xu, 2010). Further, deletion of DA D1 receptors in mice produces

144

higher pCREB levels in the striatum (El-Ghundi et al., 2010), suggesting that CREB
phosphorylation is stimulated by DA D1 receptor activation. ERK activation is coupled to
activation of CREB (Nakayama et al., 2001; Ying et al., 2002) and, in turn, supports adaptive
processes such as long-term potentiation and psychostimulant-induced sensitization (Ying et
al., 2002; DiRocco et al., 2009). It has been reported that Tat, gp120 and other viral proteins
have higher expression in the PFC compared to other brain regions of HIV-1Tg rats (Peng et
al., 2010). Thus, the lower basal levels of pERK2 and pCREB could contribute to the
differences in DA D1 receptor expression that was previously reported between HIV-1Tg
rats and the F344 controls (Liu et al., 2009). Moreover, although the regional high
expression of these viral proteins may contribute to the PFC-specific changes of pERK2 and
pCREB, it is also possible that these signaling proteins in PFC are more sensitive to HIV-1
viral protein insult. Together, the molecular data show that the basal levels of particular
transcriptional factors, which are implicated in the regulation of mesocorticolimbic function,
are altered in HIV-1Tg animals.
Repeated nicotine administration significantly decreased pCREB in the PFC of
F344-nicoitne rats compared to F344-saline group. Although delivering chronic nicotine
through drinking water increased the ratio of pCREB/CREB in the PFC in C57BI/6J mice
(Brunzell et al., 2003), another report showed that the levels of CREB and pCREB were
decreased in the cortex of rats 18 h after withdrawal from repeated administration of 2 mg/kg
of nicotine (Pandey et al., 2001). Thus, nicotine-mediated regulation of CREB activity is
largely dependent on the species, dosage, route of administration, and the time needed to
harvest brains (Pandey et al., 2001; Brunzell et al., 2003). The current results show that
repeated nicotine increased pCREB in cortical tissue of HIV-1Tg rats, with no change in
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CREB. This finding is interesting for two reasons. First, F344 rats exhibited decreased
pCREB following repeated nicotine administration, and second, the nicotine-induced
increase in pCREB occurred despite lower basal levels of this transcription factor in HIV1Tg rats relative to F344 controls. This suggests that the processes that mediate the lower
basal levels of pCREB in the transgenic rats do not prevent repeated nicotine from regulating
CREB signaling. Rather, the current results suggest that nicotine and HIV-1 viral proteins
act synergistically to alter CREB signaling in the PFC. Decreased CREB activity is
associated with an increase in drug reward and food preference (Carlezon et al., 1998). In
general, this suggests that an aberrant decrease in CREB activity, as is shown in the present
experiment, may negatively impact normal function of the mesocorticolimbic DA system.
Determining if PFC CREB activity is also implicated in the reduced rate of nicotine-induced
reward in HIV-1Tg rats is of future interest.
Regarding the ERK experiments, we observed significant alterations in pERK2
levels in the PFC, NAc, and VTA with no change in ERK1, ERK2, or pERK1 in either HIV1Tg or F344 rats. Notably, the overall levels of pERK2 in the PFC were similar to those
changes observed with pCREB in the PFC. Basal levels of pERK2 from the HIV-1Tg-Saline
rats were lower than that of the F344-Saline rats, which indicates that the presence of viral
proteins reduces pERK2 in the PFC. Following repeated nicotine injection, F344 animals
exhibited a trend for decreased pERK2 relative to F344-Saline rats, whereas HIV-1Tg
showed increased pERK2 relative to their saline controls. Regarding the VTA, basal pERK2
levels did not differ by genotype in the saline control group, but repeated nicotine decreased
this transcriptional factor in HIV-1Tg rats relative to the saline controls. In the NAc,
however, there were no differences between levels of pERK2 in the HIV-1Tg-Nic and HIV-
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1Tg-Saline rats, but the nicotine sensitized F344 rats exhibited decreased pERK2 relative to
controls. This is consistent with the diminished pCREB levels observed in the PFC of HIV1Tg rats, and this result indicates that viral proteins manipulate ERK signaling in a region
specific manner.
Our results suggest that viral protein-induced changes in ERK phosphorylation may
exacerbate the plasticity related to the magnitude of the attenuated nicotine-induced
sensitization observed in the behavioral part of our experiment. This conclusion is supported
by recent reports (Valjent et al., 2005; Valjent et al., 2006; Girault et al., 2007; Iniguez et al.,
2010). For example, blocking ERK1/2 activity by SL327, a selective inhibitor of mitogenactivated protein kinase, prevented the induction of locomotion sensitization by repeated
injection of cocaine or amphetamine (Valjent et al., 2005; Valjent et al., 2006). Further,
discrete manipulation of ERK2 within the VTA, using viral-mediated dominant negative
mutant of ERK2, blunted the expression of cocaine-induced behavioral sensitization (Iniguez
et al., 2010). The current findings suggest that low levels of prefrontal pERK2 may
contribute to the blunted nicotine-induced locomotor activity observed in transgenic rats.
Thus, the present study provides evidence that HIV-1 viral proteins impair ERK signaling,
thereby contributing to the long-term behavioral changes induced by repeated nicotine.
Additional research is needed to elucidate the role of HIV-1 viral proteins on ERK and
CREB signaling in the PFC on nicotine reward. As mentioned above, whether the combined
effects of nicotine and HIV-1 viral proteins alter the rewarding effects of nicotine cannot be
inferred from the present experiment. Nonetheless, these findings further indicate that HIV1 positive individuals who smoke cigarettes may experience a synergistic effect of viral
proteins and nicotine on transcriptional factors that regulate mesocorticolimbic function.
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The current study found no differences in basal TH levels regardless of region or
genotype, which is consistent with the findings of a recent report showing no change in
protein levels of TH in the striatum of naive HIV-1Tg rats (Webb et al., 2010). Notably,
regardless of the nicotine-induced changes in pCREB and pERK in the PFC, repeated
nicotine injection did not alter the level of TH in any region. This is in contrast to the
findings of Brunzell et al. who reported that chronic nicotine exposure in drinking water
increased TH levels in the PFC in mice 1.5 h after the last nicotine injection; an increase that
returned to normal levels 24 h after withdrawal (Brunzell et al., 2003). The discrepant
findings between the current and previous experiments may be related to differences in
species and in the route of nicotine administration. However, a recent report showed that in
vitro exposure to nicotine only increased TH mRNA levels of mouse midbrain slices within
1 hour, but did not change TH protein for different periods of time up to 48 hours (Radcliffe
et al., 2009).

Hence, it is possible that nicotine stimulation transiently changes

transcriptional TH levels, without changing the protein levels of TH.
In conclusion, the current results suggest that genetically expressed HIV-1 viral
proteins in rats diminish basal expression levels of pERK2 and pCREB in the PFC, which
may explain, at least in part, the low baseline locomotor activity of HIV-1Tg rats. The
opposite effects of nicotine on pERK2 and pCREB in the PFC between HIV-1Tg rats and
F344 rats may play a role in the blunted locomotor response to repeated administration of
nicotine noted in HIV-1Tg rats. Determining how HIV-1 viral proteins and nicotine
influence ERK and CREB signaling in the mesocorticolimbic system will be important to
understand why HIV-1 positive individuals exhibit increased vulnerability for nicotine
addiction.
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Figure 5.1 Body weights of HIV-1Tg and F344 rats during the nicotine or saline treatment
period. Beginning at 12 weeks of age, rats were injected subcutaneously with nicotine or
saline prior to locomotor measurement. Data are presented as the mean ± S.E.M. n=8 rats
per group.
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Figure 5.2 The time-course data during the habituation and the saline baseline sessions. Panels A and B show the total horizontal activity
(mean ± S.E.M.) during the first 30 min of the habituation period. Panel C shows the total horizontal activity (mean ± S.E.M.) across the
first 30 min of the session following saline injection. * p < 0.05, difference between HIV-1Tg and F344 rats at the corresponding time
interval. n=8 rats per group.
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Figure 5.3 The time-course data during the behavioral sensitization phase. HIV-1Tg and F344 rats were administered nicotine (Nic; 0.35
mg/kg; s.c.) or saline (Sal) on Days 1-19. Panel A shows the total horizontal activity (mean ± S.E.M.) during the 30 min pre-injection
habituation period. Panel B shows the total horizontal activity (mean ± S.E.M.) during 60 min following nicotine or saline injection. n=8
rats per group.
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Figure 5.4 The time-course data for total horizontal activity during day 1 and day 19 of the
behavioral sensitization phase. Panels A and B show the total horizontal activity (mean ±
S.E.M.) across the 60-min session. Panels C and D show the time course of the total
horizontal activity (mean ± S.E.M.) during each 5-min time interval. * p < 0.05 difference
between HIV-1Tg and F344 rats. # p < 0.05 difference between nicotine- and salinetreatment group. n=8 rats per group.
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Figure 5.5 Levels of ERK, CREB and TH proteins in the PFC in HIV-1Tg and F344 rats.
(A) Representative western blots showing the protein density of CREB, pCREB, ERK1/2,
pERK1/2, TH and β-tubulin in nicotine or saline treated HIV-1Tg (HIV-1Tg-Nic, HIV-1TgSal) and F344 rats (F344-Nic, F344-Sal). (B) Total and phosphorylated protein levels of
ERK1, ERK2 and CREB along with levels of TH after chronic nicotine or saline injection.
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Ratios are presented as the mean percentage of β-tubulin ± S.E.M. * p < 0.05 difference
between HIV-1Tg and F344 rats. # p < 0.05 difference between the nicotine- and salinetreatment groups. n=8 rats per group.
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Figure 5.6 Levels of ERK, CREB and TH proteins in the NAc in HIV-1Tg and F344 rats.
(A) Representative western blots showing the protein density of CREB, pCREB, ERK1/2,
pERK1/2, TH and β-tubulin in the nicotine or saline treated HIV-1Tg (HIV-1Tg-Nic, HIV1Tg-Sal) and F344 rats (F344-Nic, F344-Sal). (B) Total and phosphorylated protein levels of
ERK1, ERK2 and CREB along with levels of TH after chronic nicotine or saline injection.
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Ratios are presented as the mean percentage of β-tubulin ± S.E.M. # p < 0.05 difference
between the nicotine- and saline-treatment groups. n=8 rats per group.
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Figure 5.7 Levels of ERK, CREB and TH proteins in the VTA in HIV-1Tg and F344 rats.
(A) Representative western blots showing the protein density of CREB, pCREB, ERK1/2,
pERK1/2, TH and β-tubulin in the nicotine or saline treated HIV-1Tg (HIV-1Tg-Nic, HIV1Tg-Sal) and F344 rats (F344-Nic, F344-Sal). (B) Total and phosphorylated protein levels of
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ERK1, ERK2 and CREB along with levels of TH after chronic nicotine or saline injection.
Ratios are expressed as the mean percentage of β-tubulin ± S.E.M. # p < 0.05 difference
between the nicotine- and saline-treatment group. n=8 rats per group.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
6.1 SUMMARY AND CONCLUSIONS
Increasing evidence suggest that the alarming rise in HIV-1 associated
neurocognitive disorder is, at least in part, associated with HIV-1 viral proteins shed from
infected macrophages/microglia, including the nonstructural viral protein Tat, despite the
success of anti-retroviral therapies. Tat enhances extra synaptic DA levels by inhibiting
DAT, and the concerted effects of Tat and cocaine escalate the severity and amelioration of
the HAND. In order to develop adjunctive therapies that can stabilize the altered DA system
in the HIV-1 positive brains, it is crucial to understand the underlying mechanism for Tat
inhibitory effects on DAT function. The research described in this dissertation focused on
addressing the central hypothesis- ‘HIV-1 Tat protein via allosteric modulation of DAT
induces inhibition of DA transport, leading to dysfunction of the DA system’. This chapter
summarizes the findings that were presented in earlier chapters with the following
subheadings: (1) protein-protein interactions between Tat and DAT, (2) molecular dynamics
simulated structure of HIV-1 Tat and DAT binding complex, (3) mutational analysis of DAT
residues involved in HIV-1 Tat-DAT binding complex, (4) effect of HIV-1 Tat protein on
trafficking dependent regulation of DAT, (5) effect of HIV-1 Tat protein on VMAT2
function, and (6) released Tat is more potent than synthetic Tat. Finally, the chapter
concludes with the proposed model for HIV-1 Tat protein effects on DAT and VMAT2
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functions, and future directions for this work.
PROTEIN-PROTEIN INTERACTIONS BETWEEN TAT AND DAT
The preliminary evidence for protein-protein interaction between Tat and DAT
comes from Zhu et al. (2009), using a biophysical technique, surface plasmon resonance.
This real time measurement using immobilized membranes that overexpress hDAT-GFP
revealed that the transporter interacts with Tat protein but not with Tat Cys22. This proposed
biomolecular interaction was further strengthened by the lack of inhibitory effects of Tat
mutant proteins Tat∆31-61 and Tat Cys 22 on DA transport. However, there is lack of evidence
for this protein-protein interaction from a biochemical perspective. In the current dissertation
work, I addressed this gap by performing Co-IP and GST-pull down assays to confirm the
direct interaction between Tat and DAT proteins (Chapter 2) (Midde et al., 2013). In Chapter
2, it was shown that recombinant Tat protein can immuneprecipitate DAT from the rat
striatal synaptosomes and Glutathione S-transferases (GST)-tagged Tat protein was able to
pull-down DAT (Figure 2.1B and C). Taken together, these results strongly support that Tatmediated inhibitory effect on DAT function is triggered by a protein-protein interaction
between these two proteins.
MOLECULAR DYNAMICS SIMULATED STRUCTURE OF HIV-1 TAT AND DAT BINDING COMPLEX
The above described experimental evidence provides a strong base to further evaluate
the mechanism of Tat binding and to predict molecular determinants for DAT and Tat
interaction. Binding structure of DAT-Tat-DA-Cocaine was constructed based on the
crystallized structure of the leucine transporter (Yamashita et al., 2005) – the bacterial
homolog of NSS family proteins, modeling studies of DA substrate and inhibitor cocaine
binding to DAT (Huang and Zhan, 2007; Beuming et al., 2008; Huang et al., 2009), and
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nuclear magnetic resonance structure of Tat (Peloponese et al., 2000). As displayed in Figure
2.1C (Chapter 2) and Figure 6.1, the proposed binding of Tat protein at the substrate entry
tunnel region through electrostatic inter-molecular interactions does not directly interfere
with DA binding sites. However, the cocaine binding site is located inside the substrate
transport path in the vicinity of DA binding site, and cocaine binding has a direct impact on
affinity and transport kinetics of substrate.
According to the most embraced model, the alternating access model of Jardetzky
(1966), the substrate binding site is only available to either side of membrane surface at a
given time during the DA translocation process. This model proposes that the transporter
exists primarily in an outward facing conformation and stabilization of this conformation
require a network of intra-molecular interactions. Binding of substrate, two Na+ and one Clions trigger allosteric rearrangements of the transporter to the inward facing conformation
followed by initiation of substrate release into the intracellular milieu. A schematic showing
the outward open state structure of DAT is depicted in Figure 3.3A and B (Chapter 3).
According to this model and Singh et al. (2008), residues located in TM1b (TM,
transmembrane) and TM6a helices are highly required for conformational transitions during
functional DA translocation. These two helices move as group to the inner side of transporter
during conversion from outward-open to inward-open state of DAT. TM1b and TM6a
involve in a direct interaction with TM11 and EL4 (EL, extracellular) helices. As part of
extracellular gating creation Arg85 and Asp476 form a salt-bridge (joint hydrogen and ionic
interactions), which drives EL6 to stabilize the TM10 by hydrophobic interaction with
Tyr470. Tyr470 is critical to overcome the impermeable barrier of conformational alterations
between outward-open and outward-occluded state. Furthermore, this salt-bridging enhances
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the flexibility of TM1b for easy movement than TM6a. As a result salt-bridge between
Lys92 and Asp313 play an essential role for synchronizing motion of TM1b and TM6a.
Thus, residues Tyr88, Lys92 and Asp313 support to stabilize TM1b and TM6a through
hydrophobic or electrostatic intra-molecular interactions, and Tyr470 is the key residue in
the hydrophobic core of the central cavity of the plasma membrane.
Molecular modeling and molecular dynamics simulations predict the plausible
interaction of Tat protein with DAT as presented in Figure 3.2 (Chapter 3). According to this
model, the aromatic ring of Tyr470 of DAT interacts with the amino terminal of Met1 of Tat
through cation-π interaction. Hydroxyl group of Tyr88 of DAT participates in hydrogen
bond attractions with ε-amino group of Tat Lys19. Besides, the side chain of Lys92 of DAT
forms hydrogen bond with carbonyl group of main chain of Pro18 of Tat protein. This initial
binding structure of Tat and DAT binding complex demonstrates that Tat molecule is
associated with DAT through inter molecular electrostatic attractions and complementary
hydrophobic interactions.
MUTATIONAL ANALYSIS OF DAT RESIDUES INVOLVED IN HIV-1 TAT-DAT BINDING COMPLEX
As described above, DAT residues that are involved in favorable inter-molecular
interaction with Tat are part of the conformational stabilizing network that is critical for
smooth conformational transitions during DA transport cycle. Consequently, mutation of
these residues may cause alterations in the conformation of the transporter that will
manipulate affinity and kinetics of DA transporting process. The research shown in this
dissertation uses a systemic mutagenesis approach to define the predicted binding sites in
DAT for Tat binding. As a proof of concept, initially Y470H mutant was generated in DAT
with the expectation that Y470H disrupts critical cation-π interaction required for Tat
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binding (Chapter 2) (Midde et al., 2013). In Y470H mutant, the effect of recombinant Tat1-86
on DA uptake was attenuated compared to 38% decrease in WT-hDAT transfected cells that
are exposed to Tat1-86, suggesting the antagonistic nature of Tat to inhibit transporter function
through direct interaction with Tyr470 of hDAT (Figure 2.4). As our hypothesis regarding
role of Tyr470 in Tat interaction with DAT was verified to be correct, additional
substitutions at 470 – Y470F, Y470A and mutation of other predicted residues such as Tyr88
and Lys92 of DAT would be expected to show similar attenuation in response to Tat
treatment (Chapter 3). Indeed, all other mutants exhibited similar diminution in Tat-induced
inhibition of DA uptake except Y470F (Figure 3.5) emphasizing the importance of aromatic
ring of Tyr470 in Tat binding with DAT, and the involvement of Y88 and K92 in Tat and
DAT interaction. Thus, these observations further confirm our prediction that Tyr470, Tyr88
and Lys92 are part of the critical network that is required for DA transport and Tat reduces
the transporter efficiency by altering the conformation of the transporter by interacting with
these residues.
Pharmacological characterization revealed that Y470H and K92M mutations were
not only accompanied by decreased Vmax with no noticeable change in Km for DA uptake,
but also by significant increase in apparent affinities (IC50) for inhibitors (Chapter 2 and 3).
Whereas the apparent affinity for substrate DA was not significantly different from WT, the
apparent affinities for cocaine and GBR12909 inhibitors were significantly increased to
inhibit [3H]DA uptake (Table 2.1 and 3.1). These results indicate that Tat binding sites do
not overlap with the binding sites of substrate DA and do not influence the affinity for DA
uptake. However, increased apparent inhibitor affinities suggest the direct involvement of
Tat binding sites with cocaine binding. This close proximity of Tat and cocaine binding sites
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was further supported by Tat-induced decrease in Bmax for [3H]WIN35,428 binding (Chapter
3, Table 3.2 and (Zhu et al., 2009)). These observations are in line with previous report
demonstrating that Tat protein allosterically interacts with the transporter and modulates
cocaine binding sites (Zhu et al., 2011). In addition, Y88F and K92M mutants displayed
decreased IC50 values for cocaine and GBR12909 to inhibit [3H]WIN35,428 binding, a
structural derivative of cocaine. Cocaine and GBR12909 belong to different DAT inhibitor
classes that are structurally distinct and label different binding sites on the transporter.
Furthermore, substantial evidence indicate that inhibitor binding require a specific
conformational state of the DAT and cocaine –like compounds prefer the outward facing
conformation (Reith et al., 2001; Schmitt et al., 2013). It is interesting to note that mutants
increased both cocaine and GBR12909 apparent affinities similarly but with varying degrees
of impact. One possible explanation for this variability is that Tat-mediated allosteric effects
cause subtle conformational alterations in the transporter which consequently enhances DA
uptake potencies for cocaine. An alternative possibility is that GBR12909 can bind to several
conformations or is less dependent on conformation of the DAT (Schmitt and Reith, 2011).
Nevertheless, these inferences underscore the importance of extensive characterization of
predicted Tat recognition residues before concluding the influence of Tat binding on
inhibitors affinities. Taken together, it is evident that Tat through allosteric modulation of
transporter function escalates the inhibitory action of cocaine on DA translocation.
To explore the molecular basis for mutants altered pharmacological properties and
thereby to substantiate our hypothesis that Tat down regulates DAT function through
allosteric regulation, this research employed DA uptake and WIN35,428 binding studies in
the presence of zinc, a noncompetitive DAT inhibitor that blocks the DA uptake but
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potentiates WIN35,428 binding by stabilizing the transporter in the outward facing state
(Norregaard et al., 1998; Loland et al., 2003). Ample evidence indicates that specific
conformational effects in DAT that differ in response to bound ligand or mutations can be
investigated by Zn2+. In the presence of zinc, the uptake ability in Y470H was increased but
not in all other four mutants (Chapter 2 and 3). Interestingly, zinc-induced increase in
WIN35,428 binding was attenuated not only in Y470H but in all tested mutants with
different proportions. It was reasoned that Y470H mutation may cause the transporter to stay
principally in an extreme inward facing conformation that is highly suitable to reverse Zn2+mediated effects on DA uptake and WIN35,428 binding (Guptaroy et al., 2009; Liang et al.,
2009). In the case of Y88F, K92M, Y470F and Y470A mutations induce an inward
conformation that is able to abolish the binding preference for WIN35,428 without
interfering with zinc stimulated down regulation in DA uptake. These conformational
preferences of the mutants were further screened by measuring basal efflux (DAT-mediated
release of preloaded substrate). Y470H and Y470A displayed significant increase in both DA
and MPP+ efflux but not the Y470F and Y88F (Chapter 3). The most likely reason for the
low retention of substrate is that elevation of efflux without improving the uptake capacity
i.e. forward transport. Curiously, the K92M mutant exhibited considerable increase in the
DA basal efflux but not MPP+ efflux. It was interpreted that this may be due to K92M
inclination for a conformation that is not suitable for MPP+ binding (Liang et al., 2009).
Alternatively, the observed DA efflux in K92M is merely a quick leakage of substrate by
non-specific diffusion as MPP+ was showed to exhibit less diffusive properties compared to
DA in heterologous expression systems (Scholze et al., 2001). However, provided that the
effect of mutants on kinetic differences, increased inhibitor apparent affinities and the
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attenuation of zinc-mediated increase in WIN35,428 binding, it was deduced that the
reported mutants adopt similar molecular mechanisms that are ranging from closed-to-out
(occluded) to open-to-in (inward) conformational states. While these results strongly support
the allosteric mode of regulation by Tat protein to inhibit DAT function, further strategies
are required to confirm specific conformational states that are attributed to the identified
residues in transporter. For example substituted-cysteine accessibility method (Javitch, 1998;
Norregaard et al., 2003; Loland et al., 2008) and amphetamine-induced substrate efflux
(Khoshbouei et al., 2004; Guptaroy et al., 2011) can be used to further support the above
stated inferences for Tat induced effects on DAT structure and function.
EFFECT OF HIV-1 TAT PROTEIN ON TRAFFICKING DEPENDENT REGULATION OF DAT
A recent NMR spectroscopy study has shown Tat as a “natively unfolded” protein
with no distinctive three-dimensional structure but with fast dynamics (Shojania and O'Neil,
2006). Moreover, the unique genetic arrangement of Tat sequence and post-translational
modifications (Hetzer et al., 2005) enhances the likelihood of Tat protein interaction with
multiple cellular proteins. As described earlier, due to the complex nature of the DAT
regulation it is possible that Tat may impact other regulatory partners of DAT because of its
flexible and versatile nature, which ultimately leads to the reduction in DA uptake. As
previous studies (Aksenova et al., 2006; Zhu et al., 2009) indicated exposure to Tat reduces
Vmax of [3H]DA uptake with no change in the total DAT immunoreactivity levels. It clearly
suggests that there is no degradation of DAT protein due to Tat treatment at least in the acute
treatment time periods. However, it remains uncertain whether Tat causes any alterations in
the surface expression levels of the transporter. Ample experimental evidence has
demonstrated that redistribution of DAT proteins to and away from the presynaptic
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membrane is a predominant mechanism of DAT regulation (Chen et al., 2010). In an attempt
to understand the effects of Tat on DAT surface localization, rat striatal synaptosomes were
exposed to Tat protein for 15 min and it was found that DAT immunoreactivity levels were
decreased by 46% in the plasma membrane enriched fractions (P3) with no changes in the
total synaptosomal fractions (P2) (Chapter 4) (Midde et al., 2012). It was reasoned that Tat
could promote the redistribution of surface DAT to intracellular compartments possibly
through manipulating trafficking events, results in the reduction of DAT density at the
surface, which causes the observed decrease in Vmax of DA uptake. This hypothesis was
further supported by the decrease in Bmax of [3H]WIN 35,428 binding in P3 of Tat-treated
samples.
These findings raise vital questions, what is underlying mechanism for Tat-induced
shift in the surface DAT? Is it due to acceleration of endocytosis or diminution of recycling
to the membrane, or a combination of both? Numerous studies have demonstrated that DAT
undergo both constitutive and regulated endocytic trafficking. Following internalization,
DAT can be recycled back to the plasma membrane via the endocytic recycling pathways, or
targeted to lysosomal degradation pathways (Sorkina et al., 2009). Since PKC has been
shown as a key mediator for regulating recycling to the plasmalemma and internalization of
DAT to the early/late endosomes (Loder and Melikian, 2003; Chen et al., 2010), we exposed
rat striatal synaptosomes to the Tat protein that were pre-treated with PKC inhibitor,
bisindoylmaleimide-I (BIM-I) and observed the attenuation of Tat inhibitory effects on DA
uptake (Chapter 4). This outcome indicates that Tat exploits PKC-dependent signaling
pathway to modulate the functional regulation of the DAT. However, it is worth noting that
residues 587-596 at carboxyl-terminal of the DAT are required for the PKC-mediated
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internalization of the transporter (Holton et al., 2005). Furthermore, studies suggest that
mutating classical PKC consensus serine and threonine sites (Chang et al., 2001) and
truncation of amino-terminal of DAT (Granas et al., 2003) prevent direct phosphorylation of
the transporter but not the internalization. Collectively, these findings suggest that Tat may
manipulate the structural determinants that lead to rapid PKC-stimulated internalization of
DAT. Alternatively, Tat potentially interferes with functions of other downstream kinases
and/or scaffolding proteins in the PKC signaling cascade (Yang et al., 2010). Future studies
are necessary to address whether Tat-mediated influences on DAT endocytic trafficking is
phosphorylation dependent or independent.
EFFECT OF HIV-1 TAT PROTEIN ON VMAT2 FUNCTION
In the central nervous system, vesicular monoamine transporter 2 (VMAT2, Slc18a2)
is the only transporter that sequesters cytoplasmic monoamines, in particular DA, into
synaptic vesicles for storage and subsequent release (Zheng et al., 2006; Vergo et al., 2007).
This packaging process is highly regulated and dysfunction plays a role in a variety of
disorders including Parkinson’s disease (Caudle et al., 2008; Taylor et al., 2009; Rilstone et
al., 2013), Huntington’s disease (Ondo et al., 2002; Paleacu et al., 2004; Morrow, 2008), and
neuropsychiatric disorders (Zubieta et al., 2001; Zucker et al., 2001; Eiden and Weihe,
2011). Moreover, VMAT2 is one of the principal targets for amphetamine-derived
psychoactive drugs (Sulzer et al., 2005; Fleckenstein et al., 2007; Fleckenstein et al., 2009).
Having proven evidence for Tat induced effects on dopaminergic neurons especially on DAT
it was hypothesized that Tat may follow a similar mode of action to impair VMAT2
function.
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To test this hypothesis, synaptic vesicular uptake in the presence of 1 µM Tat was
performed and demonstrated that inhibitory effects of Tat are more profound in VMAT2
(35%) than DAT (25%) protein. Importantly, current data show that Tat potency for
inhibiting vesicular DA uptake (IC50 =0.21 µM) (Chapter 4) is 15-fold higher than that for
inhibiting synaptosomal DA uptake (IC50 = 3.1 µM) (Zhu et al., 2009). These results visibly
imply the essential role played by Tat protein in the impairment of VMAT2 that results in the
reduction of the loading and storage of DA into the synaptic vesicles. Moreover, mutant Tat
Cys22 (Cys22Glys) protein attenuates Tat-induced decrease in VMAT2 function, which is
similar to reported attenuation of Tat effects on DAT function (Zhu et al., 2009). Along these
lines, Theodore et al. (2012) using in vivo microdialysis reported that striatal synaptic
vesicles incubated with Tat show ~35% decrease in DA uptake and ~30% reduction in K+ evoked total DA overflow in rats injected with Tat. Taken together, these findings tempting
to speculate that Tat may directly influence VMAT2 structure through protein-protein
interactions. However, future investigations are necessary to delineate this possible
mechanism. Furthermore, recent studies proposed a physical and functional coupling
between DAT and VMAT2 to regulate dopaminergic tone in response to normal and druginduced stimuli (Zhu and Reith, 2008; Egaña et al., 2009; Sager and Torres, 2011),
suggesting that Tat protein may increase the neurodegeneration of dopaminergic terminal by
simultaneously targeting both DAT and VMAT2. In addition, it was reported that
simultaneous exposure of Tat protein and amphetamine synergistically impairs DAT
function in vitro (Cass et al., 2003; Theodore et al., 2006) and in vivo (Kass et al., 2010).
Having established evidence for VMAT2 as a target for amphetamine class of drugs (Sulzer
et al., 2005; Sulzer, 2011), it is conceivable that co-exposure of Tat protein and abused drugs
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by complementing each other may further deteriorate neuronal terminal loss that eventually
contribute to HAND (Purohit et al., 2011; Purohit et al., 2013).
RELEASED TAT IS MORE POTENT THAN SYNTHETIC TAT
Unconventional secretion of Tat (Pugliese et al., 2005; Rayne et al., 2010; Bachani et
al., 2013) by infected cells without cell lysis causes neurotoxicity to the neighboring
uninfected cells including neurons (Li et al., 2009). This extracellularly released Tat is
biologically active and can interact with DAT (Zhu et al., 2009; Midde et al., 2013)
suggesting that Tat protein is very flexible and can assume a unique conformation to bind
with the target molecule. It was demonstrated that a point mutation in Tat that substitutes
cysteine with alanine at 22 (Tat Cys22) attenuates Tat-mediated inhibition of DA uptake
(Zhu et al., 2009). In addition, this study also showed that deletion of residues 31-61 (Tat∆3161)

abolishes inhibitory effects of Tat on DAT function indicating that specific recognition

residues of Tat are responsible for Tat and DAT interaction. However, one caveat here is that
synthetic Tat used for these experiments is substantially less potent than Tat released from
Tat-expressing astrocytes (Li et al., 2008). Degradation of Tat during purification process,
high susceptibility of Tat to freeze/thaw cycles, and ability to get oxidized easily are the most
likely reasons for less Tat activity (Nath et al., 2000). As a part of this dissertation work, Tatconditioned medium which was obtained from the cells that were transiently transfected with
Tat plasmid DNA was evaluated to confirm whether it can be substituted for commercially
available recombinant Tat in the proposed experiments (Chapter 2) (Midde et al., 2013). This
approach was chosen because extracellularly released Tat exhibits more relevant
constitutively produced Tat effects than recombinant protein (Nath et al., 2000). As shown in
Figure 2.5B secreted Tat1-72, Tat1-86 or Tat1-101 variants exhibited a similar inhibitory pattern

171

which decreased DA uptake in heterologous cells that were expressing hDAT, and this
diminished effect was attenuated when released Tat was immunodepleted with anti-Tat
antibodies (Figure 2.5C). Furthermore, released Tat displayed ~4000 times more potent
inhibitory effects on DA uptake than recombinant Tat (Chapter 2). Therefore, these results
indicate that secreted Tat is more neurotoxic and Tat-conditioned media can be used as a
source of extracellular Tat (by producing different Tat mutant proteins) to characterize
unique binding sites of Tat that are required for functional interaction with DAT.
OVERALL CONCLUSIONS
In summary, the Tat protein plays a significant role in the impairment of DA system
by affecting regulatory pathways that control the functional attributes of DAT and VMAT2.
A graphical representation of potential ways by which Tat protein exerts its actions are
depicted in Figure 6.2 that include (1) direct protein-protein interaction with DAT, (2)
stimulation of PKC-mediated endocytosis, (3) diminution of recycling of DAT to the plasma
membrane, (4) alteration of direct phosphorylation state of the DAT, and (5) direct proteinprotein interaction with VMAT2 protein. Even though most of these regulatory components
are interconnected, here they were shown separately for the sake of clarity. It is quite
possible that Tat interaction or influence at one molecular component can trigger activation
of other factors or cellular events that ultimately lead to dysregulation of the DA system. As
described in this work, it appears that Tat will have a profound impact on DA translocation
process principally by altering the conformational states of the DAT through direct proteinprotein interaction. We do not know whether this Tat-mediated impact on structure of DAT
could also prompt increased endocytosis to early/recycling endosomes or diminished
recycling to the surface. Curiously, recent findings suggest that modifications in the
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conformational equilibrium of the DAT influence the endocytic trafficking of the transporter
molecules (Sorkina et al., 2009).
6.2 FUTURE DIRECTIONS
Several studies with various approaches and models tried to explain the evolution of
neuroAIDS. HAND begins as HIV-1 enters the brain and ARTs have little impact on viral
reservoir in the CNS, insisting the need to develop adjunctive therapies to treat neurological
complications associated with HIV-1 infection that can improve the HIV-1 positive
individual’s capability to perform daily activities. With increasing evidence it is almost
certain that HIV-1 viral proteins dysregulate the dopaminergic system and cause subsequent
neurodegeneration (Purohit et al., 2011; Barreto et al., 2014). However, delineating the
mechanism of action of Tat protein on target molecules, such as DAT, is a key step forward
to combat the progression of neuronal damage in HIV-1 infected brains. As described above,
the initial findings show that Tat recognition residues Tyr88, Lys92 and Tyr470 of DAT are
part of the crucial framework of substrate permeation pathway in DAT. Nonetheless, this
information is not sufficient to completely understand Tat and DAT interaction. Doubtlessly,
identification and characterization of other recognition residues is necessary to construct a
ligand-binding pocket for the functional interaction of Tat with DAT. Moreover, the
fundamental role of these DAT domains involved in DAT-Tat interaction are subject of great
debate, and shedding light on these regions will greatly improve our understanding of the
basic functionality of DA transport process. As it is hypothesized that neurocognitive deficits
and alterations in DA homeostasis are more severe in HIV-1 positive drug abusers (Nath,
2010; Gaskill et al., 2013), understanding how concerted effects of Tat and cocaine
manipulate the structural and functional attributes of the transporter is an important goal for
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future research in this area. Finally, the major obstacle would be how to translate these
computational and in vitro findings into a preclinical setting. This is very important because
evaluating the molecular mechanisms in a relevant model system is a key step before
exploiting them as clinically effective strategies. Hence, HIV-1 Tg rat model that was
utilized to demonstrate that genetically expressed HIV-1 viral proteins modify the locomotor
sensitization in response to nicotine administration (Chapter 5) (Midde et al., 2011) could be
used to investigate perturbations of DA neurotransmission that are present in HIV-infected
brains. Considering the alteration in dopaminergic biomarkers and behavioral evaluations
(Persidsky and Fox, 2007; Vigorito et al., 2007; Lashomb et al., 2009; Webb et al., 2010;
Rao et al., 2011), HIV-1 Tg rat model may be an appropriate model to evaluate the ligandbinding pocket in DAT for Tat binding and to screen potential small molecules that can
block Tat-specific effects on DAT functional regulation.
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Figure 6.1 Structure of DAT-Tat-Dopamine-Cocaine complex. DAT, Tat, cocaine, and
dopamine are colored in cyan, orange, red and blue respectively. Tat, cocaine and dopamine
bind to different region of DAT. Cocaine can block the entry of substrate dopamine, but not
Tat protein.
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Figure 6.2 Proposed model of HIV-1 Tat protein effects on DAT and VMAT2 proteins. Tat
protein may elicit its effects on DA system by influencing the structure, function and
endocytic trafficking of the DAT. (1) physical interaction of Tat with DAT induces
transporter down regulation and this physical coupling may encourage (2) PKC-stimulated
endocytosis and/or, (3) reduced recycling to the surface. Tat may also play a role in
alterations of (4) phosphorylation status of the DAT. (5) The direct interaction of Tat with
VMAT2 is also an important mechanism to dysregulate DA synaptic vesicular loading
through VMAT2.
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APPENDIX A
GENERAL STATISTICAL ANALYSES CONSIDERATIONS
1. Replicates
For all the experiments performed in this dissertation, I used a minimum of two or
three technical replicates. These replicates were either cell culture wells or tubes carrying
same amount cell suspension. The reason for such technical replicates was to establish the
validity of the method (e.g. pipetting errors). Three to eight biological replicates (sample
size) were used to differentiate the random effect from “true” biological difference that is
triggered by the treatment. The major advantage with the replicates is that they provide the
ability to run various statistics to evaluate the variability. Ability to detect smaller but
important changes and the capacity to spot the outliers in a dataset are the other benefits
that can be achieved from the replicates. Using both technical and biological replicates in
the experimental design increases the confidence of conclusions drawn from these
experiments.
2. Power Analyses
A priori type power analysis was conducted for behavioral experiments for HIV-1
Tg and nicotine project using G*power software (Faul et al. 2007). This analysis indicated
that a total sample of 32 animals would be needed to detect medium effects (0.40) with
80% power using an analysis of variance with alpha set at 0.05. A detailed statistical design
for behavioral assays was described in the data analysis section of chapter 5. For the in
vitro assays a priori power analysis was not estimated, however 0.75 to 0.99 ‘observed
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power’ was noted after experimental data was analyzed. Nevertheless, this post-hoc power
analyses doesn’t convey any new information as the significant p value (<0.05) indicates
actually observed effect (Hoenig and Heisey, 2001; Levine and Ensom, 2001). Factorial
design and statistical methods used for analysis of pharmacological data were elaborated
in respective chapters in the dissertation.
3. Outlier detection
The outlier labeling rule (Hoaglin and Iglewicz, 1987) was used to identify the
outliers in the data set. The formulae Upper limit = Q3 + (2.2 * (Q3 - Q1)); Lower limit =
Q1 - (2.2 * (Q3 - Q1)) were used to detect extreme values from both ends. If an outlier was
spotted, a root cause analysis was performed to determine the potential reason (e.g.
measurement error). The data points were trimmed which accounts for only less than 5%
of total data set for further analyses.
4. Randomization
To minimize the possibility of bias in the behavioral experiments, both HIV-1 Tg and
F344 rats were randomly assigned to two treatment groups such as nicotine and saline.
Sixteen HIV-1 Tg and 16 F344 animals were randomized into blocks of 8, 8 respectively.
The randomization scheme was generated by using the Web site Randomization.com
(http://www.randomization.com). Animal handling, drug treatment and placing the
animals into locomotor chambers were performed by three technicians to further insure
against human introduced bias into the procedure. Overall, randomization eliminates the
selection bias and assures equality of treatments for accurate statistical analyses.
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